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Bone marrow-derived mesenchymal stem/ stromal cells (BMSC) are self-renewing, 
multipotent cells that can give rise to multiple lineages including osteoblasts (bone), 
chondrocytes (cartilage) and adipocytes (fat). Interestingly, various pathways that promote 
BMSC osteogenesis/chondrogenesis simultaneously suppress adipogenesis and vice versa. The 
basic Helix-Loop-Helix (bHLH) transcription factor, TWIST-1 is highly expressed by BMSC 
and plays an important role in BMSC proliferation, lifespan, differentiation and commitment. 
Enforced expression of TWIST-1 enhances proliferation potential and lifespan of BMSC. It 
also enhances the adipogenic potential of BMSC yet inhibits chondrogenesis and osteogenesis. 
However, the underlying mechanisms mediating TWIST-1 regulation of BMSC growth and 
differentiation are not fully understood. 
 
In order to identify novel TWIST-1 gene targets involved in BMSC proliferation and 
osteogenic differentiation, previous studies from our laboratory have compared the gene 
expression profile of BMSC, which express either endogenous or enforced expression of 
TWIST-1 during either normal growth conditions or osteogenic inductive conditions, using 
microarray analysis. Two novel differentially expressed genes were identified, HOPX and 
CMTM8, as being suppressed by TWIST-1. The aim of this thesis is to determine whether 
HOPX and CMTM8 are novel targets of TWIST-1 in BMSC and whether they are involved in 
mediating the effects of TWIST-1 on cell proliferation and lineage commitment. 
 
To assess the functional role of HOPX and CMTM8 in the context of BMSC biology, 
expression of HOPX and CMTM8 were overexpressed using retroviral transduction and 
supressed using siRNA. The present thesis demonstrated that HOPX counteracts TWIST-1/ 
xix 
 
EZH2 regulation of BMSC cell fate determination via suppression of adipogenic genes such 
as C/EBPα, ADIPOQ, FABP4, PLIN1 and PLIN4, while HOPX is also a promoter of BMSC 
proliferation. This thesis also reported that CMTM8 is a suppressor of BMSC osteogenic 
differentiation and promoter of proliferation and cell migration via the EGFR signalling 
pathway. 
  
This thesis provides better understanding of the downstream molecular mechanisms of 
TWIST-1 in bone development and post-natal homeostasis and therefore, provides insight into 

















Multipotent bone marrow mesenchymal stromal/ stem cells (BMSC) are currently being 
assessed for their efficacy in a wide range of skeletal tissue engineering and regenerative 
medicine based clinical trials. However, the mode of action of BMSC in clinical trials is not 
fully understood with little consensus within the literature on the relative levels of contribution 
of paracrine effects stimulating host cells verses direct reconstitution of affected tissues by 
implanted BMSC. Therefore, a better understanding of the precise molecular mechanisms that 
direct BMSC growth and cell fate determination will help develop more potent preparations of 
BMSC for clinical use.  
 
TWIST family genes have been shown to play an important role in early embryonic 
development and postnatal skeletal homeostasis [1-3]. However, the molecular mechanisms of 
how TWIST genes influence MSC self-renewal or commitment to a particular cell lineage have 
yet to be fully determined. This thesis examines two molecular mechanisms which mediate 
Twist-related protein 1 (TWIST-1) control of BMSC growth and differentiation, and provides 
new insight into the downstream gene target(s) of TWIST-1. This thesis lays the foundation 
for future work that could facilitate the development of more potent tissue engineering and 
regenerative medicine therapies, for different orthopaedic based disorders and diseases. 
 
This introduction describes the basic biology of bone and skeleton, and the important roles of 
BMSC in bone remodelling, together with the molecular mechanisms that regulate the 
physiology of these cells. Specifically, it describes the functional role of TWIST-1 in BMSC 
proliferation, differentiation, migration and cell fate commitment as well as suggesting possible 
cellular processes regulated by TWIST-1.  
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1.2 Skeletal Development 
1.2.1 Macroscopic organisation of skeletal system 
Bone is a dynamic and rigid organ and has several functions including: provides mechanical 
support and protection for internal organs, produces white and red blood cells, acts as a storage 
for minerals and fats, and serves as muscle anchor sites to enable locomotion (reviewed in [4]). 
Human adult skeleton is composed of 206 bones can be categorised into two major groups 
based on gross anatomy: the long bones, comprising the humerus, femur and tibia, and the flat 
bones, such as the cranial bones, scapulae and the ribs. 
 
Long bones can be divided into three segments: the epiphyses (proximal and distal), which 
make up the extremities of the bones; the diaphysis, cylindrical shaft between the proximal and 
distal ends of the bone; and the metaphysis, which is the intermediate region between the 
epiphyses and the diaphysis of the bone (Figure 1.1). Between the epiphysis and the metaphysis 
contains the epiphyseal plate (growth plate), which is a layer of hyaline cartilage in growing 
bone. The outer surface of the bone is covered with a fibrous membrane called the periosteum, 
which contains nerves, blood vessels and lymphatic vessels that nourish the bone. Underneath 
the fibrous sheet are dense layers of calcified bone, known as the cortical bone, which encases 
the haematopoietic bone marrow in the medullary cavity. The marrow of young animals 
contain higher numbers of haematopoietic stem cells and mesenchymal stem cells in contrast 
to marrow derived from ageing animals, where the marrow produces more adipocytes (yellow 
marrow), with lower incidences of different stem cell populations. The medullary cavity, 
metaphysis and epiphysis of long bones are filled with a meshwork of spongy calcified bone 
struts, known as trabecular bone. In general, the trabecular bone is more metabolically active 



























1.2.2 Bone matrix and composition 
The mineralized extracellular matrix of the bone is mainly made up of type I collagen in the 
structure of fibrils and contains a minor proportion of serum-derived globular proteins, such as 
osteopontin, osteonectin and bone sialoprotein [5-14]. Within the mature bone are tightly 
bundled collagen fibres that arranged into layers (lamellae), which allow the construction of 
high density collagen in bone tissue. Moreover, bone contains inorganic mineral such as 
calcium and phosphate in the form of hydroxyapatite crystals [Ca10(PO4)6(OH)2] (reviewed in 
[15]). In the case of fracture healing, the collagen fibres in the bone form in a random oriented 
fashion which result in woven bone [16]. Woven bone is then progressively resorbed and 
replaced by more organised lamellar bone. 
 
1.2.3 Cell types in bone tissues 
Bone is composed of many different cell types including osteoprogenitors, osteoblasts, 
osteocytes and osteoclasts [17]. Osteoprogenitors are derived from multipotent mesenchymal 
stem cells, capable of differentiating into osteoblasts, the mature and non-proliferative cuboidal 
bone cells. Osteoblasts secrete osteoid (uncalcified bone matrix) that consists mainly of type I 
collagen and proteoglycans [18], and express alkaline phosphatase (ALP) required for 
mineralization of the osteoid. Once osteoblasts are surrounded by mineralized bone, they 
become osteocytes, which are terminally differentiated bone cells that regulate bone 
homeostasis by maintaining oxygen and mineral levels in the bone [19].  
 
Many distinct morphologies and biomarkers of the different stages of bone cell differentiation 
have been identified. Morphologically, osteoblasts are larger and cuboidal cell while osteocytes 
appear to be smaller in size but have larger nuclei and multiple cytoplasmic extensions [20, 
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21]. Biochemically, runt-related transcription factor 2 (RUNX2) [22], Msh homeobox 
homolog 2 (MSX2) [23] and ALP [24-26] are commonly used early differentiation markers, 
while osteocalcin (OCN) and osteopontin (OPN) act as late differentiation markers of the 
mature osteoblast [26-29]. Other markers of the differentiation from osteoprogenitors to 
osteoblasts include fibroblast growth factor receptor I (FGFR1) and FGFR2 [30, 31], bone 
morphogenetic proteins (BMP) [32] and collagen I (COL I) [21]. 
 
Another cell type that is important in bone development and homeostasis is osteoclasts, derived 
from hematopoietic stem cells, which have a critical function in bone resorption [33]. 
Osteoclasts resorb the bone surface into its essential constituents via acid filled vesicles. 
Osteoporosis is a disease where there is overproduction of osteoclasts, leading to excess bone 
degradation resulting from the imbalance of bone homeostasis [34]. Thus, an imbalance 
between these cell types can lead to conditions of low bone mass such as osteoporosis. 
 
1.2.4 Cartilage matrix and composition 
Cartilage is an elastic and smooth connective tissue. It functions to cover and protects the ends 
of long bones at the joints such as elbows, ankles and knees. Moreover, cartilage acts as a 
template to provide structural support during bone formation via endochondral ossification. 
Cartilage is also an important structural component of other structures such as the nose, ear 
and rib cage, which exhibits a flexible property in contrast to the hard and stiff qualities of 
bone. However, cartilage has very limited repair capabilities due to the poor migration ability 




Chondrogenesis is the process where the cartilage is formed and is the earliest step of 
skeletogenesis. This process begins with the condensation a group of mesenchymal cells that 
further differentiate into chondroblasts and then chondrocytes [36]. Chondrocytes can be 
subdivided into non-hypertrophic and hypertrophic chondrocytes by their distinct 
morphologies, gene expression profiles and their specific functions. Non-hypertrophic 
chondrocytes include resting and proliferating chondrocytes. These chondrocytes are cartilage-
forming cells as they express aggrecan (ACAN) and collagen II (COL II), the major 
components of the cartilaginous extracellular matrix required for cartilage template formation. 
At the same time, these group of chondrocytes regulate the rate of differentiation of 
hypertophic chondrocytes [37]. Once a cartilage template is formed, the innermost 
chondrocytes differentiate into pre-hypertrophic chondrocytes expressing low level of COL II. 
Pre-hypertrophic chondrocytes are located below the proliferating chondrocytes. This 
population of cells is larger than proliferating chondrocytes and begin to express RUNX2, a 
key factor of bone formation. Hypertrophic chondrocytes on the other hand are even larger 
cells that express vascular endothelial growth factor (VEGF) and collagen X (COL X) instead 
of COL II [38].  
 
1.2.5 Bone formation - Intramembranous Ossification  
Bone can form through two different mechanisms: intramembranous ossification and 
endochondral ossification. During intramembranous ossification, both the spongy and compact 
bones arise directly from sheets of condensed mesenchymal connective tissues. An ossification 
centre is primarily formed when a group of mesenchymal stem cells gather and commit to the 
osteogenic lineage, which then become osteoprogenitor cells. Osteoprogenitor cells then 
differentiate into early osteoblasts within the ossification centre. These osteoblasts secret 
osteoid and later trapped within the ossification centre and then differentiate into osteocytes 
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for further bone homeostasis. This event also stimulates the surrounding osteoprogenitor cells 
to differentiate into new osteoblasts allowing further bone formation [39]. 
 
1.2.6 Bone formation - Endochondral Ossification 
Most of the bones in the body such as bony plates at the base of the skull and long bones form 
via endochondral ossification. In endochondral ossification (Figure 1.2), a hyaline cartilage 
template is initially formed, providing the structural support for the formation of bone. Primary 
ossification centre is then formed in the middle of the cartilage as described previously in 
Section 1.2.5, resulting in compact calcified matrix in the middle of the cartilage and spongy 
uncalcified matrix in the surrounding. As calcification occurs, the cartilage template is 
degraded. This allows the development of secondary ossification centres at each pole of the 
cartilage template, leading to formation of articular cartilage and epiphyseal plate that allow 
continuing growth of the bone [39]. 
 
1.2.7 Bone homeostasis - Remodelling 
Bone is a dynamic tissue that is gradually remodelled over time, where complete replacement 
of the human skeleton occurs approximately every 10 years [40-42]. The remodelling and 
regenerating ability of bone is dependent on the balance between the different cell types. An 
average person reaches their peak bone mineral density (BMD) at around 30 years of age, and 
the BMD starts to decline after the peak, leading to bone loss conditions such as osteoporosis 
[43]. Therefore, understanding the precise stimuli responsible for the processes of every stages 
of this complex bone remodelling will help to control the process and possibly delay or prevent 

















Figure 1.2: Endochondral Ossification. (a) Mesenchymal stem/ stromal cells condense and 
differentiate into chondrocytes. (b) Formation of the cartilage template of the future skeleton 
and the perichondrium. (c) Penetration of capillaries into cartilage template and transformation 
of perichondrium into periosteum. Primary ossification center start to develop. (d) Cartilage 
and chondrocytes expand at both ends of the bone. (e) Secondary ossification centers start to 
develop. (f) Chondrocytes remains at epiphyseal (growth) plate. Adapted from [39]. 
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1.3 Mesenchymal Stem Cells 
Friedenstein and colleagues first identified a population of non-hematopoietic stromal cells in 
the bone marrow of rodents, based on their capacity to form single-cell adherent colonies in 
vitro that resemble fibroblastic cells, called colony forming unit-fibroblasts (CFU-F) [44]. 
These stromal cells have subsequently been referred to as mesenchymal stem cells (MSC), due 
to their capacity for differentiation into multiple cell types, ability to recapitulate a bone 
marrow supporting organ in vivo (Figure 1.3) [44-48]. However, the methodologies for the 
isolation of primary BMSC have relied upon the rapid plastic-adhesion of BMSC, followed by 
their proliferation in vitro [44, 49-51]. Such methods resulted in the isolation of a 
heterogeneous population of marrow stromal cells, vascular smooth muscle cells and 
macrophages, comprised only of a small proportion of multipotent BMSC. Following the 
generation of antibody reagents that identified clonogenic BMSC in human bone marrow 
aspirates, it is now possible to isolate a more homogeneous population of adult human BMSC 
based on their co-expression of perivascular markers such as STRO-1, VCAM-1 (CD106) and 
MUC-18 (CD146) [46, 52-55]. This isolation protocol provides a means to isolate purified 
populations of BMSC for basic research and for their use in tissue engineering and regenerative 
medicine therapies. 
 
The International Society for Cell Therapy later proposed minimum criteria to define MSC, 
which include (1) ability to adhere to plastic in standard culture conditions; (2) expression of 
the surface molecules CD73, CD90, CD105 in the absence of the hematopoietic markers 
CD11b, CD14, CD19, CD34, CD45, CD79a, and class II antigen HLA-DR; and (3) capability 







Figure 1.3: Multilineage potential of BMSC. Schematic diagram of signalling molecules and 








However, these criteria were established only to standardize human MSC isolation as MSC 
from different species may express different surface markers [57]. Furthermore, the definition 
is lack of assessment of multidifferentiation and self-renewal capacity in vivo. Therefore, more 
recently MSC have typically been defined by their multipotency and self-renewal capability 
[46, 54, 55]. 
 
MSC-like populations have also been isolated from various human tissues, but have 
significantly diverse growth and differentiation capabilities, morphology and gene expression 
profiles [58]. These observations suggest that MSC-like populations from different tissues may 
be biologically distinct and exhibit unique self-renewal and multipotential capabilities. For 
example, MSC isolated from bone marrow [46, 50], umbilical cord blood [59], peripheral blood 
[60], adipose tissue [61], dental tissue [62, 63], synovial tissue [64] and lung tissue [65] exhibit 
different paracrine properties, growth and differentiation potential, but show similar surface 
marker expressions [66]. Therefore, MSC-like populations derived from different tissue 
sources makes it challenging to determine the most appropriate cell population for specific 
tissue engineering and regenerative medicine applications. 
 
1.3.1 Bone marrow-derived mesenchymal stem cells migration 
BMSC are one of the most common stem cell source used in cell therapy in regenerative 
medicine. During bone homeostasis or tissue healing, BMSC migrate from bone marrow to 
remodelling or injury sites through peripheral circulation [45, 67, 68]. Therefore, the efficacy 
of BMSC in bone remodelling and cell therapy depends on their homing ability [68, 69]. The 




1.3.2 Chemical factors that regulate BMSC migration 
Factors involved in BMSC migration such as cytokines, growth factors and chemokines have 
been reviewed in [70]. The stromal derived factor 1 (SDF-1)/chemokine receptor 4 (CXCR4) 
axis is critical for inducing BMSC migration and recruitment to injury sites. It has been shown 
that increased concentration of SDF-1 can upregulate CXCR4 expression and promotes BMSC 
migration and tissue regeneration in various tissues such as liver, brain, skeletal muscle and 
heart [71-75]. In additions, growth factors such as hepatocyte growth factor (HGF), insulin-
like growth factor (IGF-1), transforming growth factor β1 (TGF-β1), vascular endothelial 
growth factor (VEGF), platelet-derived growth factor (PDGF) and basic fibroblast growth 
factor (bFGF) showed the ability to regulate BMSC migration.  
 
HGF is a pleiotropic growth factor of mesenchymal origin that binds to its receptor, c-Met [76]. 
Activation of c-Met signalling can promote the proliferation, survival and migration of various 
cell populations including BMSC [77]. It was shown in rat and mouse systems that HGF 
increases BMSC migration via the Akt/FAK and PI3K pathways. [78, 79]. 
 
In addition, the PI3K signalling pathway has also been intergrated by IGF-1, where IGF-1 is a 
mitogen that can induce migration of multiple cell types [80, 81]. Studies have shown that 
overexpression of Igf-1 in rat BMSC improves cell survival and promotes cell recruitment via 
paracrine action of Sdf-1 [82]. Further investigation showed that IGF-1 increased the 
expression of SDF-1 receptor, CXCR4, which then increased BMSC migration via the PI3K 




TGF-β1 is a another growth factor that can increase BMSC recruitment and migration via 
regulating signalling pathways such as PI3K/AKT, FAK, ERK1/2, p38 and N-cadherin [83]. 
In mice myocardial tissues that experienced ischemia/reperfusion injuries, high expression of 
Tgf-β1 was found to enhance homing of BMSC to the injuries sites via modulation of Cxcr4 
[84].  
 
Nonetheless, VEGF is a growth factor that plays an important role in the growth and migration 
of various types of cells [85]. It has been shown that enforced expression of VEGF in human 
BMSC can increase expression of SDF-1α in infarcted hearts, resulting in increased migration 
of BMSC and cardiac stem cells to the affected sites [85]. Moreover, VEGF can signal through 
PDGF receptors and enhances BMSC proliferation and migration [86]. Studies have shown 
that PDGF is a highly potent growth factor that promotes BMSC migration, recruitment and 
tissue repair [87, 88]. Blocking of PDGF-dependent signalling pathways inhibits MSC 
migration and survival in colon cancer [89]. In addition, bFGF was found to promote BMSC 
migration through upregulation of αVβ3 integrin and thus activates the MEK/ERK pathway 
and PI3K/AKT pathway [90, 91].  
 
1.3.3 Transcriptional regulation of osteoblast differentiation 
Osteoblast development is promoted through the regulation of different transcription factors 
and growth factors (Figure 1.4). Master regulatory genes for osteoblast lineage commitment 
include RUNX2, osterix (OSX), distal-less homeobox 5 (DLX5) and MSX2 [92-97]. RUNX2 
(also known as CBFA1) is an early osteogenic marker essential for osteoblast differentiation, 
which activates various bone associated markers such as OCN, OPN and bone sialoprotein 
(BSP) [93]. OSX is one of the downstream targets of RUNX2, which is predominantly 
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expressed by osteogenic progenitors but is expressed at low levels by pre-hypertrophic 
chondrocytes [97]. In mice, Osx is expressed as early as the commitment of MSC to the 
osteoblast lineage, and its expression increases as osteoblast differentiation occurs [98]. 
Following initiation of the osteogenic differentiation via Runx2 [93], other genes such as Dlx5 
and Msx2 participate in the maintenance and regulation of osteoblast differentiation [94, 95].  
 
1.3.4 Transcriptional regulation of chondrocytes differentiation 
In vitro and in vivo studies have identified a number of transcription factors that play important 
roles in chondrocyte development, from their lineage commitment to their terminal maturation 
(Figure 1.5). SOX9 is a key transcription factor of chondrogenesis and is necessary for 
commitment of MSC towards the chondrogenic lineage [99, 100]. SOX9 was reported to 
activate chondrogenic markers such as ACAN, COL II and COL X [101-105], and trigger the 
expression of SOX5 and SOX6 [99], which then interact with SOX9 to promote chondrocyte 
differentiation [106]. Loss-of-function mutation in SOX9 results in early maturation of pre-
hypertrophic chondrocytes into hypertrophic cells [99, 107]. On the other hand, overexpression 
of SOX9 in the growth plate slows down chondrocyte maturation process [108]. Furthermore, 
SOX9 also represses hypertrophic chondrocyte-specific genes such as VEGFα and COL10a1 
[109, 110]. Interestingly, SOX9 has been demonstrated to interact directly with RUNX2 and 
block its activity [111]. It was further shown that SOX9 prevents the differentiation of 
chondrocytes into osteoblasts by suppressing both β-catenin signalling and RUNX2 expression 
[112]. Together, these findings suggest that SOX9 plays an important role in chondrogenic 
lineage commitment and differentiation via regulating multiple chondrogenic genes. 
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1.3.5 Transcriptional regulation of adipocyte differentiation 
Figure 1.6 shows the major transcription factors and growth factors that are required for each 
stage of adipocyte differentiation. Two identified master regulatory transcription factors of 
adipocyte differentiation, CCAAT/enhancer binding protein alpha (C/EBPα) and peroxisome 
proliferator-activated receptor gamma 2 (PPARγ2) have been demonstrated to activate 
adipocyte-specific genes. Transcription factors of the C/EBP family play an important role in 
adipocyte differentiation. It has been shown that C/EBP-β and C/EBP-δ are involved in the 
induction of adipocyte differentiation at an earlier stage than C/EBPα and PPARγ2, and that 
the promoter region of the PPARγ2 gene contains binding sites for C/EBP [113, 114]. C/EBPα 
expression has also been observed before the expression of most adipogenic genes, and is 
required for the adipogenic induction [115, 116]. Moreover, C/EBPα and PPARγ2 have been 
shown to act cooperatively during adipocyte differentiation through activating each other’s 
expression and therefore regulating the expression of other adipogenic genes [113]. As one of 
the most essential transcription factors for adipocyte differentiation, PPARγ2 is expressed 
before most adipogenic genes [117]. Activation of PPARγ2 leads to cell cycle arrest and 
subsequent activation of other adipogenic genes [118]. PPARγ2 was found to promote 
adipogenesis and inhibit osteoblastogenesis [119, 120]. Reduced expression of PPARγ2 was 
associated with reduced marrow adipogenesis, increased osteoblastogenesis in vitro as well as 
increased trabecular bone volume in vivo [121]. In vitro culture of Pparγ2+/- mice BMSC 
showed increased expression of Runx2 and Osx, resembling increased osteoblast formation 
[122]. These studies showed that C/EBPα and PPARγ2 are master regulatory transcription 

















Figure 1.4: Osteoblast differentiation. The stem cell marker, STRO-1 and transcription 
factor, TWIST-1 inhibit BMSC differentiation and maintain BMSC in an immature and 
proliferative state. The transcription factors Runx2 and Osterix initiate BMSC differentiation 
down the osteoblast lineage. Osteocalcin, osteonectin and osteopontin are involved in the 


















Figure 1.5: Chondrocyte differentiation. The transcription factor Sox9, together with drives 
chondrocyte differentiation and proliferation. Chondrocyte hypertrophy is driven by the 
















Figure 1.6: Adipocyte differentiation. The transcription factors C/EBPα and PPARγ initiate 
BMSC differentiation down the adipocyte lineage. Adiponectin, Adipsin and Leptin are 





1.3.6 Crosstalk/ signalling interactions between BMSC osteogenesis, chondrogenesis and 
adipogenesis 
In the bone marrow, the differentiation of BMSC into osteoblasts and adipocytes is 
competitively balanced. The commitment of BMSC to the adipogenic lineage may result in 
increased adipocyte formation and decreased osteoblast numbers as observed in  age-related 
bone loss [126]. Numerous in vitro experiments performed on BMSC have revealed that factors 
that promote adipocyte formation inhibit osteoblastogenesis [127, 128], and conversely, factors 
that promote osteoblast formation inhibit adipogenesis [125]. This mainly occurs through the 
interaction between different signalling pathways, outlined below and the action of the 
transcription factor TWIST-1. 
 
WNT (Wingless-related Integration Site) molecules are cysteine-rich glycoproteins that 
regulate cell migration, proliferation, differentiation via two distinct pathways: canonical via 
β-catenin and non-canonical/calcium [129]. Canonical WNT/β-catenin signalling pathway was 
shown to promote bone formation via promotion of stem cell self-renewal [130], promotion of 
osteoblast differentiation [131] and inhibition of adipogenesis [132] via suppressing C/EBPα 
















Figure 1.7: The canonical Wnt and TGF-β signalling pathway. Wnt ligand bind to the Wnt 
receptor on the cell surface and stimulates activation of β-catenin. Binding of β-catenin on to 
Wnt response genes results in upregulation of osteogenesis and downregulation of 
adipogenesis. TGF-β binds to its receptor on cell surface and activates SMAD proteins. 
Binding of SMAD protein on to TGF-β response genes results in upregulation of 






TGF-β (transforming growth factor-beta) family members are involved in skeletal 
development and regulation of chondrocyte differentiation [50, 139, 140]. TGF-β cytokines 
serves various functions from embryogenesis to homeostasis, including proliferation and 
differentiation [141]. TGF-β has been found to stimulate expression of WNT and β-catenin and 
therefore promote osteo/chondrogenesis while inhibiting adipogenesis [138]. TGF-β3 
promotes chondrogenic differentiation of MSC through intracellular cascades, such as SMAD 
proteins, JNK, p38, extracellular-signal regulated kinase (ERK1/2) and mitogen-activated 
protein (MAP) kinases [137, 139, 142] (Figure 1.7).  
 
BMP (bone morphogenic protein) molecules are part of the TGF-β superfamily of growth 
factors that involved in the regulation of cell migration, apoptosis, proliferation, differentiation 
and also development and functions of tissues, including bone and cartilage [143]. BMP-2, -4, 
-6, -7 have been proven to play roles in osteo/adipogenic differentiation of MSC [144-150]. 
Chen et al. (1998) proposed that BMP affects cell fate determination of MSC via binding to 
different receptors, which then stimulate different downstream signalling cascades [151]. For 
example, binding of BMP to BMPR-1A activates adipogenic factors PPARγ2 and C/EBPα, 
which promote adipocyte differentiation, whilst binding of BMP to BMPR-1B activates 
osteogenic factors RUNX2 and OSX, which commit MSC into osteoblast lineage [151]. 
Furthermore, BMP effects on lineage commitment of MSC is dose-dependent with low level 
of BMP-2 favors adipocyte differentiation while high level of BMP-2 favors 
osteo/chondrogenic differentiation [152]. 
 
mTOR (mammalian target of rapamycin) molecules are a member of the phosphatidylinositol 
3-kinase-related kinase (PI3K) protein family that primarily senses nutrient in mammalian 
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cells. mTOR can assemble into two distinct multiprotein complexes, termed mTORC1 and 
mTORC2 [153]. The mTORC1 signalling pathway has previously been reported to play an 
important role in osteoblast proliferation and differentiation [154, 155]. Inhibition of either the 
PI3K or mTOR signalling pathways in osteoprogenitor cells promote osteogenic differentiation 
in human embryonic stem cells and human and murine MSC [155-158]. Furthermore, the 
mTORC1 signalling pathway has also been shown to be involved in adipocyte differentiation 
by activating key adipogenic transcription factors, such as PPARγ2 and C/EBPα [159, 160].  
 
FGF (fibroblast growth factors) family members control MSC differentiation differently. 
FGF1, 2, 10 promote adipocytes differentiation [161-164]. However, FGF2 was also shown to 
promote proliferation and osteoblastogenic differentiation of BMSC [165-168]. Therefore, the 
impacts of FGF on adipo/osteoblastogenesis depends on the mode of signalling, nature of 
ligands and other extracellular stimuli. Moreover, adipocytes may affect bone homeostasis 
through secretion of adipokines and fatty acids with paracrine actions [169]. Other molecules 
shown to regulate MSC growth and differentiation include TWIST-1 [1]. 
 
1.4 TWIST-1 Regulation in BMSC 
1.4.1 TWIST-1 is highly expressed by BMSC 
TWIST-1 gene is mapped to 7q21.2 and encodes for a basis helix-loop-helix (bHLH) 
transcription factor that is important in skeletal and head mesodermal tissue development [170, 
171]. This bHLH molecule acts as either a homo- or heterodimer with other bHLH molecules, 
and binds to a highly conserved E-box region (CANNTG) on the promoter region of genes 
[172]. Human BMSC express high levels of TWIST-1, yet expression is downregulated 
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following BMSC ex vivo expansion and maturation, correlating to a reduced lifespan potential 
[1, 46, 54, 173]. 
 
Isenmann et al. (2009) performed functional studies to determine the effect of TWIST-1 on 
BMSC proliferation and lifespan [1]. TWIST-1 high expressing BMSC lines demonstrated a 
higher proliferation rate and lifespan compared with the vector control BMSC lines. Supportive 
studies demonstrated that overexpression of the TWIST-1 can inhibit the senescence of BMSC, 
leading to increased cellular proliferation and extended lifespan [2] (Figure 1.8).  
 
1.4.2 TWIST-1 regulates epithelial-to-mesenchymal transition (EMT) of cells 
EMT is a critical process in embryogenesis and cancer metastasis, which is thought to be a 
hallmark of cancer stem cell and many progenitor cell populations [174]. Cells that undergo 
EMT lose their polarity and intracellular adhesion molecules, thereby enable them to migrate 
[174]. Other studies have highlighted the role of TWIST-1 as a master regulator of cell 
migration by promoting EMT during embryogenesis and cancer metastasis [175]. It was 
discovered that using mouse mammary tumour cell lines, increase Twist-1 expression results 
in breast cancer invasion and metastasis; while suppression of Twist-1 expression inhibits 
metastasis of carcinoma cell from mammary gland to the lung [176]. Furthermore, Twist-1 has 
been shown to bind to the E-box in the promoter of E-cadherin (epithelial associated gene) and 
represses the transcription [176]. Cleavage of E-cadherin ectodomain create fragments capable 
of inducing EMT, invasion and proliferation of MCF-7 mammary carcinoma cells in a 
paracrine manner via the epithelial growth factor receptor (EGFR) signalling [177]. EGFR has 















Figure 1.8: Functions of TWIST-1 in BMSC proliferation and differentiation. TWIST-1 
overexpressing BMSC showed increased proliferation and adipogenic differentiation capacity, 





Nuclear translocation of EGFR directly supress transcription of miR-1, where miR-1 is an 
upstream suppressor of TWIST-1 [178]. Therefore, increased levels of nuclear EGFR leads to 
release of suppression on TWIST-1 expression by miR-1, which then allows EMT and cell 
migration to occur. These studies demonstrated that TWIST-1 is a promoting factor of cell 
EMT and migration, possibly modulated by EGFR signalling pathway.  
 
1.4.3 TWIST-1 regulated transcription factors and signalling pathways 
TWIST-1 regulates a range of transcription factors and signalling pathways involved in 
osteogenic differentiation of BMSC (Figure 1.9) such as tyrosine kinase receptor C-ROS-1 
oncogene (C-ROS-1) [3], enhancer of zeste homolog 2 (EZH2) [2], Hes family bHLH 
transcription factor 4 (HES4) [179], BMP [180], β-catenin [181], WNT [182], MSX2 [95], 
FGFR2, ERK1/2, PI3K [183] and RUNX2 [92]. TWIST-1 has been demonstrated to be a 
negative transcription factor in bone cell development [184, 185]. Furthermore, Twist-1 
heterozygous mice reveal increased expression of FGF2 and BMP signalling [186, 187]. 
 
1.4.4 The role of TWIST-1 in bone pathology 
TWIST-1 family genes have been shown to play an important role in early embryonic 
development, however, the molecular mechanisms of how TWIST-1 genes influence MSC 
commitment to a particular cell type or stay as multipotent stem cells has yet to be fully 
determined. Studies in mice showed that Twist-1-/- embryos are lethal but Twist-1+/- 










Figure 1.9: Factors regulated by TWIST-1. TWIST-1 regulates transcription factor MSX2 
during cranial bone development. In BMSC, TWIST-1 negatively regulates a number of 
transcription factors including C-ROS-1, HES4, EZH2 and RUNX2; and other factors such as 
WNT, BMP and FGFR2, resulting in inhibition of BMSC osteogenic and chondrogenic 
differentiation. Moreover, TWIST-1 also positively regulates PPARγ2, Adipsin and Leptin and 

























In humans, TWIST-1 haploinsufficiency leads to a bone disorder called Saethre-Chotzen 
Syndrome (SCS) which is characterized by craniofacial (premature suture fusion and 
asymmetrical face) (Figure 1.10) and limb anomalies (brachydactyly and cutaneous 
syndactyly) [191, 192]. It was demonstrated that cranial parietal bone cells derived from SCS 
patients have reduced TWIST-1 expression compared with normal cranial bone cells (CBC) 
and exhibit a profound capacity to generate mineralised nodules in vitro under osteogenic 
conditions [2]. In addition, it was reported that decreased level of TWIST-1 in SCS cranial cells 
causes changes of gene expression which leads to a decrease in osteoprogenitor proliferation 
and increased osteogenesis, resulting in premature fusion [193].  
 
In growth plate, studies have shown that TWIST-1 negatively regulates chondrogenesis [194]. 
It was found that TWIST-1 expression is restricted to proliferating, immature chondrocytes 
within the growth plate during postnatal development and absent in hyperthophic 
chondrocytes. Further in vivo studies suggest that postnatal bone formation is inhibited in 
Twist-1 overexpressing mice, characterised by shorten limbs at two-week age [195]. Moreover, 
abnormal growth plate structure and vascular invasion were also observed in these mice at 
various timepoints during postnatal development. These findings demonstrate that alteration 
of TWIST-1 expression can modulate growth plate organization and lead to abnormal postnatal 

















Figure 1.10: Patient with SCS. Frontal and side photo and CT scans of a 5 months old child 
with bulging forehead (provided by co-supervisor Prof. Anderson). Arrows indicate fused 












1.4.5 Association between TWIST-1 and EZH2 in BMSC functions 
Previous studies have demonstrated an association between TWIST-1 and Enhancer of zeste 
homolog 2 (EZH2) in BMSC, where TWIST-1 increased EZH2 expression [2]. High levels of 
TWIST-1 expression in BMSC enhance recruitment of Ezh2 to silence the Ink4A/Arf locus (a 
promoter of p53), resulting in histone methylation (H3K27me3) along the locus to repress 
Ink4A/Arf activation, to inhibit cellular senescence and increase the lifespan of BMSC [2]. 
Further functional studies found that EZH2 regulates BMSC lineage specification, where high 
expression of EZH2 in BMSC promotes adipogenic differentiation and inhibits osteogenic 
differentiation [196]. Therefore, TWIST-1 regulation of EZH2 was exploited for its 
downstream molecular mechanisms during BMSC proliferation and differentiation.  
 
1.5 Significance/ Contribution to the Discipline 
Decreased levels of TWIST-1 affect the growth of both cranial (intramembranous ossification) 
and long bone (endochondral ossification). Many of the underlying mechanisms of how 
TWIST-1 regulates MSC division and differentiation still remain poorly understood. As a 
consequence, ineffective control of cell proliferation and lineage commitment remains a hurdle 
to be overcome to permit the clinical use of BMSC. Thus, understanding the downstream 
molecular mechanisms of TWIST-1 in bone development and post-natal homeostasis proposed 
in this study will provide insight into possible future therapeutic strategies that will alter the 






Our previous data demonstrated that there is a possible negative correlation between TWIST-1 
and the putative target genes,  homeodomain-only protein homeobox (HOPX) and chemokine-
like factor superfamily 8 (CMTM8). We therefore proposed that suppression of TWIST-1 
increases the levels of these genes, leading to increased bone formation and decreased 
adipogenesis in bone marrow stromal cell populations. 
 
1.7 Aims 
Aim 1: To identify putative TWIST-1 gene targets from preliminary microarray analysis using 
real-time PCR and chromatin immunoprecipitation techniques in human BMSC. 
 
Aim 2: To assess the functional role of TWIST-1 gene targets during BMSC proliferation and 
cell fate determination. 
 
Aim 3: To investigate the molecular mechanisms and signalling pathways which are altered 





















2.1 Table 2.1 Suppliers of Commonly Used Reagents 
Reagent Catalogue No. Supplier 
10x Tris/Glycine buffer  1610771 Bio-Rad 
Acetic Acid glacial AA009-2.5L-P Chem Supply 
Acetone AA008-2.5L-P Chem Supply 
Acrylamide/BIS 30% 37.5:1 ratio 
500mL 
1610158 Bio-Rad 
Agar Bacto 214010 BD (Beckton Dickinson) 
Agarose 9010E Scientifix 
Alizarin Red S LR  AL080-100G Chem Supply 
Ammonium persulphate (APS) A3678 Sigma Aldrich 
Annexin V Alexa Fluor 488 A13201 Thermo Fisher 
Annexin V Binding Buffer 422201 Australian Biosearch 
Annexin V PE 640908 Australian Biosearch 
Anti-Tubulin antibody ab6160 Abcam 
Bovine serum albumin A9418-100G Sigma Aldrich 
Calcium chloride CA01940500 Scharlau 
Cell Proliferation ELISA, BrdU  11647229001 Sigma Aldrich 
ChIP-Grade Protein G Magnetic Bead  CST.9006S Genesearch eFreezer 
Chloroform AR stabilized with 
Ethanol 
CA038-2.5L Chem Supply 
CMTM8 Polyclonal Antibody 15039-1-AP United Bioresearch 
Complete EDTA free Protease 
Inhibitor cocktail tablets 
4693132001 Sigma Aldrich 
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DAPI 10mg D9542-10mg Sigma Aldrich 
DBL Dexamethasone Sodium 
Phosphate  
163199 RAH Pharmacy 
Difco LB Broth 240230 BD (Beckton Dickinson) 
Dimethyl Sulfoxide (DMSO) DA013-2.5L-P Chem-Supply 
Distilled water Ultrapure 10977015 Life Technologies 
Dithiothreitol (DTT) 10197777001 Sigma Aldrich 
DNASE1 amplification grade 18068015 Life Technologies 
dNTP's mix (1mL of 10mM solution)  FISBIODN-10M/01 Adelab 
Erlotinib 10mg 5083S Genesearch efreezer 
Ethanol 100% Undenatured EA043-2.5L-P Chem Supply 
Ethanol 70% w/w (80%v/v) AJA726-20L Thermo Fisher 
Ethanol Undenatured 80% v/v  EL156-20L-P Chem Supply 
Ethylenediaminetetraacetic acid 
(EDTA) 
ED-500G Sigma Aldrich 
Faramount Aq mounting medium  S302580-2 Agilent Technologies 
Foetal Bovine Serum 500mL Batch: 
F21701 (FCS) 
AU-FBS/PG CellSera 
Formaldehyde, 40% (w/v) FL010-10L-P Chem Supply 
Formalin, 10% neutral buffered AJA2518-5L Thermo Fisher 
Glycerol (Glycerine) GA010-2.5L-P Chem Supply 
Glycine GA007-500G Chem Supply 
Haematoxylin MHS1-100ML Sigma Aldrich 
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Hanks’ buffered saline solution 
(HBSS) 
H9394-500ML Sigma Aldrich 
HEPES Solution 1 M, pH 7.0-7.6 H0887-100ML Sigma Aldrich 
Human HGF (HeK293) 100-39H-25 Lonza 
Hydrochloric Acid 32% HT020-500M Chem Supply 
Hydrogen Peroxide 30% H2O2 MERC1.07209.0500 BioStrategy 
IgG2a: 200μg/mL SANTSC-13119 bio-strategy (VWR) 
KAPA2G Fast Genotyping Mix  KK5121 Sigma Aldrich 
L-Ascorbic acid 2-phosphate A8960-5G Sigma Aldrich 
L-Glutamine 200mM  G7513-100ml Sigma Aldrich 
LIPOFECTAMINE 3000 L3000015 Life Tech Supply Centre 
LIPOFECTAMINE RNAIMAX 13778150 Life Technologies 
Methanol MA004-2.5L-P Chem Supply 
N,N,N,N-tetramethylethylenediamine 
(TEMED) 
T9281-100ML Sigma Aldrich 
Negative control siRNA 5nmol  4390843 Life Technologies 
Nonidet® P40 substitute 74385 FLUKA BioChemika 
Oligo-dT 18418012 Life Technologies 
Paraformaldehyde P6148-500G Sigma Aldrich 
PBS D8537-500ml Sigma Aldrich 
Penicillin/Streptomycin P4333-100ML Sigma Aldrich 
pGem-Teasy Vector System A1360 Promega eFreezer 
Pico Green DNA Kit            P11496 Life Technologies  
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Precision Plus Protein Dual Color 
Standards 
1610374 Bio-Rad 
Propan-2-ol-AR (isoPropyl Alcohol) PA013-2.5L-P Chem Supply 
Protein Assay Reagent A 5000113 Bio-Rad 
Proteinase K  25530-015 Life Technologies 
QIAquick PCR Purification Kit 28104 Qiagen 
Rabbit IgG, poly - Isotype Ctrl (ChIP 
Grade) 
ab171870 Abcam 
Random Hexamers RP-6 Geneworks 
RC reagent I 5000117 Bio-Rad 
RC reagent II 5000118 Bio-Rad 
Recombinant human EGF AF-100-15 Peprotech 
Recombinant human HGF 100-39H-25 Lonza 
Recombinant Human Insulin 100mg 91077C-100MG Sigma Aldrich 
Roche Glycogen 20mg/mL 10901393001 Sigma Aldrich 
RT2 SYBR Green ROX qPCR 
Mastermix 
330523 Qiagen 
Senescence β-Galactosidase Staining 
Kit 
9860S Genesearch eFreezer 
Sodium Acetate anhydrous (di sodium 
hydrogen) 
SA005-500G Chem Supply 
Sodium azide 8591 Sigma Aldrich 
Sodium bicarbonate S6014-1KG Sigma Aldrich 
Sodium carbonate SA099-500G Chem Supply 
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Sodium chloride LR 2.5L SL046-2.5KG Chem Supply 
Sodium dodecyl sulphate (SDS) 11667289001 Sigma Aldrich 
Sodium fluoride 1614002-1G Sigma Aldrich 
Sodium hydroxide, pellets SA178-500G Chem Supply 
Sodium hypochlorite 8-12.5% ST044-5L Chem Supply 
Sodium phosphate 342483-500G Sigma Aldrich 
Sodium pyrophosphate P8010-500G Sigma Aldrich 
Sodium pyruvate 100mM S8636-100ml Sigma Aldrich 
Sodium pyruvate 25G powder P5280-25G Sigma Aldrich 
Sodium vanadate S6508 Sigma Aldrich 
Standard Molecular Grade Agarose 9010E Scientifix 
STRO-1  39-8401 Thermo Fisher 
SUPERSCRIPT IV 10,000 units 18090050 Life Tech Supply Centre 
Tris (Sigma-7-9®) T1378 Sigma Aldrich 
TRIS ultra-pure 99.9% TRIS01-1KG Chemsupply 
TritonX-100 X100-1L Sigma Aldrich 
TRIzol® 15596018 Life Tech Supply Centre 
Trypan blue (0.4%) T8154-100ML Sigma Aldrich 
Trypsin 10x T4174-100ML Sigma Aldrich 
Tween 20 P1379-500ML Sigma Aldrich 
α-Modified Eagle's medium (α-MEM) M4526-500ML Sigma Aldrich 
β-glycerophosphate G9422-50G Sigma Aldrich 





2.2 Solutions, Buffer and Media for Cell Culture 
2.2.1 Alpha Modified Eagle’s Medium (α-MEM) 
α-MEM (Sigma-Aldrich, M4526-500ML) was supplemented with 10% (v/v) FCS (Cell Sera, 
AU-FBS/PG), 50U/mL Penicillin, 5μg/mL Streptomycin (Sigma Aldrich, P4333-100ML), 
1mM Sodium Pyruvate (Sigma Aldrich, S8636-100ml), 100μM L-ascorbate-2-phosphate 
(Sigma Aldrich, A8960-5G), 2mM L-Glutamine (Sigma Aldrich, G7513-100ml) and 10mM 
HEPES (Sigma Aldrich, H0887-100ML). The medium was subsequently filter-sterilised 
through a 0.2μm bottle top filter and stored at 4°C. 
 
2.2.2 High Glucose Dulbecco’s Modified Eagle’s Medium (DMEM)  
High Glucose Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich, D6546-500ML) was 
supplemented with 10% (v/v) FCS (Cell Sera, AU-FBS/PG), 50U/mL Penicillin, 5μg/mL 
Streptomycin (Sigma Aldrich, P4333-100ML), 1mM Sodium Pyruvate (Sigma Aldrich, 
S8636-100ml), 100μM L-ascorbate-2-phosphate (Sigma Aldrich, A8960-5G), 2mM L-
Glutamine (Sigma Aldrich, G7513-100ml) and 10mM HEPES (Sigma Aldrich, H0887-
100ML). The medium was subsequently filter-sterilised through a 0.2μm bottle top filter and 
stored at 4°C. 
 
2.2.3 Osteogenic Inducing Medium 
α-MEM (Sigma-Aldrich, M4526-500ML) was supplemented with 5% (v/v) FCS (Cell Sera, 
AU-FBS/PG), 50U/mL Penicillin, 5μg/mL Streptomycin (Sigma Aldrich, P4333-100ML), 
1mM Sodium Pyruvate (Sigma Aldrich, S8636-100ml), 100μM L-ascorbate-2-phosphate 
(Sigma Aldrich, A8960-5G), 2mM L-Glutamine (Sigma Aldrich, G7513-100ml), 10mM 
HEPES (Sigma Aldrich, H0887-100ML), 10-7M dexamethasone phosphate (RAH Pharmacy, 
163199) and 1.8mM inorganic phosphate, KH2PO4 (BDH Chemicals, UK). 
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2.2.4 Adipogenic Inducing Medium 
α-MEM (Sigma-Aldrich, M4526-500ML) was supplemented with 5% (v/v) FCS (Cell Sera, 
AU-FBS/PG), 50U/mL Penicillin, 5μg/mL Streptomycin (Sigma Aldrich, P4333-100ML), 
1mM Sodium Pyruvate (Sigma Aldrich, S8636-100ml), 100μM L-ascorbate-2-phosphate 
(Sigma Aldrich, A8960-5G), 2mM L-Glutamine (Sigma Aldrich, G7513-100ml), 10mM 
HEPES (Sigma Aldrich, H0887-100ML), 0.5μM hydrocortisone (Sigma-Aldrich, St. Louis, 
MO, USA), 60μM indomethacin (Sigma-Aldrich, St. Louis, MO, USA) and 10-7 M 
dexamethasone phosphate (RAH Pharmacy, 163199). 
 
2.2.5 Table 2.2 Culture Media 







α-MEM (Sigma-Aldrich, M4526-500ML) 
10% FCS (Cell Sera, AU-FBS/PG) 
50U/mL, 5μg/mL Penicillin, Streptomycin (Sigma Aldrich, 
P4333-100ML) 
1mM Sodium Pyruvate (Sigma Aldrich, S8636-100ml) 
100μM L-ascorbate-2-phosphate (Sigma Aldrich, A8960-5G) 
2mM L-Glutamine (Sigma Aldrich, G7513-100ml) 




High glucose DMEM (Sigma-Aldrich, D6546-500ML) 





50U/mL, 5μg/mL Penicillin, Streptomycin (Sigma Aldrich, 
P4333-100ML) 
1mM Sodium Pyruvate (Sigma Aldrich, S8636-100ml) 
100μM L-ascorbate-2-phosphate (Sigma Aldrich, A8960-5G) 
2mM L-Glutamine (Sigma Aldrich, G7513-100ml) 
10mM HEPES (Sigma Aldrich, H0887-100ML) 
JM109 LB media 10g/L Tryptone Peptone (Becton Dickinson, Sparks, MD, USA) 
5g/L Yeast Extract (Becton Dickinson, Sparks, MD, USA) 





α-MEM (Sigma-Aldrich, M4526-500ML) 
5% FCS (Cell Sera, AU-FBS/PG) 
50U/mL, 5μg/mL Penicillin, Streptomycin (Sigma Aldrich, 
P4333-100ML) 
1mM Sodium Pyruvate (Sigma Aldrich, S8636-100ml) 
100μM L-ascorbate-2-phosphate (Sigma Aldrich, A8960-5G) 
2mM L-Glutamine (Sigma Aldrich, G7513-100ml) 
10mM HEPES (Sigma Aldrich, H0887-100ML) 
10-7 M dexamethasone phosphate (RAH Pharmacy, 163199) 





α-MEM (Sigma-Aldrich, M4526-500ML) 
5% FCS (Cell Sera, AU-FBS/PG) 
50U/mL, 5μg/mL Penicillin, Streptomycin (Sigma Aldrich, 
P4333-100ML) 
1mM Sodium Pyruvate (Sigma Aldrich, S8636-100ml) 
100μM L-ascorbate-2-phosphate (Sigma Aldrich, A8960-5G) 
2mM L-Glutamine (Sigma Aldrich, G7513-100ml) 
10mM HEPES (Sigma Aldrich, H0887-100ML) 
0.5μM hydrocortisone (Sigma-Aldrich, St. Louis, MO, USA) 
60μM indomethacin (Sigma-Aldrich, St. Louis, MO, USA) 












2.2.6 Table 2.3 Cell Culture Buffers 
 
Buffer Name Components 
1x PBS MilliQ water (Media production unit, IMVS) 
10% Phosphate Buffered Saline, Ca+/Mg+ free (Sigma-Aldrich, USA) 
HHF Buffer Hanks’ Buffered Saline Solution (Sigma Aldrich, H9394-500ML) 
5% FCS (Cell Sera, AU-FBS/PG) 
50 U/mL, 5μg/mL Penicillin, Streptomyciin (Sigma-Aldrich, USA) 
Blocking Buffer HHF 
5% normal human serum (Red Cross, SA, Australia) 
FACS Buffer 1x PBS 
3% FCS (Cell Sera, AU-FBS/PG) 
5mM EDTA 
MACS Buffer 1x PBS 
1% BSA (SAFC, Lenexa, KS, USA) 
5mM EDTA (Merck, Kilsyth, VIC, Australia) 





2.2.7 Cell Culture Conditions 
All cell culture procedures were conducted in a Class II laminar flow hood (Top Safe 1.2, Bio 
Air, Siziano, Italy). Cells cultured for expansion were maintained in MCO-18AIC Sanyo CO2 
incubators (Sanyo Oceania, North Ryde, NSW, Australia), at 37°C, 5% CO2 in a humidified 
environment. Eppendorf 5810 centrifuge (Eppendorf South Pacific, North Ryde, NSW, 
Australia) was used for centrifugation of cell suspensions during expansion. The use of cells 
obtained from human subjects was approved by the Royal Adelaide Hospital ethics committee 
under protocol numbers 940911a and REC1033/06/2019. 
 
2.2.8 Isolation of Mesenchymal Stem Cells Using Magnetic Activated Cell Sorting 
(MACS) 
This MSC isolation method was based on the protocol described previously [197]. Following 
informed consent in accordance with procedures approved by the Human Ethics Committee of 
the Royal Adelaide Hospital, South Australia (protocol number 940911a), approximately 
40mL of human bone marrow was aspirated from the posterior iliac crest of healthy young 
volunteers (18-35 years old). The samples were then diluted with an equal volume of blocking 
buffer (HHF supplemented with 5% (v/v) normal human serum), mixed well and strained 
through a 70μm cell strainer (Becton Dickinson Biosciences, San Jose, CA, USA). 
Lymphoprep density gradient separation was performed to isolate the mononuclear cells as 
described in section 2.2.9. Cells were then pooled and enumerated using a haemocytometer. 
Following enumeration, cells were resuspended in 500μL of STRO-1 supernatant per 5 x 107 
cells and incubated on ice for one hour with occasional agitation. Cells were then washed twice 
in HHF wash buffer and resuspended in 0.5mL HHF containing biotinylated goat anti-mouse 
IgM (Southern Biotechnology Associates, Birmingham, UK) and incubated at 4°C for 45 
minutes. The cells were then washed three times in MACS buffer (Ca2+ and Mn2+ free PBS 
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was supplemented with 1% BSA in PBS, 5mM EDTA and 0.01% sodium azide) before being 
resuspended in 450μL of MACS buffer to which 50μL of streptavidin microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany) were added (10μL of microbeads/107 cells in 90μL 
MACS buffer). The mixture was incubated on ice for 15 minutes before being washed once in 
ice-cold MACS buffer and loaded onto the mini MACS column (Miltenyi Biotec, MS column). 
Cells reactive to STRO-1 antibody were bound to the magnetised matrix of the column. The 
column was washed three time with 500μL MACS buffer to remove any non-specifically 
bound STRO-1- cells. The column was removed from the magnetic field and the STRO-1+ cells 
were collected by flushing the column with 1mL of MACS buffer. The STRO-1+ cells were 
then culture expanded as described in section 2.2.9. 
 
2.2.9 Culture of Human BMSC 
Following immunoselection with STRO-1, bone marrow cells were cultured in 75cm2 tissues 
culture flasks at 30 x 103 cell per cm2 in α-MEM + additives, at 37°C in a humidified 
environment supplemented with 5% CO2. Cells were cultured to 80-90% confluence at which 
time; cells were harvested by enzymatic digestion with 0.05% trypsin (2.2.12) (SAFC, Lenexa, 
KS, USA) then used for experiments or reseeded (8 x 103 cell per cm2) for further expansion. 
 
2.2.10 Isolation of Human CBC 
Human parietal bone calvarial cells were derived from the cranium of donors with informed 
consent by the Human Ethics Committee of the Women’s and Children’s Hospital, South 




2.2.11 Culture of Human CBC 
Human CBC were obtained by collagenase digestion and explant culture following the method 
described by [199]. Briefly, dissected suture CBC samples were minced into 1mm fragments 
and incubated in 0.25% collagenase for 2 hours at 37°C. Samples were centrifuged and 
supernatant removed. Following three washes in 1 x PBS, samples were plated at 5 bone 
fragments per well, in 12-well plates, and cultured in α-MEM + additives, at 37°C in a 
humidified environment supplemented with 5% CO2. Cells were cultured to 80-90% 
confluence at which time; cells were harvested by enzymatic digestion with 0.05% trypsin 
(2.2.12) (SAFC, Lenexa, KS, USA) then used for experiments or reseeded (8 x 103 cell per 
cm2) for further expansion. 
 
2.2.12 Trypsin Digestion 
Trypsin was used to detach cells from the surface of tissue culture flasks. Briefly, culture media 
was aspirated and cells were washed once with PBS or Hanks’ solution to remove any 
remaining proteins. Enough 0.05% trypsin solution (SAFC, Lenexa, KS, USA) was added to 
cover the cells. Cells were incubated at 37°C for 3-5 minutes to enable enzymatic digestion of 
proteins bonding the cultured cells to the tissue culture flask.  
 
2.2.13 Adherent Retroviral HEK293T Packaging Cell Line 
Cells were cultured in T75 tissue culture flasks in high glucose DMEM + additives, at 37°C in 
a humidified environment supplemented with 5% CO2. Cells were cultured to 80-90% 
confluence at which time; cells were harvested by enzymatic digestion with 0.05% trypsin 





2.2.14 Cryopreservation of Cells 
Cells were cryopreserved in FCS containing 10% (v/v) of dimethyl sulfoxide (DMSO; Chem 
Supply DA013-2.5L-P). Immediately prior to freezing, 1ml of pre-prepared ice cold FCS 20% 
DMSO solution was added drop wise to ~1 x 106 cells in 1mL of FCS on ice. Cell suspension 
were then transferred to 2mL ampoules and cryopreserved in a Mr. Frosty (C1562 Freezing 
Container, Nalgene, USA) placed into a -80°C  freezer for at least 4 hours. The Mr. Frosty 
freezing container ensures the cells are cooled at the appropriate rate of 1°C per minute. Once 
at -80°C the ampoules were then transferred to the vapour phase of liquid nitrogen for extended 
storage at -196°C. 
 
2.2.15 Thawing of Cryopreserved Cells 
Cells were removed from liquid nitrogen (-196°C) and immediately thawed in a 37°C water 
bath. Once thawed, cell suspension in FCS 10% (v/v) of DMSO were immediately transferred 
to a 14mL polypropylene tube containing 11mL of appropriate growth media. This preparation 
was centrifuged at 1,400 x g for 5 minutes at 4°C. Cell pellets were then resuspended in 10mL 
of appropriate growth media and plated at a density of 8 x 103 cells/cm2.  
 
2.2.16 Counting Cells 
Washed cells were resuspended in 1mL of appropriate media. From this cell suspension, 10μL 
was removed for counting. Depending on the estimated cell number, a dilution factor between 
two and ten was used to count cells. Cells were counted using trypan blue (Sigma Aldrich, 
Castle Hill, Australia). Trypan blue enters the cell membranes of dead cells and all cells that 
are not blue can be counted as live cells. To obtain an accurate cell number at 100 cells were 
counted using a haemocytomoter.  
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2.2.17 Table 2.4 Cytokines and Inhibitors Used In This Study 
Cytokine Source 
Human  Recombinant EGF  (Peprotech, AF-100-15) 
Human Recombinant HGF  (Lonza, 100-39H-25) 
Human Recombinant Insulin  (Sigma Aldrich, 91077C-100MG) 
Erlotinib    (Genesearch, 5083s) 
 
All cytokines were reconstituted according to manufacturer’s instructions and diluted to the 
appropriate concentration in serum-free media or PBS as required and stored at -80°C. 
 
2.3 Chromatin Immunoprecipitation 
Human BMSC (1 x 106) from were cultured under growth, osteogenic or adipogenic inducing 
conditions for 7 days and chromatin immunoprecipitation (ChIP) performed using the Magna 
ChIP kit (Millipore Corporation, Billerica, MA, www.merckmillipore.com.au) in accordance 
with manufacturer’s instructions. Briefly, when cells reached 80-90% confluence, 37% 
formaldehyde was added dropwise (final concentration 0.75%) for 10 minutes at room 
temperature to crosslink protein and DNA within the cells. After 10 minutes, glycine was added 
(final concentration 125mM) to the media and incubate for 5 minutes at room temperature to 
quench the formaldehyde and terminates the crosslink reaction. Cells were then centrifuged 
(1,000 x g, 4°C, 5 minutes) and washed twice with ice cold 1 x PBS. Cell pellets were scraped 
from each flask, transferred to 14mL propylene tubes and centrifuged (1,000 x g, 4°C, 5 
minutes). Supernatant was removed and cells were resuspended in 400μl cells lysis buffer 
containing 1:10 dilution of protease inhibitor cocktail. Resuspended lysed cells were sonicated 
using a Bioruptor bath sonicator (Diagenode, Liège, Belgium) at 3 watts for 30 seconds in an 
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ice bath to obtain crosslinked DNA from ~200-500bp in length. Sonicated samples were 
centrifuged (8,000 x g, 4°C, 15 minutes) to remove any insoluble material, transferred to fresh 
microcentrifuge tubes and stored at -80°C.   
 
When required, sheared crosslinked chromatin was thawed on ice and diluted with 600μl RIPA 
buffer containing 1:10 dilution of protease inhibitor cocktail. At this stage, 10μl of sample was 
removed to be used as an input control and stored at 4°C. Samples were pre-clear with 20μl 
protein G-conjugated magnetic beads (9006S, Cell Signalling, Danvers, Massachusetts, USA) 
at 4°C for 2 hours. A magnetic rack was used to separate magnetic bead/antibody/chromatin 
complex out of the solution and supernatant transferred to new microcentrifuge tubes. An anti-
mouse TWIST-1 antibody (ab50887, 1μg, Abcam, Melbourne, Victoria), anti-rabbit EZH2 
antibody (49-1043, 1μg, Life Technologies, Mulgrave, VIC, Australia) and anti-IgG control 
antibodies (normal mouse IgG and normal rabbit IgG, 1μg), were added to respective samples 
and incubate overnight at 4°C with constant rotation.  Magnetic bead/antibody/chromatin 
complex were separated out of the solution and supernatant transferred to new microcentrifuge 
tubes. Magnetic bead/antibody/chromatin complex were washed three times in 1mL of Low 
Salt Immune Complex Wash Buffer and three times in High Salt Immune Complex Wash 
Buffer. Washed protein/DNA complexes were incubated at 65°C in 120μl ChIP elution 
buffer/1μl Proteinase K for 4 hours with shaking at 800rpm to reverse protein/DNA crosslinks 
and bonds between antibodies and magnetic beads. Samples were cooled to room temperature, 
magnetic beads were isolated and supernatant containing DNA transferred to a fresh 
microcentrifuge tube. DNA was purified using QIAquick PCR Purification Kit (28104, 
Qiagen, USA) in accordance with manufacturer’s instructions. Immunoselected genomic DNA 
was then used in real-time PCR as previously described [2]. 
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2.3.1 Table 2.5 ChIP primers  
Gene   Accession No.  Fwd 5’ -3’   Rev 5’-3’ 
EZH/CMTM8_S1 NM_178868.5  aggaaataacaccgggctct          tgatgtggtacctcgaatgc 
EZH/CMTM8_S2 NM_178868.5  ctgggaagaaagggttgtga        cacgtggagatcaggtgaga 
EZH/HOPX_S1  NM_001145459.1 tgctcatctgttggaaaacg           caactccccttcctccaaat    
EZH/HOPX_S2 NM_001145459.1 tcccacagatgatctcacca        tgcatgcagagtgtgacaga 
EZH/HOPX_S3 NM_001145459.1 aagcccacaggtggaagttt          gttccccgcaagacaagtta 
GAPDH  NM_002046.7  tgtcagtgcgttccagtctc        aggaacaggagggaaaagga 
POSTN  NM_006475.3  ctctggaaaggattgcagaat        agttgtgggagggaacactg 
P14TSS  NM_000077.4  ggagcgatgtgatccgttatc       tgaaatcccaatcgtcttccac 
TWIST/CMTM8_S1 NM_178868.5  ctcccaaagtgctgggatta           gcccaggagtttgtggttac 
TWIST/CMTM8_S2 NM_178868.5  cacaaactcctgggcttga         cagtactgtgagaggccaagg 
TWIST/CMTM8_S3  NM_178868.5  ggatatcaattgtcccagca         cagcatggtactggcataaga 
 
 
2.3.2 Table 2.6 Antibodies Used in ChIP 
Anti-rabbit EZH2 (49-1043, Life Technologies, Mulgrave, VIC, Australia) 
Anti-mouse TWIST (ab50887, Abcam, Melbourne, Australia), 
Normal Mouse IgG  (12-371, Sigma Aldrich, St Louis, MO, USA),     






2.3.3 Table 2.7 ChIP Buffers 
Buffer Name Components 
Cell Lysis Buffer 50mM HEPES KOH pH7.5 
140mM NaCl 
1mM EDTA pH8 
1% Triton X-100 
0.1% Sodium Deoxycholate 
0.1% SDS 
1 x Protease Inhibitors 
RIPA Buffer 50mM Tris-HCl pH8 
150mM NaCl 
2mM EDTA pH8 
1% NP40 
0.5% Sodium Deoxycholate 
0.1% SDS 
1 x Protease Inhibitors 
Low Salt Immune Complex Wash Buffer 0.1% SDS 
1% Triton X-100 




20mM Tris-HCl pH8 
High Salt Immune Complex Wash Buffer 0.1% SDS 
1% Triton X-100 
2mM EDTA pH8 
500mM NaCl 
20mM Tris-HCl pH8 




2.4 Molecular Biology Techniques 
RNATechniques 
2.4.1 Preparation of Total Cellular RNA 
Total cellular RNA was extracted from 0.2–5 x 106 cells using the TRIzol® Method 
(Invitrogen, Australia). Briefly, cells were washed in 1 x PBS, and lysed in 1mL TRIzol® 
solution. The RNA was extracted by the addition of 1/5 volume of chloroform, mixed with 
vigorous shaking, and incubated for 3 minutes at RT. Samples were centrifuged at 12,000 x g 
for 5 minutes at 4°C to separate phases, and the aqueous phase (containing RNA) was carefully 
removed and transferred to a fresh RNase-free 1.5mL eppendorf tube. Total RNA was 
precipitated by the addition of 500μL isopropanol and 2μL ribonuclease (RNase)-free 
51 
 
glycogen, and incubated on ice for 10 minutes or overnight at 4°C. The RNA was pelleted by 
centrifugation at 12,000 x g for 15 minutes at 4°C, washed with 75% (v/v) ethanol before being 
centrifuged at 7,500 x g for 5 minutes at 4°C. The RNA was resuspended in 10μL RNase-free 
DEPC-treated Milli-Q water and heated to 60°C for approximately 10 minutes to facilitate 
solubilisation of RNA. The RNA was used immediately for cDNA synthesis or stored at -80°C 
until required. 
 
2.4.2 Determination of RNA Concentration and Purity 
The concentration of RNA in solution was determined by measuring the absorption at 260nm 
on a UV spectrophotometer (Nanodrop-8000, Thermo Fisher Scientific, USA), assuming that 
an A260 of 1.0 represents 40μg/mL of RNA. The purity of the RNA was determined by the 
ratio of A260:A280, where a ratio of >1.8 is considered to represent highly pure RNA. The 
A260:A280 were consistently in the range of 1.8-2. 
 
2.4.3 Synthesis of Complementary DNA (cDNA) 
Total cellular RNA was extracted from cell lines with TRIzol® as described in Section 2.4.1. 
Total RNA (1μg) was reverse transcribed into single-stranded cDNA using Superscript IV 
(Invitrogen, Australia) according to manufacturer’s instructions. Briefly, 1μL oligo(dT), 1 μg 
total RNA, 1μL dNTP mix, 250ng/μL random hexanucleotide primers and distilled water to a 
total volume of 13μL was added to each microcentrifuge tube. This mixture was heated to 65°C 
for 5 minutes and then incubated on ice for at least 1 minute in order to denature the RNA. The 
heat denatured RNA was added to 4μL of 5x first strand buffer, 1μL of 0.1M DTT solution 
and 1μL Superscript IV enzyme (Invitrogen, Australia). The reaction mixture was incubated 
for 10 minutes at 23°C then 10 minutes at 45°C and finally at 80°C for 10 minutes. The cDNA 
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samples were then diluted 1:10 with RNase-free DEPC-treated water and either used 
immediately for PCR or frozen at –20°C.  
 
2.4.4 Real-Time Polymerase Chain Reaction (PCR) 
Real-Time PCR reactions were performed in a CFX Connect Real-Time PCR Detection 
System (Bio-Rad) according to the parameters outlined in Table 2.8. For each reaction, 2μL of 
cDNA (previously diluted 1:10 with RNase-free DEPC-treated water) was used in a reaction 
mixture containing 4.75μL RNase-free DEPC-treated water, 0.75μL forward and reverse 
primer (10μM working stock) and 7.5μL Sybr Green Mix (Qiagen, 330523).  
 
2.4.5 Table 2.8 Cycling Parameters for Real-Time PCR 
50°C - 2 min 
95°C - 15 min (enzyme activation) 
Cycling 95°C - 15 sec (denaturation) 
60°C - 30 sec (primer annealing) 48-52 cycles 
72°C - 10 sec (primer extension) 
72°C - 30 sec (final extension) 










2.4.6 Table 2.9. Real-time PCR Primers Used In This Study (Human) 
Gene   Accession No.  Fwd 5’-3’   Rev 5’-3’  
ADIPOQ  NM_009605.4  cctaagggagacatcggtga  gtaaagcgaatgggcatgtt 
ADIPSIN  NM_001928.4  gacaccatcgaccacgac  ccacgtcgcagagagttc 
AOC3   NM_003734.4  gtctttgtccccatggct  cacttgttgctgtggttgct  
C/EBPα  NM_004364.4  gggcaaggccaagaagtc  ttgtcactggtcagctccag  
C-MET  NM_001127500.3 acatccagtaccctgatgctacag gtgggtttcagcactctggt  
CMTM8   NM_178868.5  tgggcctgtgctttaacgg  gtatttccagcgtagcagatgg 
CNN1   NM_001299.6  aggctccgtgaagaagatca  ccacgttcaccttgtttcct 
COL4A1          NM_001845.6  ccattggtgacaaaggacaa  gaaagcctcggtctccttg 
E-CAD            NM_004360.5  ggccaggaaatcacatccta  ctcaaaatcctccctgtcca 
EZH2   NM_004456.4  actgctggcaccgtctgatg   cctgagaaataatctccccacag 
FABP4  NM_001442.3  tactgggccaggaatttgac  gtggaagtgacgcctttcat 
G0S2   NM_015714.4  ggaagatggtgaagctgtacg cttgcttctggagagcctgt 
GPD1   NM_005276.4  aaacgccactggcatatctc  tttggtgtctgcatcagctc  
HOPX  NM_001145459.1 tcaacaaggtcgacaagcac  gtgacggatctgcactctga 
KRT19             NM_002276.5 ctgaaggaagagctggccta  tcatattggcttcgcatgtc  
OPN   NM_001040058.2 gcagacctgacatccagtacc gatggccttgtatgcaccattc 
PLIN1  NM_002666.5  ctctcgatacaccgtgcaga  tggtcctcatgatcctcctc 
PLIN4  NM_001367868.2 ccttcggaaaagatggtgtc  taagtgcagaccgagtggtg 
RUNX2  NM_001024630.4 gtggacgaggcaagagtttca catcaagcttctgtctgtgcc 
SLUG              NM_003068.5  catgccattgaagctgaaaa  ggtaatgtgtgggtccgaat  
TWIST-1          NM_000474.4 tcttacgaggagctgcagacgca  atcttggagtccagctcgtcgct 
VIMENTIN      NM_003380.5 gaaattgcaggaggagatgc  tcctggatttcctcttcgtg 
β-ACTIN  NM_001101.3  gatcattgctcctcctgagc  gtcatagtccgcctagaagcat 
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2.5 Molecular Biology Buffers and Reagents 
2.5.1 Diethyl Pyrocarbonate (DEPC)-Treated (RNase-free) Milli-Q Water 
Milli-Q water for RNA and cDNA work was treated with 0.1% (v/v) DEPC (Sigma, USA), a 
potent inhibitor of RNases. The mixture was incubated overnight at RT, and then autoclaved 
to remove all traces of DEPC that might otherwise modify purine residues in RNA by 
carboxymethylation. 
 
2.5.2 Luria Broth (L-Broth) 
A broth containing 1% (w/v) Bacto-tryptone (Becton Dickinson, USA), 0.5% (w/v) yeast 
extract (Becton Dickinson, USA), and 1% (w/v) NaCl was prepared in Milli-Q water. The 
solution was pH adjusted to pH 7.0 with NaOH, and sterilised by autoclaving on a fluid cycle. 
The broth was stored at RT until required. 
 
2.5.3 LB Agar 
1.5% (w/v) Bacto-agar (Becton Dickinson, USA) was dissolved in L-broth, autoclaved on a 
fluid cycle and cooled with gentle mixing to prevent solidification. Ampicillin (100μg/mL) 
was added to the LB agar when cool enough to handle, and plates poured into 100mm bacterial-
grade petri dishes. LB agar plates were stored at 4°C. 10g/L Tryptone Peptone (Becton 
Dickinson, Sparks, MD, USA), 5g/L Yeast Extract (Becton Dickinson, Sparks, MD, USA), 
10g/L NaCl (Sigma Aldrich, Castle Hill, Aus). 
 
2.5.4 SDS “Running Buffer” for Electrophoresis 
A buffer comprising 0.3% (w/v) Tris-HCl, 1.44% (w/v) Glycine, 0.1% (w/v) SDS was prepared 




2.5.5 SDS-PAGE “Transfer Buffer” for Electrophoresis 
A buffer comprising 0.3% (w/v) Tris-HCl, 1.44% (w/v) Glycine, 15% Methanol (v/v), and 
0.1% SDS was prepared in water, pH adjusted to pH 8.3 and stored at 4°C. Each batch of 
transfer buffer was used twice and then discarded. 
 
2.6 Retroviral Transfection and Infection Techniques 
2.6.1 Cloning and Expression Vectors 
(a) pRUFiG2-IRES-GFP (Figure 2.1) - a 6071 base pair MMLV-based retroviral vector was a 
kind gift from Mr Paul Moretti (Hanson Institute, South Australia). This vector was used to 
create the HOPX, and CMTM8 over-expressing cell lines.  
 
(i) pRUFiG2-IRES-GFP-HOPX - The HOPX coding region (NCBI Accession number: 
NM_001145459.1) was generated from cDNA synthesized from HOPX high expressing 
BMSC and cloned into pGem®-T Easy vector. HOPX coding region was then excised from 
pGem®-T Easy using BamHI and XhoI enzymatic digestion, blunt-ended using Klenow 
fragment and ligated into the pRUFiG2-IRES-GFP vector, which had been digested with 
BamHI and XhoI.  
 
(ii) pRUFiG2-IRES-GFP-CMTM8 - The CMTM8 coding region (NCBI Accession number: 
NM_178868.5) was generated from cDNA synthesized from HOPX high expressing BMSC 
and cloned into pGem®-T Easy vector. CMTM8 coding region was then excised from pGem®-
T Easy using BamHI and XhoI enzymatic digestion, blunt-ended using Klenow fragment and 






2.6.2 Preparation of Chemically Competent DH5α Cells 
A single colony was inoculated into 10mL L-Broth grown overnight in a 37°C shaking 
incubator. This starter culture was then used to inoculate 200mL L-Broth and was grown at 
37°C, shaking until the culture reached OD600 = 0.6. The bacteria were incubated on ice for 30 
minutes, then pelleted at 3,000 x g, 4°C for 5 minutes. The cells were then resuspended in 
25mL ice-cold 0.1M MgCl2 and pelleted again at 3,000 x g, 4°C for 5 minutes. Cells were 
resuspended in 8mL ice-cold 0.1M CaCl2 + 15% glycerol and incubated on ice for 1 hour. 
Aliquots were frozen and stored at -80°C until required.  
 
2.6.3 Transformation of Competent Cells 
For transformation of ligations into competent E.coli, 10μL of the ligation reaction (Section 
2.6.7) was added to 100μL competent cells, mixed gently and incubated on ice for 30 minutes. 
The cells were then heat-shocked at 42°C for 90 seconds and then placed back on ice for 5 
minutes. After incubation, 200μL SOC medium was added to the cells and incubated for 30 
minutes in a 37°C shaking incubator. Of this mixture, 100μL was plated onto L-Agar plates 
containing 100μg/mL Ampicillin and incubated at 37°C overnight. Transformed colonies were 
picked and used to inoculate L-broth for subsequent plasmid purification. 
 
2.6.4 Preparation of Glycerol Stocks 
Glycerol stock cultures of log phase bacterial cultures were prepared by the dilution of an 





2.6.5 Purification of Plasmid DNA from Bacterial Cultures 
2.6.5.1 Small Scale Plasmid DNA Extraction (Mini-Prep) 
Mini-Prep DNA extractions were performed according to manufacturer’s instructions using 
the Qiagen Plasmid Midi-prep kit (Qiagen, USA). 
 
2.6.5.2 Medium Scale Plasmid DNA Extraction (Midi-Prep) 
Midi-Prep DNA extractions were performed according to manufacturer’s instructions using 
the Qiagen Plasmid Midi-prep kit (Qiagen, USA). 
 
2.6.6 Manipulation of DNA Products 
2.6.6.1 Quantitation of DNA 
The concentration of DNA in solution was determined by measuring the absorption at 260nm 
on a UV spectrophotometer (Nanodrop-8000, Thermo Fisher Scientific, USA), assuming that 
an A260 of 1.0 represents 50μg/mL of DNA (1cm light path). 
 
2.6.6.2 Restriction Digestion of DNA 
Restriction digestion of DNA were performed by digesting 1μg of DNA with 10 units of 
restriction enzyme in the presence of 1x digestion buffer in a total reaction volume of 10μL. 
The reaction was incubated at 37°C for 1-2 hour. 
 
2.6.7 DNA Ligation 
Ligations were routinely carried out in a total volume of 10μL containing DNA insert:vector 
of 3:1 (molar ratio), 1x ligation buffer (50mM Tris HCl pH 7.8, 10mM MgCl2, 10mM DTT, 





















Figure 2.1 The pRUF-IRES-GFP Mammalian Expression Vector. This 6071bp retroviral 
vector was used to create the HOPX and CMTM8 overexpressing BMSC. 
59 
 
2.6.8 DNA Sequencing 
A PCR reaction using the conditions described below (table) was used to amplify target DNA. 
Following PCR, samples were transferred to a 1.5mL Eppendorf tube containing 80μL 75% 
isopropanol and 1μL Glycogen (29mg/mL). These samples were incubated for 15 minutes at 
room temperature away from light before DNA was pelleted by centrifugation at 16,000 x g 
for 15 minutes at room temperature. Supernatant was then aspirated and DNA pellets washed 
with 200μL 75% ethanol before being centrifuged at 16,000 x g for 2 minutes. Ethanol was 
aspirated and pellets allowed to dry for 10 minutes. Samples were then delivered to AGRS 
sequencing centre and stored at -20°C until analysed. 
 
2.7 Transfection and Infection Techniques 
2.7.1 Transfection of HEK293T Packaging Cell Line with GFP-Encoding Plasmids 
Twenty four hours prior to transfection, 6cm tissue culture dishes were seeded with 2 x 106 
HEK293T cells in a volume of 3mL of high glucose DMEM-10 (equating to approximately 
50-60% confluence on the day of transfection) and incubated in a humidified environment at 
37°C in the presence of 5% CO2. At the time of transfection, the media was removed from the 
dishes and replaced with 2mL of high glucose DMEM. The following two mixtures were 
prepared for each 6cm tissue culture dish – Mix 1: 5μg retroviral GFP plasmid DNA and 5μg 
pEQPAM3 plasmid (encoding GAG, Pol and viral envelope protein) in 500μL serum-free 
DMEM; Mix 2: 13μL Lipofectamine 3000 (Invitrogen, USA) added drop-wise to 500μL 
serum-free DMEM. Mix 2 was incubated at RT for 5 minutes, then added drop-wise to Mix 1. 
This DNA/Lipofectamine mixture was incubated for a further 20 minutes at RT, at which point 
it was added drop-wise to the HEK293T cells. The cells were incubated in a humidified 
environment at 37°C in the presence of 5% CO2 for 48 hours, and the efficiency of the 




2.7.2 Viral Infection of Cells 
At 48 hours post-transfection, the supernatant from the HEK293T cells (containing viral 
particles) was filtered through a 0.45μm low protein binding syringe filter (Nalgene, USA) to 
remove any cellular debris, diluted 1:1 with fresh media (in which the cells to be infected are 
grown) and 4μg/mL polybrene (Sigma, USA) was added immediately prior to its addition to 
the cells. The cells to be infected were plated at 2 x 105 cells/mL. Infection was repeated two 
times after every 24 hours. After three times of viral infection, the viral supernatant was 
removed, and the cells were cultured in their normal growth medium. GFP expression was 
assessed using a UV microscope (Olympus, Japan). The infected cells were then sorted for 
GFP expression by FACS, using a BD FACSAria™ Fusion flow cytometer 
(http://www.bdbiosciences.com). 
 
2.8 siRNA Knockdown Transfections 
BMSC were seeded at 2.2 x 104 cells per well (24-well plate) the day before siRNA knockdown 
was performed. Sequence specific siRNAs against HOPX and CMTM8 (Ambion/Life 
Technologies, Mulgrave, VIC, Australia, http://www.lifetechnologies.com/) were used at 
12pM to achieve a > 90% knockdown of transcript levels. The siRNA used in this study were: 
HOPX s39106, HOPX s39107, CMTM8 s45676, CMTM8 HSS135801 and Silencer® Select 
Negative Control #1 siRNA. The procedure was performed following manufacturer’s 





2.8.1 Table 2.10 siRNA Used In This Study 
siRNA   Catalogue No.    Supplier 
siHOPX   s39106, s39107, s39108  Life Technologies 
siCMTM8   s45676, HSS135801   Life Technologies 
 
2.9 Functional Analysis of HOPX and CMTM8 overexpressing MSC 
2.9.1 BrdU Proliferation assay 
Proliferation (4 to 6 days) was performed as per the manufacturer’s instructions using the Cell 
Proliferation ELIZA, BrdU kit (11647229001; Roche Diagnostics Corporation, Indianapolis, 
IN). 
 
2.9.2 Senescence Assay 
A Cell Signalling Technology’s Senescence Assay Kit was used to measure the presence of 
senescence-associated β-galactosidase (Cell Signalling Technology, Boston, MA, USA). 
Growth media was removed and cells were rinsed once with 1 x PBS. Rinsed cells were fixed 
with 1mL of 1 x Fixative Solution and incubated at room temperature for 15 minutes. 
Following fixation, cells were rinsed twice with 1 x PBS before 1mL of β-galactosidase 
staining solution was added to each well and plates incubated at 37°C overnight in a dry-air 
incubator. Once stained, cells were enumerated manually.  
 
2.9.3 Assessment of Osteogenic Differentiation Potential 
In vitro mineralization assays were performed as previously described [46, 52]. Briefly, BMSC 
or CBC were seeded at 8 x 103 cells/cm2 in 24 well plates and cultured in mineralization media 
for up to 28 days with media changes twice weekly. At 18-28 days the well were washed three 
62 
 
times in 1x PBS and fixed with 10% Neutral Buffered Formalin (NBF) (Thermo Fisher, 
AJA2518-5L) for 1 hour. Mineralized cultures were stained with 2% Alizarin Red S (Sigma 
Aldrich Inc., St Louis, MO, USA) in RO water. For quantitative assessment of mineral 
deposition, cells were seeded at 8 x 103 cells/cm2 in 96 well plates and cultured in 
mineralization induction media for up to 28 days with media changes twice weekly. At 18-28 
days the well were washed three times in 1 x PBS and the mineralized matrix dissolved in 
100μL of 0.6M HCL (Merck, Kilsyth, VIC, Australia) for 1 hour at room temperature. The 
dissolved mineral solution was then transferred to 96 well microtitre plates and calcium levels 
were quantitated using the Arsenazo III (C7529-500 PT, PM Separations). Briefly, 4μL of each 
supernatant was transferred to a single well of a fresh microtitre plate. A calcium chloride 
(calcium/hosphorous combined standard (Sigma Aldrich, St Louis, MO, USA) standard curve 
was also established in triplicate. Arsenazo was added to each well at 200μL per well. The 
plates were shook to mix and incubated at room temperature for 1 minutes and the absorbance 
was read at 650nm on a microplate reader (iMark™ Microplate Absorbance Reader, BIO-
RAD). 
 
Following dissolution of the mineral with HCl, the wells were washed with 1x PBS and the 
cells were digested with 100μL of proteinase K (100μg/mL) (Invitrogen, Carlsbad, Canada) 
for 2-4 hours at 55°C. The cells were then triturated thoroughly to ensure complete disruption, 
50μL volumes were transferred to a white 96 well microtitre plate (Costar, Corning, New York, 
NY, USA). DNA content per well was then quantified using the Pico Green assay as described 




2.9.4 Pico Green DNA Assay 
Following digestion (2.9.3) 50μL of DNA standards (Table 2.3) were added to appropriate 
wells and 50μL of sample digests to appropriate wells. Pico Green stock was diluted 1:300 into 
1x TE buffer. Diluted Pico Green (150μL) was added to all wells and the plate gently agitated 
to mix and protected from light (Quant-iT dsDNA Assay Kit, P11496, Invitrogen, Mulgrave, 
Victoria, Australia). The Plate was then read on the VictorTM X4, PerkinElmer 2030 Multilabel 
Reader, under fluorescence settings with the following parameters. 
 
2.9.5 Table 2.11 Microplate Pico Green Settings and High Molecular Weight DNA 
standards 
Excitation filter: 485P 
Emission filter: 520P 
Gain: 1300 
Optics: 3mm liquid light guides 
Number of cycles: 1 
Number of flashes: 10 
Shake time: 10s on medium before reading cycle 
 
Standards – High molecular weight DNA (Sigma, D4522, 5mg) 
Prepare 10mg/mL stocks in sterile RO water and dilute standards to 5mg/mL, 2.5mg/mL, 




2.9.6 Assessment of Adipogenic Differentiation Potential 
Adipogenic assays were performed as previously described [46, 50]. BMSC were seeded at 8 
x 103 cell/cm2 in 24 well plates and cultured for 28 days in the presence of adipogenic media 
with media changes twice a week. At 28 days, the wells were washed three times with 1x PBS 
and cells fixed in 10% NBF for 1 hour at room temperature. Oil Red O staining solution was 
prepared by dissolving 0.5g of Oil Red O stain (MP Biomedicals, Solon, OH) in 100mL of 
isopropanol (Ajax Finechem, Taren Point, NSW, Australia) and further diluted 1.5:1 in RO 
water. Formation of lipid-laden fat cells was determined by Oil Red O staining. For quantitative 
assessment, overexpressing MSC were seeded at 8 x 103 cells/cm3 in 96 well plates and were 
cultured for up to 28 days in the presence of adipogenic media with media changes twice a 
week. At the conclusion of the assay, wells were washed three times with 1x PBS, fixed in 
10% Neutral Buffered Formalin for 1 hour at room temperature and stained with Nile Red and 
DAPI (4μg/mL) (Sigma Aldrich, Australia #N3013 and #D9542) before being imaged using 
an Olympus iX70 multi-wavelength inverted fluorescent microscope (Olympus, Tokyo, Japan) 
and enumerated manually. 
 
2.9.7 Migration Assay  
In vitro scratch assay: 3 x 104 cells were seeded into a 24-well plate to create a confluent 
monolayer. Cell monolayer was scraped in a straight line to create a ‘‘scratch’’ with a p200 
pipet tip. Debris was removed by washing the cells once with 1 ml of the 1 x PBS and then 
replace with 1mL of normal growth medium. To obtain the same field during the image 
acquisition, markings were created to be used as reference points close to the scratch on the 
outer bottom of the plate with an ultrafine tip marker.  Images were taken using phase contrast 
microscope and after initial scratch (T0). Cells were then incubated at 37 °C in 5% CO2 for 16 
hours. Images were taken again at post 16 hours incubation (T16) at the same spot using the 
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reference point. The area and length of uninvaded space within each well was measured using 
ImageJ at T0 and T16. 
 
2.9.8 Flow Cytometric Analysis  
Cells were prepared as a signal cell suspension using trypsin, cells were washed with HHF and 
past through a 70M cell strainer, centrifuged at 1,400 rpm (Eppendorf, 5810R) for 5 minutes 
and resuspended in 10mL blocking buffer (5% horse serum, 10% BSA, 1% penicillin/ 
streptomycin, 5% FCS in HEPES media).  A cell count was performed and cells were incubated 
with blocking buffer for 30 minutes on ice. Cells were separated into 5mL polypropylene tubes, 
corresponding to the antibodies being used. Samples were centrifuged (DiaCent-12) for 2 
minutes; the blocking buffer was aspirated. Cells were resuspended in 200 L of 20 g/mL of 
purified primary antibody and incubated for 1 hour on ice, shaking. Samples were washed 
twice with HHF and then resuspended with the corresponding secondary antibody (1:50). 
Samples were incubated for 45 minutes on ice, washed twice in HHF, the supernatant was 
aspirated, samples were vortexed and resuspended in 500L of FACS FIX. Samples were 
analysed with EPICS XL-MCL (Beckman Coulter, ADC) and EXPO32 software. 
 
2.10 RNA-sequencing 
BMSC with either empty vector and HOPX overexpressing vector were cultured at 2.5 x 104 
cells in normal growth (Ctrl) or adipogenic (Adipo) inductive media for two weeks. RNA was 
isolated and purified using TRIzol® (Sigma-Aldrich Inc., Sydney, NSW, Australia) in 
accordance with manufacturer’s instructions. 1μg of RNA was processed and sequenced by 
David Gunn Genomic Facility, SAHMRI, SA, Australia on the Illumina Nextseq 500 with a 
75 cycle v2.5 High Output sequencing kit. Initial raw read processing was performed using an 
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in-house pipeline developed at SAHMRI. Raw 75bp single-end FASTQ reads were assessed 
for quality using FastQC [200] and results aggregated using R/Bioconductor package 
ngsReports [201]. Reads were then trimmed for sequence adapters using AdapterRemoval 
[202] and aligned to the human genome GRCh38/hg38 using the RNA-seq alignment 
algorithm STAR [203]. After alignment, mapped sequence reads were summarised to the 
GRCh38.p13 (NCBI: GCA_000001405.28) gene intervals using featureCounts [204], and 
count table transferred to the R statistical programming environment for expression analysis. 
Effect of sequence duplicates were also investigated using the function MarkDuplicates from 
the Picard tools package (http://broadinstitute.github.io/picard). 
 
2.10.1 Differential gene expression and pathway analysis 
Gene expression analyses were carried out in R using mostly Bioconductor packages edgeR 
[205, 206] and limma [207]. Gene counts were filtered for low expression counts by removing 
genes with less than 1 count per million (cpm) in more than two samples and then normalised 
by the method of trimmed mean of M-values [208]. Differential gene expression was carried 
out on log-CPM counts and precision weights available from the voom function in limma [209], 
with linear modelling and empirical Bayes moderation. Annotation of results were carried out 
using Ensembl annotations (http://grch37.ensembl.org) available in biomaRt [210], and 
expression results displayed in heatmaps using the pheatmap package [211]. 
 
2.11 Western Blotting Reagents 
2.11.1 Blocking Solution 
On the day of use, 1g membrane blocking agent (skim milk) was dissolved in 20mL TBS-
Tween at room temperature with agitation. 
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2.11.2 Non-reducing Lysis Buffer 
One protease inhibitor tablet was dissolved in 5.6mL RO water with agitation. Tris (200μL; 
1M; pH7.5), 20μL EDTA (0.5M), 750μL sodium chloride (2M), 100μL Nonidet P40, 200μL 
sodium vanadate (100mM), 500μL sodium fluoride (0.5M), 100μL SDS (10% w/v), 400μL 
sodium pyrophosphate (250mM), 1250μL glycerol (80% v/v), 200μL sodium vanadate (0.5M) 
and 50μL phenylmethylsulfonyl fluoride (100mM) were then added and mixed thoroughly. 
The resulting solution of 1% Nonidet P40, 20mM Tris, 150mM sodium chloride, 1mM 
ethylenediaminetetraacetic acid, 25mM sodium fluoride, 10mM sodium phosphate, 2mM 
sodium vanadate and 0.5mM phenylmethylsulfonyl fluoride, supplemented with complete 
protease inhibitors, was stored in 1mL aliquots at -20°C for up to 3 months. 
 
2.11.3 Polyacrylamide Gel (Stacking Gel) 
RO water (5.42mL), 1.24mL 40% acrylamide, 0.66mL 2% bis-acrylamide, 2.52mL Tris-HCl 
(0.5M; pH6.8), 100μL SDS (10% w/v) and 50μL APS (10% w/v) were combined and were 
mixed by inversion. Immediately before use, 10μL TEMED was added and the solution was 
mixed carefully to avoid creating bubbles. 
 
2.11.4 7.5% Polyacrylamide Gel (Separating Gel) 
RO water (4.415mL), 1.875mL 40% acrylamide, 1.0mL 2% bis-acrylamide, 2.5mL Tris-HCl 
(1.5M; pH8.8), 150μL SDS (10% w/v) and 50μL APS (10% w/v) were combined and were 
mixed by inversion. Immediately before use, 10μL TEMED was added and the solution was 




2.11.5 13.6% Polyacrylamide Gel (Separating Gel) 
RO water (2.127mL), 3.4mL 40% acrylamide, 1.813mL 2% bis-acrylamide, 2.5mL Tris-HCl 
(1.5M; pH8.8), 100μL SDS (10% w/v) and 50μL APS (10% w/v) were combined and were 
mixed by inversion. Immediately before use, 10μL TEMED was added and the solution was 
mixed carefully to avoid creating bubbles. 
 
2.11.6 Reducing Loading Buffer, 5x 
Glycerol (25mL), 25mL Tris (1.0M, pH6.8), 8g SDS, 400mg bromophenol blue, 8mL β-
mercaptoethanol and 25mL RO water were mixed, the solution was filtered using a 0.45μm 
syringe filter and 2.5mL aliquots were stored at -20°C. Thawed aliquots were stored at 4°C 
until use. Cell lysates for Western blotting were diluted 1:4 in loading buffer for a final 
concentration of 50mM Tris, 1.6% SDS, 0.08% (w/v) bromophenol blue and 1.6% β-
mercaptoethanol. 
 
2.11.7 Running Buffer, 10x 
Tris (30.3g), 144g glycine and 10g SDS were dissolved in RO water, the pH was adjusted to 
8.3 and the volume was made up to 1L. The solution was stored at room temperature and was 
diluted 1:9 in RO water prior to use for a final concentration of 0.3% (w/v) Tris-HCl, 1.44% 
(w/v) glycine and 0.1% (w/v) SDS.  
 
2.11.8 Tris-buffered Saline (TBS), 10x 
Tris (24.2g) and 80g sodium chloride were dissolved in RO water, the pH was adjusted to 7.6 
and the volume was made up to 1L. The solution was stored at room temperature and was 




2.11.9 1% Tween/TBS (TBS-Tween) 
Tween 20 (1mL) was added to 100mL TBS (10x) and 899mL RO water and was carefully 
mixed to avoid bubbles. Solution was stored at room temperature until use. 
 
2.11.10 TBS-Tween with 10% BSA 
BSA (0.5g) was dissolved in 50mL TBS-Tween, with agitation. The solution was filtered using 
a 0.45μM syringe filter and was stored at 4°C. The solution was diluted 1:9 in TBS-Tween 
prior to use. 
 
2.11.11 Transfer Buffer, 1x 
Tris (12.104g) and 57.66g glycine were dissolved in 3L RO water, 0.6L methanol was added 
and the volume was made up to 4L. The solution was stored at 4°C and was used up to 2 times 
before discarding. 
 
2.12 Protein Analysis 
2.12.1 Preparation of Protein Lysates 
Whole cell lysates were prepared on ice from 3 x 106 MSC. Cells were washed once with 10mL 
of ice cold PBS before 300μL of Lysis Buffer was added and cells were scraped off the dish 
using a cell scraper. Cell lysate was transferred to an Eppendorf tube and vortexed. This 
preparation was incubated on ice for approximately 30 minutes. Cell lysate was then 
centrifuged for 30 minutes at 16,000 x g at 4°C. Centrifugation was sufficient to separate out 
the nuclear proteins and other cellular debris which formed a pellet at the bottom of the tube. 
The supernatant was transferred to a new tube from which an aliquot was taken and protein 
70 
 
concentration quantitated using RC/DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, 
USA) according to the manufacturer’s instructions. 
 
2.12.2 RCDC Protein Estimation 
The protein concentration of all cell extracts was determined using the RCDC Protein Assay 
Kit (BioRad, USA) according to manufacturer’s instructions. Serial dilutions of BSA (2mg/mL 
stock) were used to create a standard curve. 
 
2.12.3 Preparation of Samples for SDS-PAGE 
Cell lysates were thawed on ice and equivalent amounts of protein, as determined by RC/DC 
assay, were transferred to 1.5mL microfuge tubes. Appropriate volumes of 5 x reducing 
loading buffer were added and the samples were incubated for 5 minutes at 95°C on a heat 
block. The samples were cooled on ice, quickly centrifuged and the samples were loaded onto 
SDS-PAGE gels with a pre-stained protein marker (Bench-mark; catalogue number 10748-
010; Invitrogen). 
 
2.12.4 SDS-PAGE Gel Preparation 
Spacer plates (1.5mm; catalogue number 1653312; Bio-Rad) and short plates (catalogue 
number 1653308; Bio-Rad) were assembled in a gel casting frame. Immediately following 
addition of TEMED, separating gel was poured until it was 2cm below the top of the short 
plate. The gel was then covered with water-saturated butanol to remove bubbles and was left 
for 15 minutes to set. When the gel was set, the butanol was poured off, the stacking gel was 





2.12.5 Loading and Running of SDS-PAGE Gels 
The gels were assembled with the Mini-Protean® 3 (Bio-Rad) electrode assembly and 
clamping frame, the assembly was placed in a tank and the combs were removed. The inner 
chamber was filled with running buffer, ensuring the wells were well-rinsed with buffer. The 
tank was then half-filled with running buffer and the prepared samples and protein markers 
were loaded in appropriate wells. The lysates were run through the stacking gel at 20mA and 
were then resolved through the separating gel at 40mA.  
 
2.12.6 Transfer of Protein to Polyvinylidene Difluoride (PVDF) Membranes  
PVDF membrane (Hybond-P membrane, Amersham Biosciences, GE Healthcare, Little 
Chalfont, UK) was cut to size (6 x 9cm) and was pre-equilibrated in methanol for 5 minutes. 
The membrane, blotting paper and fibre pads were then soaked in transfer buffer until use. 
Following electrophoresis, the gel assembly was dismantled and the electrophoretic transfer 
cell (Mini Trans-Blot, Bio-Rad) was assembled, following the instructions of the manufacturer. 
Briefly, 2 sheets of blotting paper were placed on a fibre pad on the black side of the gel cassette 
holder and the gel was carefully placed on top. The pre-equilibrated membrane was laid over 
the gel, followed by 2 sheets of blotting paper, any air bubbles were expelled by rolling over 
the filter paper with a pipette and a final fibre pad was placed on top. The assembly was then 
placed in a tank with a cooling unit (cooled to -20°C), the tank was filled with transfer buffer 
and the protein transfer was carried out overnight at 30mA or for 2 hours at 200mA. 
 
2.12.7 Protein Detection 
Following Western blotting, the PVDF membrane was rinsed in TBS-Tween before being 
incubated for 1 hour in blocking buffer with agitation. The membrane was then probed with 
primary antibody (Table 2.12) diluted in blocking buffer overnight at 4°C with agitation. The 
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membranes were then washed 3 times for 5 minutes in TBS-Tween and the immunoreactive 
proteins were subsequently detected by incubation with alkaline-phosphatase-conjugated 
antibodies against rabbit immunoglobulin (Ig) (catalogue number AP182A; Chemicon, 
Melbourne, VIC) or mouse Ig (catalogue number AP322A; Chemicon), diluted 1:2000 in 1% 
BSA/TBS-Tween, for 1 hour at room temperature with agitation. The membranes were then 
washed 3 times for 5 minutes in TBS-Tween at room temperature with agitation.  
 
The protein was then detected by imaging using LI-COR Odyssey CLX machine at 700nm and 
800nm excitation. Quantitation was performed using Image Studio Lite Version 5.2 software. 
Where required, membranes were stripped of antibodies using a commercial stripping buffer 
(Western blot recycling kit; catalogue number 90100; Alpha Diagnostics, San Antonio, USA), 
following the instructions of the manufacturer. The blots were then rinsed in TBS-Tween and 
incubated for 1 hour in blocking buffer before reprobing with primary antibody. 
 
2.12.8 Table 2.12 Primary Antibodies Used In Western Blot 
Antibodies    Catalogue No.  Supplier 
Anti-HOPX    11419-1-AP  United Bioresearch  
Anti-HOPX    ab106251  Abcam 
Anti-CMTM8    15039-1-AP  United Bioresearch  
Anti-CMTM8    AV53386-100UL Sigma Aldrich 
PhosphoPlus EGFR (Tyr1065) kit  11862S  Genesearch  
Anti-AKT    9272   Cell Signalling 





2.13 Statistical Analysis 
Data analysis was carried out using Microsoft GraphPad Prism 7 (GraphPad Software, LA 
Jolla, CA, http://www.graphpad.com/), which was used for the generation of graphs and 
statistical significance. Statistical differences (*) of p<0.05 between samples are shown based 








Chapter 3: Identification of TWIST-1 Target 






Studies of skeletal development have shown that TWIST-1 expression correlates with bone cell 
immaturity where TWIST-1 expression is downregulated as bone cells mature [187, 212, 213]. 
In addition, previous work from our laboratory showed that freshly isolated STRO1+ BMSC 
express high levels of TWIST-1, which is downregulated rapidly when BMSC are expanded ex 
vivo [1]. Moreover, TWIST-1 overexpressing BMSC have an increased proliferation rate, 
lifespan and adipogenic differentiation capacity, but decreased capacities for osteogenic and 
chondrogenic differentiation [1]. Other studies demonstrated that positive correlation between 
high levels of TWIST-1 expression and high levels of STRO-1 expression, together with 
increased gene expression of the transcription factors, Id-1 and Id-2, which are associated with 
cellular proliferation [214]. Furthermore, the enhanced capacity for adipogenic differentiation 
by TWIST-1 overexpressing BMSC was accompanied by an increased in the expression of the 
adipogenic master regulator, PPARγ2 [1]. Interestingly, high levels of TWIST-1 are associated 
with increased levels of osteogenic master regulators, RUNX2 and MSX2, and decreased levels 
of late osteogenic differentiation markers, OPN, OCN and BSP [1]. These findings are 
supported by other studies that reported increased RUNX2 expression is correlated with 
decreased expression of its target genes and reduction in osteoblast differentiation [215-217]. 
Overall, TWIST-1 appears to be a positive regulator of BMSC growth and an inhibitor of 
osteo/chondrogenic differentiation, which allows BMSC to differentiate along a default 
adipogenic pathway.  
 
The aim of this study was to identify the downstream molecular mechanisms of TWIST-1 in 
BMSC cell lineage commitment. In order to identify novel TWIST-1 gene targets, TWIST-1 
overexpressing BMSC and controls were assessed in gene microarray studies [3]. Assessment 
of the data sets using Volcano plot analysis identified differentially expressed genes in vector 
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control BMSC during osteogenic differentiation (Figure 3.1A) and between vector control 
BMSC and TWIST-1 overexpressing BMSC cultured under growth and osteogenic conditions 
(Figure 3.1B).  A number of differentially expressed genes were identified, which appeared to 
be regulated by TWIST-1 during bone formation in vitro [3]. Expression of two genes, 
cytochrome P450 family 26 subfamily B member 1 (CYP26B1) and cathepsin K (CTSK) were 
found to be inhibited/repressed in BMSC during osteogenic differentiation. Conversely, these 
two genes were expressed at high levels in TWIST-1 overexpressing BMSC during osteogenic 
differentiation when compared to control BMSC. CYP26B1 and CTSK have been shown to 
play a role in BMSC function [218-221]. Interestingly, the expression of the majority of 
differentially expressed genes was upregulated in BMSC during osteogenic differentiation but 
were found to be repressed in TWIST-1 overexpressing BMSC during osteogenic 
differentiation since TWIST-1 inhibits the osteogenic potential of cells it is likely that these 
genes have a role in promoting osteogenesis. Differentially expressed genes were selected 
based on a P-value < 0.05 with a fold change of 2 fold (a log fold change (logFC) >=|1| or >=|-
1|), then ranked according to fold change and plotted on a volcano plot, generated by plotting 
statistical significance over magnitude of fold change (F). The top 30 differentially expressed 
genes during osteogenic differentiation of TWIST-1 overexpressing BMSC compared to vector 
only BMSC were selected based on the statistical significance and magnitude of fold change 
(Table 3.1). The microarray results obtained for the top 8 genes were validated using 
quantitative real-time PCR by our group (Figure 3.2A, 3.6A and data not shown). In order to 
select potential novel TWIST-1 target genes, a literature search was performed on published 
papers and publicly available databases for relationships between TWIST-1 and the top 8 genes 
























Figure 3.1. Volcano plot depicting statistical significance over magnitude of fold change 
for 79 differentially expressed genes. Volcano plot showing fold change of identified genes 
to their significance of the fold change between (A) BMSC cultured under growth and 
osteogenic conditions. (B) TWIST-1 overexpressing BMSC and control BMSC during 
osteogenic differentiation.  
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Table 3.1. Top 30 differentially expressed genes during osteogenic differentiation of 
TWIST-1 overexpressing BMSC compared to vector only BMSC. Rankings were 







3.1.1 Homeodomain only protein homeobox (HOPX)  
HOPX is the smallest homeobox important in cardiogenesis [222]. Inhibition of Hopx in mouse 
and zebrafish results in disruption of cardiac development and lethality. Hopx is found to be 
expressed in cardiomyoblasts, which interacts physically with activated Smad4 and functions 
to coordinate local Bmp signals to inhibit Wnt pathway, promoting cardiomyogenesis [223]. 
Studies have shown that Twist-1 is a target of Wnt/β-catenin signalling pathway in mouse 
cranial mesenchyme [182]. TWIST-1 was also found to be required for cranial bone lineage 
commitment by maintaining WNT responsiveness [182]. Therefore, there may be a positive 
feedback circuit between TWIST-1 and WNT and that TWIST-1 negatively regulates HOPX, 
which may affect bone formation through WNT/BMP signalling pathway. However, little is 
known about the biological function of HOPX in BMSC and CBC during bone formation. 
Interestingly, previous studies have demonstrated an association between TWIST-1/ Enhancer 
of zeste homolog 2 (EZH2) and EZH2/ HOPX in BMSC, where TWIST-1 increased EZH2 
expression and EZH2 decreased HOPX expression [2, 224]. EZH2 is a histone 
methyltransferase that trimethylates the histone 3 lysine 27 (H3K27me3), which then leads to 
chromatin condensation and gene repression [225]. Therefore, HOPX may have a role in 
BMSC growth and differentiation.  
 
3.1.2 Tyrosine Kinase Receptor C-ROS-1 oncogene (C-ROS-1) 
C-ROS-1 is a transmembrane orphan tyrosine kinase receptor with no known ligand. Previous 
study from our laboratory have demonstrated that C-ROS-1 is expressed by BMSC and CBC 
and is a downstream target of TWIST-1 [3]. Furthermore, it has been demonstrated that C-
ROS-1 signalling affects the PI3K/AKT/mTOR signalling cascade in BMSC [3]. Overall, this 
study has shown that C-ROS-1 is involved in BMSC fate switching between osteogenesis and 
adipogenesis, mediated via PI3K/AKT/mTORC1 signalling.  
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3.1.3 Integrin Subunit Alpha 5 (ITGA5) 
Integrin is a family of transmembrane proteins that induce intracellular signals [226, 227]. The 
α5β1 integrin is a cell surface receptor for fibronectin that has been implicated in cell spreading, 
proliferation, differentiation, migration, and survival in different cell types [228-230]. Various 
studies have shown that ITGA5 is involved in osteogenic differentiation of BMSC [231-233]. 
It was reported that ITGA5 expression is upregulated during osteogenic differentiation of the 
human MSC. Moreover, enforced expression of ITGA5 results in increased osteogenic 
differentiation capacity in vivo and in vitro, which is mediated by ERK1/2-MAPK and PI3K 
signalling pathways [231]. 
 
3.1.4 Scavenger Receptor class A member 3 (SCARA3)  
SCARA3 encodes a macrophage scavenger receptor-like protein of 606 amino acids [234]. It 
has a leucine zipper motif that overlaps with a transmembrane domain at its N-terminus, 
followed by two central coiled regions and a C-terminal collagen-like domain [234]. 
Additionally, an alternative splice variant of the SCARA3 gene encodes for a 466 amino acid 
protein identical to that described above, except that it possesses only a short C-terminal tail 
and lacks the collagen-like domain. It was found to be primarily secreted in myeloid cells and 
plays a role in microbial pattern recognition of innate immunity [234]. SCARA3 functions to 
protect cells by scavenging reactive oxygen species and harmful products of oxidation [235, 
236]. Moreover, SCARA3 can bind endogenous ligands, such as extracellular matrix proteins 
(biglycan, decorin, denatured collagens) and modified LDLs (AcLDL, OxLDL) [237]. 
Functional studies have shown that SCARA3 controls lipid homeostasis which is critical in the 
osteoblast/adipocyte differentiation balance [237]. The shift in bone/fat marrow ratio towards 
fat might lead to decreased bone mineral density. Another study has shown that SCARA3 
expression was downregulated in post-menopausal osteoporotic bone tissue, which may have 
82 
 
a prominent role in antibody clearance, phagocytosis, pathogen recognition and inflammatory 
response [238]. In addition, SCARA3 can interact with cleavage and polyadenylation-specific 
factor 3 (CPSF3), an enzyme necessary for polyadenylation of RNA. The binding of SCARA3 
to CPSF3 subsequently alter subcellular distribution and induce cell death [239]. However, 
little is known about the underlying molecular mechanism of SCARA3, particularly during 
BMSC cell fate determination, and in the context of bone disorders involving an imbalance of 
bone/ fat ratio such as osteoporosis.  
 
3.1.5 Collagen Type IV Alpha 4 Chain (COL4A4) 
COL4A4 is a main structural component of basement membranes. Mutations in COL4A4 are 
associated with Alport syndrome (hereditary glomerulonephropathy). Studies have reported 
that col4a4 expression is downregulated during early stage of osteoblast differentiation in the 
mouse MC3T3-E1 cell line, suggesting that Col4a4 may have a role in preventing premature 
osteoblasts to enter maturation [240]. Therefore, COL4A4 has known functions in bone 
biology. 
 
3.1.6 CKLF-like MARVEL transmembrane domain containing 8 (CMTM8) 
Our previous studies have found that the CMTM8 is a putative downstream target of TWIST-
1 in primary human BMSC [3]. Other studies of different cancer lines, HEK293T, human 
cervical carcinoma cell line (HeLa) and human prostate carcinoma cell line (PC3), reported 
that CMTM8, also known as CKLFSF8, suppresses the epidermal growth factor receptor 
(EGFR) signalling pathway by accelerating clearance of cell surface EGFR, resulted in a 
decrease in cell proliferation [241]. Another study showed that EGFR signalling suppresses 
osteoblast differentiation and inhibits expression of the osteoblastic transcription factors 
RUNX2 and OSTERIX, which may lead to the development of immature osteoblastic-like 
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cells characteristic of osteosarcoma [242]. The EGFR signalling pathway has also been shown 
to be important in maintaining osteoprogenitor populations in an undifferentiated stage [242]. 
In other tumor types such as hepatocellular carcinoma cells and immortalized breast epithelial 
cells, CMTM8 was reported to act as a tumour suppressor gene by suppressing the activity of 
the oncogenic protein, c-Met, and therefore leading to a decreased in EMT status of cells [243-
245]. Given that CMTM8 has been known to be involved in several signalling pathways that 
mediate cell proliferation and differentiation in other systems, there is no information of the 
role of CMTM8 during BMSC growth and cell fate determination. 
 
3.1.7 Potassium Sodium–Activated Channel Subfamily T Member 2 (KCNT2) 
KCNT2, also known as SLO2.1 or SLICK, is a Na+-activated K+ channel found to be expressed 
in the nervous system, heart, kidney and brain [246-248]. However, little is known about the 
function of KCNT2, particularly during BMSC growth and cell fate determination. 
 
3.1.8 Cytochrome P450 Family 26 Subfamily B Member 1 (CYP26B1) 
CYP26B1 is an enzyme responsible in the degradation of excess intracellular retinoic acid 
(RA). Mutations in CYP26B1 gene leads to severe skeletal anomalies such as joint synostosis, 
calvaria bone hypoplasia, advanced ageing of bone and angulated femora [249]. Vitamin A 
(retinol) has been known to be toxic to bone tissue as excessive dietary intake of vitamin A can 
result in reduced bone formation [219-221]. Therefore, CYP26B1 has known functions in bone 
biology. 
 
3.1.9 Rationale of selecting HOPX and CMTM8 
Two novel genes that were differentially expressed and appeared to have important roles in 
BMSC biology were HOPX and CMTM8. HOPX displayed the highest overall fold change and 
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P-value. Our previous work has shown relationships between TWIST-1/EZH2 and 
EZH2/HOPX during BMSC cell fate determination [224]. Furthermore, it has been reported 
that HOPX plays a dual-role in maintaining the balance of undifferentiated and differentiated 
cells [222, 250]. HOPX can promote or inhibit proliferation and differentiation of cells at 
different stages. However, the function of HOPX in BMSC growth and cell fate determination 
is novel. Therefore, HOPX was selected as one of the focus of this study. 
 
Out of the top 8 genes that were assessed C-ROS-1, ITGA5, COL4A4, CYP26B1 were excluded 
from this project due the reported roles in BSMC or bone biology. Therefore, out of the 8 only 
HOPX, SCARA3, CMTM8 and KCNT2 are presented as novel TWIST-1 targets with potential 
roles in BMSC proliferation and differentiation and were potential candidates for further 
exploration. However, using the transcription factor binding site predictor tool, no TWIST-1 
binding sites have been identified near SCARA3 promoter regions, while CMTM8 contains 
three putative TWIST-1 binding sites in the intron 1; and HOPX contains EZH2 binding sites 
in its promoter regions. Therefore, due to time constraints HOPX and CMTM8 have been 
selected as the focus of Chapter 4 and 5, respectively, as KCNT2 had the lowest fold change 









3.2.1 Identification of TWIST-1 target genes during growth and osteogenic conditions 
To identify novel TWIST-1 gene targets involved in BMSC proliferation and osteogenic 
differentiation, a microarray analysis was previously performed in our laboratory comparing 
the gene expression profile of BMSC, which express either endogenous or enforced expression 
of TWIST-1 during growth or undergoing osteogenic differentiation. Figure 3.1 displays the 
volcano plot plotting the fold change (log) of gene expression against the P-value (-log10), 
demonstrating the differentially expressed genes in vector only BMSC cultured under either 
growth condition (Control) or osteogenic inductive condition (Osteo). It is clear that during 
BMSC osteogenesis, 79 genes were upregulated and 2 genes were downregulated. The two 
downregulated genes were CTSK and CYP26B1, both are known to be involved in bone 
remodelling and bone homeostasis [218-221]. Interestingly, when comparing TWIST-1 
overexpressing BMSC to vector control BMSC during osteogenesis, the 79 genes were 
downregulated, indicating an inverse relationship between TWIST-1 and these genes (Figure 
3.1B). A table was derived from the microarray analysis to show the top 30 genes with highest 
P-value and fold change (Table 3.1), when TWIST-1 is overexpressed during osteogenesis. The 
microarray analysis provides insight into possible downstream targets of TWIST-1 in 
regulation of BMSC growth and osteogenesis. Based on the literature, a few novel candidate 
genes from Table 1 were selected for further functional confirmatory studies, including HOPX 
and CMTM8. Studies on C-ROS-1 in relation to TWIST-1 have been published by our 
laboratory [3].  
 
3.2.2 HOPX expression in BMSC  
HOPX showed the highest expression among the 79 upregulated genes in vector-control BMSC 
during osteogenesis, whilst it was expressed at the lowest level in TWIST-1 overexpressing 
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cells, suggesting that HOPX may play important roles in BMSC growth and osteogenesis. To 
confirm the microarray, HOPX expression was determined in vector control and TWIST-1 
overexpressing BMSC during growth, osteogenic or adipogenic differentiation using real-time 
PCR. At day 21, HOPX gene expression levels were found to be upregulated during BMSC 
osteogenic (Figure 3.2A) and adipogenic (Figure 3.2B) differentiation, compared to growth 
condition in both vector and TWIST-1 overexpressing BMSC. However, HOPX expression was 
downregulated in TWIST-1 overexpressing BMSC compared to vector only BMSC in all 
conditions, showing a negative correlation between TWIST-1 and HOPX in BMSC. 
 
We next examine expression pattern of HOPX during growth, osteogenic and adipogenic 
inductive conditions (Figure 3.2C). Total RNA were collected at day 4, 7, 10, 14 and 21 of 
culture, and HOPX expression was assessed by real-time PCR. HOPX transcripts were 
expressed at low levels during growth conditions and increased gradually at a very low level 
throughout the timepoints assessed. During osteogenesis, HOPX was expressed at low levels 
at day 4 and its expression peaked at day 7 and remained above control levels over time. During 
adipogenesis, HOPX was expressed at low levels at day 4 and its expression gradually 
increased over time. This data validates the microarray analysis and suggests that HOPX is a 
potential factor involved in BMSC differentiation. Further studies of the functional role of 
HOPX in BMSC growth and differentiation are detailed in Chapter 4. 
 
After confirming the expression of HOPX in BMSC, the question arose as to whether HOPX 
is expressed in human cranial bone cells (CBC), committed pre-osteoblasts with a high 
potential to form a mineralized extracellular matrix in vitro [3]. We analysed the expression of 
HOPX in human wild type CBC and in TWIST-1 haploinsufficient CBC derived from patients 









Figure 3.2. HOPX gene expression is upregulated during BMSC differentiation and is 
suppressed in TWIST-1 overexpressing cells. (A) TWIST-1 overexpressing (TWISTOE) and 
vector only BMSC were cultured under Ctrl and Osteo conditions for 21 days. cDNA was 
prepared from RNA harvested from these donors and real-time PCR was performed to measure 
levels of HOPX relative to β-actin. (B) HOPX expression was measured for TWISTOE and 
Vector BMSC cultured under Ctrl and Adipo condition as described above. (C) BMSC were 
cultured under growth (Ctrl), osteogenic (Osteo) and adipogenic (Adipo) inducing conditions. 
cDNA was prepared from RNA harvested at day 4, 7, 10, 14 and 21. Real-time PCR was used 
to measure levels of HOPX expression relative to β-actin. Graphs represent mean ± S.E.M, 
One-way ANOVA p<0.05(*), n=3 donors. (D) Human CBC from 1 normal and 2 SCS patients 
were cultured under Ctrl and Osteo conditions for 21 days. cDNA was prepared from RNA 
harvested from these donors and real-time PCR was performed to measure levels of HOPX 











decreased cell proliferation and increased osteogenesis. In the present study, CBC from un-
affected donors and SCS patients were cultured under growth or osteogenic conditions. Total 
RNA was assessed by real-time PCR. Due to the low number of donors, only CBC from one 
un-affected and two SCS donors were used. Low levels of HOPX gene transcripts were 
observed in CBC with wild type levels of TWIST-1 when cultured under growth or osteogenic 
inductive conditions (Figure 3.2D). Interestingly, SCS derived CBC exhibited increased HOPX 
gene expression levels during osteogenesis (Figure 3.2D). Thus, when the level of TWIST-1 is 
reduced there is an increase in HOPX expression. This data supports the notion of a negative 
correlation between TWIST-1 and HOPX in CBC. However, lower levels of HOPX transcripts 
were observed in normal CBC when cultured under osteogenic inductive conditions, in 
comparison to normal growth conditions, which contradict the findings from Figure 3.2A and 
3.2B. This could be due to the fact that CBC are more committed pre-osteoblast. In addition to 
this, the osteogenic inductive media used contains dexamethaxone, which could also induce 
adipogenic differentiation of BMSC. Unlike BMSC, CBC do not undergo adipogenesis. 
 
3.2.3 Regulation of HOPX by TWIST-1 
TWIST-1 is known to regulate biological processes through binding to the E-box (CANNTG) 
on the promoter of target genes or by homo- or hetero-dimerization with other protein 
molecules, leading to activation or repression of transcription or protein functions [172, 251, 
252]. To investigate whether TWIST-1 binds directly to the promoter of HOPX, in silico 
analyses were performed using the transcription factor binding site predictor, ‘Gene 
Transcription Regulation Database’ [253] and three putative TWIST-1 binding sites were 
found from 13,000kb to 16,500kb away from the 3’ end of HOPX but not at the 5’ end promoter 
region of HOPX (Figure 3.3). However, analyses did show the presence of binding sites for 


























Figure 3.3. Schematic diagram of in silico analysis showing putative binding sites of TWIST-













Figure 3.4. Schematic diagram of in silico analysis showing putative binding sites of EZH2 on 
the HOPX gene. S1, S2 and S3 indicate sites where ChIP analysis of EZH2 binding was 
















‘Eukaryotic Promoter Database, SIB’ (Figure 3.4). EZH2 is a target of TWIST-1, thus the 
presence of putative EZH2 binding sites on the HOPX promoter suggests that TWIST-1 may 
regulate the expression of HOPX through the modulation of EZH2. EZH2 is a H3K27 
methytransferase induced by TWIST-1 in BMSC and inhibits osteogenic differentiation and 
cellular senescence but increases adipogenesis [2, 196]. Therefore, it is possible that regulation 
of HOPX expression by TWIST-1 is through its interaction with EZH2. TWIST-1 positively 
regulates EZH2, which in turn binds to the promoter region of HOPX and negatively regulates 
its expression. ChIP analysis was subsequently employed to assess genomic DNA isolated 
from human BMSC under growth, osteogenic and adipogenic inducing conditions (Figure 3.5). 
ChIP analysis showed direct binding of EZH2 to one of these putative binding regions (S3) 
during growth conditions (Figure 3.5A-C), less enrichment of EZH2 was observed on all sites 
(S1, S2 and S3) during osteogenic inducing conditions (Figure 3.5D), and no enrichment of 
EZH2 was observed during adipogenic inducing conditions (Figure 3.5E). Decreased levels of 
HOPX was observed in EZH2 overexpressing BMSC when compared to vector only BMSC 
(Figure 3.5F), suggesting that HOPX expression is directly regulated by EZH2. 
 
3.2.4 CMTM8 expression in BMSC  
CMTM8 showed a fold change of -1.25 (log) and a P-value of 4.96 (-log10) in TWIST-1 
overexpressing cells during osteogenesis when compared to vector only cells, suggesting that 
CMTM8 has a role in BMSC growth and osteogenesis. To confirm the microarray, CMTM8 
expression was determined in vector control and TWIST-1 overexpressing BMSC during 
growth, osteogenic or adipogenic differentiation using real-time PCR. At day 21, CMTM8 gene 
expression levels were found to be upregulated during BMSC osteogenic (Figure 3.6A) and 
adipogenic (Figure 3.6B) differentiation compared to growth condition in both and TWIST-1 
overexpressing BMSC. However, CMTM8 expression was downregulated in TWIST-1 
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overexpressing BMSC compared to vector control BMSC in all conditions, showing a negative 
correlation between TWIST-1 and CMTM8 in BMSC. 
 
We next examined the expression pattern of CMTM8 in BMSC during growth, osteogenic and 
adipogenic inductive conditions (Figure 3.6C). Total RNA was collected at day 4, 7, 10, 14 
and 21 of culture, and CMTM8 expression was assessed by real-time PCR. CMTM8 transcripts 
were expressed at low levels during growth condition and increased gradually at a very low 
level throughout the time points assessed. During osteogenesis, CMTM8 was expressed at low 
levels at day 4 followed by fluctuate expression over time and its expression peaked at day 21. 
During adipogenesis, CMTM8 was expressed at low levels at day 4 and its expression gradually 
increased over time. This data validates the microarray analysis and suggests that CMTM8 is 
a potential factor involved in BMSC differentiation. Further studies of the functional role of 
CMTM8 in BMSC growth and differentiation are detailed in Chapter 5. 
 
After confirming the expression of CMTM8 in BMSC, the question arose whether CMTM8 is 
expressed in human CBC. Human CBC from un-affected donors and SCS patients were 
cultured under growth or osteogenic conditions. Total RNA was assessed by real-time PCR. 
Low levels of CMTM8 gene transcripts were observed in normal and SCS patient CBC when 
cultured under growth or osteogenic inductive conditions (Figure 3.6D). However, SCS patient 
CBC exhibited lower expression of CMTM8 when compared to CBC from normal patient. This 
data contradicts the microarray data, which suggests a negative correlation between TWIST-1 












Figure 3.5. ChIP analysis of three putative EZH2 binding sites located on the HOPX promoter 
(site 1 (S1), site 2 (S2) and site 3 (S3)) using control antibody (IgG) or EZH2 antibody. (A-C) 
Fold enrichment was calculated by measuring the levels of enriched genomic DNA compared 
to the input genomic DNA of three independent BMSC donors cultured in growth conditions 
by PCR. Fold enrichment was calculated by measuring the levels of enriched genomic DNA 
compared to the input genomic DNA of two BMSC donors cultured in (D) osteogenic and (E) 
adipogenic inducing conditions by PCR. Graph represents mean ± S.E.M enriched genomic 
DNA of GAPDH (negative control), p14TSS (positive control) and S1, S2 and S3 of HOPX 
promoters. Fold enrichment results for HOPX, S1, S2 and S3 were compared to GAPDH 
(negative control). Graphs represent mean ± S.D., Student’s t-test, p<0.05(*), n=2 donor. (F) 
HOPX expression was measured for EZH2OE and Vector BMSC cultured under growth 
conditions. Real-time PCR was used to measure levels of HOPX expression relative to β-actin. 
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Figure 3.6. CMTM8 gene expression is upregulated during BMSC differentiation and is 
suppressed in TWIST-1 overexpressing cells. (A) TWIST-1 overexpressing (TWISTOE) and 
Vector only BMSC were cultured under Ctrl and Osteo conditions for 21 days. cDNA was 
prepared from RNA harvested from these donors and real-time PCR was performed to measure 
levels of CMTM8 relative to β-actin. (B) CMTM8 expression was measured for TWISTOE and 
Vector BMSC cultured under Ctrl and Adipo condition as described above. (C) BMSC were 
cultured under growth (Ctrl), osteogenic (Osteo) and adipogenic (Adipo) inducing conditions. 
cDNA was prepared from RNA harvested at day 4, 7, 10, 14 and 21. Real-time PCR was used 
to measure levels of CMTM8 expression relative to β-actin, n=3 donors. (D) Human CBC from 
1 normal and 2 SCS patients were cultured under Ctrl and Osteo conditions for 21 days. cDNA 
was prepared from RNA harvested from these donors and real-time PCR was performed to 









3.2.5 Regulation of CMTM8 by TWIST-1 
In silico analyses showed three putative TWIST-1 binding sites in the first intron of CMTM8 
at approximately 9,500kb to 11,000kb 3’ away from the first exon of CMTM8 (Figure 3.7). 
However, ChIP analysis was unsuccessful in showing direct binding of TWIST-1 to these 
putative binding regions (Figure 3.8). Interestingly, the in silico analyses demonstrated the 
presence of multiple putative EZH2 bindings sites along the 5’ promoter region of CMTM8 
gene (Figure 3.9), suggesting EZH2 can directly bind to CMTM8. Unfortunately, ChIP analysis 
failed to showed direct binding of EZH2 to these putative binding regions (Figure 3.10A). 
However, decreased levels of CMTM8 was observed in EZH2 overexpressing BMSC when 








































Figure 3.7. Schematic diagram of in silico analysis showing putative binding sites of TWIST-


















Figure 3.8. ChIP analysis of two putative TWIST-1 E-box binding sites located on the 
CMTM8 intron 1 (site 1 (S1) and site 2 (S2)) using control antibody (IgG) or TWIST-1 
antibody. Fold enrichment was calculated by measuring the levels of enriched genomic DNA 
compared to the input genomic DNA of BMSC cultured in growth conditions by PCR. Fold 
enrichment results for CMTM8, S1 and S2 were compared to GAPDH (negative control). 
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Figure 3.9. Schematic diagram of in silico analysis showing putative binding sites of EZH2 on 
the CMTM8 promoter. S1 and S2 indicate sites where ChIP analysis of EZH2 binding was 


























Figure 3.10. (A) ChIP analysis of two putative EZH2 binding sites located on the CMTM8 
promoter and intron 1 (site 1 (S1) and site 2 (S2)) using control antibody (IgG) or EZH2 
antibody. Fold enrichment was calculated by measuring the levels of enriched genomic DNA 
compared to the input genomic DNA of BMSC cultured in growth conditions by PCR. Fold 
enrichment results for CMTM8, S1 and S2 were compared to GAPDH (negative control). 
Graphs represent mean ± S.E.M, Student’s t-test p<0.05(*), n=2 donors. (B) CMTM8 
expression was measured for EZH2OE and Vector BMSC cultured under growth conditions. 
Real-time PCR was used to measure levels of CMTM8 expression relative to β-actin. Graphs 
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In the present study, two candidate genes HOPX and CMTM8, with high fold change and P-
values were selected for further study to identify any potential roles in human BMSC 
proliferation and differentiation. The HOPX gene was ranked with the highest fold change and 
P-value from the microarray analysis (Table 3.1). Our previous studies have demonstrated an 
association between TWIST-1/EZH2 and EZH2/HOPX in BMSC, where TWIST-1 increased 
EZH2 expression and EZH2 decreased HOPX expression [2, 224]. EZH2 is a histone 
methyltransferase that trimethylates the histone 3 lysine 27 (H3K27me3), which then leads to 
chromatin condensation and gene repression [225]. In BMSC, TWIST-1 and EZH2 may act in 
association to inhibit HOPX expression to shutdown osteogenesis and cellular senescence, 
while allowing adipogenesis to occur [2, 196], suggesting that HOPX may play an important 
role during BMSC growth and differentiation. Microarray results were validated with real-time 
PCR, confirming an increased expression level of HOPX during both BMSC osteogenic and 
adipogenic differentiation and downregulation in the presence of enforced TWIST-1 
expression. In addition, our preliminary results found that BMSC expressed low level of HOPX 
during growth conditions, while HOPX expression levels increased dramatically during 
osteogenic and adipogenic differentiation, suggesting that HOPX is involved in BMSC 
differentiation.  
 
SCS is autosomal-dominantly inherited and is induced by loss-of-function mutations of 
TWIST-1 [192]. TWIST-1 haploinsufficient mutation in CBC results in decreased cell 
proliferation and increased osteogenesis, leading to premature bone plate fusion in the 
developing skull (craniosynostosis). To begin to determine if HOPX plays a role in CBC 
osteogenic differentiation, HOPX gene expression was assessed in the CBC from un-affected 
human patient and SCS patients. Our data did not show an increase in HOPX transcript levels 
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during CBC osteogenic differentiation. However, a robust increase in HOPX transcript levels 
were observed in CBC from SCS patients. This suggests a negative correlation between 
TWIST-1 and HOPX and that HOPX may be involved in BMSC and CBC differentiation. 
  
TWIST-1 is known to regulate biological processes through binding to the E-box (CANNTG) 
on the promoter of target genes or by homo- or hetero-dimerization with other protein 
molecules, leading to activation or repression of transcription or protein functions [172, 251, 
252]. To determine whether HOPX expression was directly regulated by TWIST-1, an in silico 
study was performed to identify putative E-box binding sites on the 5’ region of the HOPX 
promoter. No E-box binding sites were identified however, the analysis did show the presence 
of putative EZH2 binding sites. ChIP analysis was subsequently employed to assess genomic 
DNA isolated from human BMSC cultured under osteogenic inducing conditions. ChIP 
analysis showed direct binding of EZH2 to these putative binding regions, suggesting that 
HOPX expression is directly regulated by EZH2. Furthermore, a negative correlation was 
observed between EZH2 and HOPX expression. Thus, regulation of HOPX by TWIST-1 is 
likely mediated indirectly via the modulation of EZH2.  
 
Another differentially expressed gene of interest with no known function in human BMSC was  
CMTM8. Previous studies have shown that CMTM8 plays an important role in cancer cell 
growth, survival and migration via regulation of EGFR and c-Met signalling pathway [241, 
245]. EGFR and c-Met signalling have been known as crucial molecular mechanisms for cell 
expansion and motility. Both EGFR and c-Met belong to the tyrosine kinase receptor group. 
Ablation of EGFR pathway could lead to a decrease in cell proliferation and increased 
apoptosis [241]. Conversely, induced EGFR following EGF stimulation results in increased 
cell proliferation [241]. It has been shown that CMTM8 regulates EMT state of cells via c-Met 
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[245]. As a potential tumour suppressor gene, CMTM8 was thought to suppress cell metastasis 
by inhibiting c-Met signalling and the EMT changes.  
 
Data from the microarray analysis was validated with real-time PCR, confirming increased 
expression levels of CMTM8 during both BMSC osteogenic and adipogenic differentiation and 
downregulation in the presence of enforced TWIST-1 expression. In addition, our preliminary 
results found that BMSC expressed low level of CMTM8 during growth conditions, while 
CMTM8 expression levels increased gradually across time during osteogenic and adipogenic 
differentiation, suggesting that CMTM8 is involved in BMSC differentiation. It is interesting 
to note that CMTM8 expression levels were elevated at day 21 of BMSC osteogenic 
differentiation, suggesting a potential role of CMTM8 during late osteogenic differentiation.  
CMTM8 gene expression was also assessed in CBC from SCS and from un-affected donors. 
Consistent with the BMSC data, CMTM8 transcript levels were found to be upregulated during 
CBC osteogenic differentiation. However, in SCS patients, CMTM8 transcript levels appeared 
to be significantly lower compared to that of normal control CBC. Overall, these preliminary 
studies suggest a negative correlation between TWIST-1 and CMTM8 only in BMSC and that 
CMTM8 may be involved in BMSC differentiation. 
 
To determine what binding sites were present on the 5’region of the CMTM8 promoter, an in 
silico study was performed to identify putative E-box and EZH2 binding sites. Three putative 
TWIST-1 binding sites and multiple putative EZH2 binding sites were identified. However, 
ChIP analysis did not show binding of TWIST-1 or EZH2 on the promoter region of CMTM8, 
although a negative correlation between EZH2 and CMTM8 expression was observed. The 
negative correlation between TWIST-1, EZH2 and CMTM8 expression in BMSC may just be a 
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coincidence or CMTM8 expression is mediated indirectly by TWIST-1 via the modulation of 
other molecules.  
 
It is important to note that assessment of transcript levels of HOPX or CMTM8 showed 
insignificant donor-donor variability. In addition, expression levels of HOPX or CMTM8 were 
comparable between BMSC and CBC. The question arises as to whether the increased 
expressions of HOPX or CMTM8 overtime during differentiation inductive conditions is due 
to tissue culture artefact. To address this question, confirmatory experiments can be performed 
by replacing additives in our regular inductive media with differentiation inductive factor such 






Chapter 4: HOPX Counteracts TWIST-1/ 
EZH2 Regulation of BMSC Cell Fate 







The homeodomain-only protein homeobox gene (HOPX), encodes HOPX which is the smallest 
known member of the homeodomain-containing protein family with the size of 8kDa [222, 
250]. The human HOPX gene is located on chromosome 4 (4q11eq12) and contains seven 
exons, with only exons 1, 5, 6, and 7 contributing to transcription of the five mRNA transcript 
variants (National Center for Biotechnology Information; NCBI, data). Variant 1 encodes for 
a 91 amino acids protein (isoform a); Variants 2, 3 and 4 encode for a 73 amino acids protein 
(isoform b); and Variant 5 encodes for the longest isoform c protein with 112 amino acids 
(NCBI data) (Figure 4.1) [254]. In contrast, the mouse Hopx gene is located on chromosome 5 
and encodes for three 73 amino acids variants (NCBI data). Human and murine HOPX 
sequences share 92% identity at the amino acid level. Unlike other typical homeobox proteins 
that bind to DNA and regulate their expression, HOPX does not bind directly to DNA. It has 
previously been described that HOPX binds to different protein partners and act as a co-factor 
to regulate molecular mechanisms by recruiting transcription factors to gene promoters [222, 
250, 255]. Studies have demonstrated an association between TWIST-1/Enhancer of zeste 
homolog 2 (EZH2) and EZH2/HOPX in BMSC, where TWIST-1 increases EZH2 expression 
and EZH2 decreases HOPX expression [2, 224]. EZH2 is a histone methyltransferase that 
trimethylates the histone 3 lysine 27 (H3K27me3), which then leads to chromatin condensation 
and gene repression [225]. In BMSC, TWIST-1 and EZH2 may act in association to inhibit 
HOPX expression to shutdown osteogenesis and cellular senescence, while allowing 
adipogenesis to occur [2, 196]. This suggests that HOPX may play an important role during 
BMSC growth and differentiation.  
 
BMP and WNT signalling pathways have been reported to be integrated by HOPX during cell 
fate commitment of cardiomyoblasts [223]. It was shown in vivo using murine embryos that 
111 
 
Hopx physically interacts with activated Smad complex (Smad4 and phosphorylated 
Smad1/5/8) and represses Wnt responsive genes upon presence of Bmp4 [223]. Other studies 
have also identified HOPX-interacting partner such as histone deacetylase 2 (HDAC2), serum 
response factor (SRF) and enhancer of polycomb homolog 1 (EPC1) that is involved in cell 
proliferation and differentiation (Figure 4.2) [222, 250, 255-258]. Moreover, HOPX is also 
thought to act as a tumour suppressor gene, where its expression is suppressed in malignant 
tissues including; head and neck, breast, lung, oesophagus, colon/rectum, stomach, placenta, 
pancreas and uterus cancers [254, 258-267]. Hopx expression has been identified in many 
tissues including heart, liver, lung, brain, intestine and spleen, and is a critical protein in cardiac 
development [222, 250]. Various studies with conflicting data have reported that HOPX is a 
critical factor in maintaining the balance between cellular proliferation and differentiation by 
promoting or inhibiting different molecular pathways [222, 250, 268, 269]. Currently, no 
known function of HOPX has been identified during BMSC growth or differentiation. Using 
loss-of-function and gain-of-function studies, we have demonstrated that HOPX is a promoter 














Figure 4.1. Gene structures of human HOPX. Seven exons (E1-E7) of the human HOPX 
gene are represented with different colours. Introns are displayed as black lines between each 
exon. Five different spliced variants (HOPX-V1 to HOPX-V5) give rise to three isoforms: 











































Figure 4.2. Model illustrating interacting partners of HOPX. Direct interaction between 
HOPX and HDAC2 induces deacetylation of GATA4 and supresses gene transcription (left); 
Direct interaction between HOPX and SRF suppresses SRF transcriptional activity and 
modulation of growth related genes (middle); Direct interaction between HOPX and EPC1 














4.2.1 Generation of HOPX overexpressing BMSC 
Human HOPX overexpression vector constructs were generated to study the role of HOPX in 
the growth and differentiation of BMSC. The full length HOPX coding region (1.9 kb) was 
ligated into pRUF-IRES-GFP vector (6kb). Correct ligation and orientation of HOPX gene 
fragment was determined by Xho1 and BamH1 restriction digestion (Figure 4.3). pRUF-IRES-
GFP-HOPX and pRUF-IRES-GFP were transformed into bacteria cultures, then purified DNA 
was sequenced to confirm the absence of mutations and correct orientation. Retroviral 
transduction was used to overexpress pRUF-IRES-GFP-HOPX and pRUF-IRES-GFP in 
BMSC. The level of transfection and infection efficiency was visualized by GFP expression 
using a fluorescent microscope (Figure 4.4). High GFP-positive BMSC were sorted using 
fluorescence activated cell sorting (FACS) (Figure 4.5) with transfection efficiency ranging 
from 12% - 40% for vector only BMSC and 16% - 30% for HOPX overexpressing BMSC and 
then cultured in normal growth media. The flow cytometry density plot (Figure 4.5) showed 
forward versus side scatter (FSC vs SSC) gating used to identify GFP positive cells based on 
size and granularity. No obvious changes in cell size distribution were observed between vector 
only and HOPX overexpressing cells. Sanger sequencing analysis confirmed correct sequences 
of HOPX inserts, as shown by pairwise alignment of the vector construct sequences to the 
consensus sequence from the NCBI website (Figure 4.6A). Purity of the vector constructs was 
assessed by visualizing the sequencing peaks using Chromas software (Technelysium Pty Ltd, 
South Brisbane, Australia) (Figure 4.6B).  
 
4.2.2 Evaluation of HOPX overexpressing BMSC 
Western blot analysis was performed to assess HOPX overexpression in four vector only 













Figure 4.3. Restriction digest analysis on pRUF-IRES-GFP-HOPX vector ligation. 1% 
agarose gel electrophoresis separation of pRUF-IRES-GFP-HOPX vector DNA digested with 
Xho1 and BamH1 restriction enzymes. Lane 1 represents 1kb Plus DNA ladder. Lane 2, 3 and 























Figure 4.4. Enforced expression of pRUF-IRES-GFP-HOPX expressing cells. A 
representative micrograph showing GFP positive transfected HEK293T cells (Scale bar = 

































Figure 4.5. GFP positive BMSC selected with FACS. Representative flow cytometry density 
plot analyses showing GFP positive cell population (vector only & HOPX overexpressing 




























































Figure 4.6. Confirmation of correct HOPX sequence insert in the pRUF-IRES-GFP 
vector. (A) Sanger sequencing was performed on pRUF-IRES-GFP-HOPX vector using the 
Pairwise Sequence Alignment Tool. (B) The purity of the vector sequence was confirmed by 








CMTM8 vector construct sequence 













Figure 4.7. Western blot analysis to confirm expression of HOPX by pRUF-IRES-GFP-
HOPX vector infected BMSC. Protein expression of HOPX was assessed by Western blot 
analysis using two different antibodies against HOPX: anti-HOPX-1 & anti-HOPX-2. Western 

























































































no HOPX protein expression was detected using two different antibodies (over the 
concentrations of 1:200 and 1:1000) against HOPX: anti-HOPX-1 and anti-HOPX-2 (HOPX 
expected molecular weight is 8kDa), in comparison to the loading control, Tubulin. 
Nevertheless, when expression of HOPX transcript was determine in cells using real-time PCR, 
there was differential expression of HOPX in vector only BMSC compared to HOPX 
overexpressing BMSC. Interestingly, expression levels of HOPX transcripts in three pRUF-
IRES-GFP-HOPX human BMSC donors were found to be approximately 100 fold higher 
compared with vector only control pRUF-IRES-GFP BMSC (Figure 4.8A). 
 
4.2.3 HOPX is a promoter of BMSC proliferation 
In order to determine if HOPX regulates BMSC growth, cell proliferation was assessed in 
HOPX overexpressing and vector control BMSC by analysis of BrdU incorporation. The data 
showed a significant increase in the proliferation rates of BMSC following enforced expression 
of HOPX (Figure 4.8B). To further confirm that HOPX regulates BMSC proliferation, HOPX 
expression was knocked down using two independent siRNA molecules targeting HOPX 
transcripts (Figure 4.8C). Knockdown of HOPX in BMSC resulted in a significant decreased 
in proliferation rates (Figure 4.8D).  These data suggest that HOPX is a positive regulator of 
BMSC proliferation. 
 
4.2.4 HOPX is an inhibitor of BMSC adipogenesis 
To establish the role of HOPX during human BMSC adipogenic differentiation in vitro, HOPX 
overexpressing retroviral constructs or empty vector alone infected BMSC were cultured in 
control growth or adipogenic inductive media (Figure 4.9A). Overexpression of HOPX resulted 
in decreased Nile red-positive (Figure 4.9B, Ci, Cii) and Oil-red O positive (Figure 4.9Ciii,Civ) 











Figure 4.8. HOPX promotes BMSC proliferation. (A) cDNA was prepared from RNA 
harvested from HOPX overexpressing (HOPXOE) and vector only BMSC. Real-time PCR was 
used to measure levels of HOPX relative to β-actin, n=5 donors. (B) HOPXOE and vector 
BMSC were incubated for 4 days and BrdU assay was performed, n=4 donors. (C) cDNA was 
prepared from RNA harvested from BMSC treated with scramble siRNA (siScram) or siRNA 
targeting HOPX (siHOPX1 & siHOPX2). Real-time PCR was used to measure levels of HOPX 
relative to β-actin, n=4 donors. (D) siScram, siHOPX1 (n=4 donors) and siHOPX2 (n=3 
donors) BMSC were incubated for 6 days and BrdU assays performed. Graphs represent mean 






























































































































Figure 4.9. Enforced expression of HOPX inhibits BMSC adipogenesis. (A) HOPX 
overexpressing (HOPXOE) and vector only BMSC were cultured in either control (Ctrl) or 
adipogenic (Adipo) inducing conditions for 3 weeks and HOPX expression levels were 
determined relative to β-actin using real-time PCR, n=6 donors. Graphs represent mean ± 
S.E.M, One-way ANOVA p<0.05(*). (B) Lipid-containing HOPXOE and vector only BMSC 
stained with Nile red and DAPI were quantified, n=3 donors. Graph represents mean ± S.E.M, 
Student’s t-test p<0.05(*). (C) Representative images of lipid-containing (I) Vector BMSC and 
(II) HOPXOE BMSC stained with Nile red and DAPI. (C) Representative images of lipid-
containing (III) Vector BMSC and (IV) HOPXOE BMSC stained with Oil Red O. Total RNA 
was harvested at 7-14 days (n=6 donors) post induction from HOPXOE and Vector BMSC. 
Real-time PCR was performed to measure levels of (D) HOPX, (E) C/EBPα and (F) ADIPSIN 























































































































from multiple BMSC lines showed a significant reduction of lipid-containing adipocytes in 
HOPX overexpressing BMSC cultured compared with vector controls (Figure 4.9C). Changes 
in adipogenic gene transcription patterns were assessed using real-time PCR, following 
adipogenic induction. The data demonstrated that HOPX overexpressing BMSC (Figure 4.9D) 
exhibited decreased levels of key adipogenic marker genes, C/EBPα (Figure 4.9E) and 
ADIPSIN (Figure 4.9F) expression levels when compared to vector only BMSC, under 
adipogenic inductive conditions.  
 
To verify these findings, siRNA-mediated knockdown using two independent siRNA targeting 
HOPX transcripts in BMSC was performed (Figure 4.10A). The data showed a dramatic 
increase in Nile red-positive (Figure 4.10B, C, D) and Oil-red-O positive lipid forming 
adipocytes (Figure 4.10E) following adipogenic induction, compared with BMSC treated with 
control scramble siRNA (Figure 4.10B-E). Furthermore, siRNA knockdown of HOPX resulted 
in an increase in C/EBPα (Figure 4.10F) and ADIPSIN (Figure 4.10G) transcript expression 
compared with scramble siRNA-treated cells following adipogenic induction. Future 
experiments could examine other early adipogenic marker genes such as PPARγ2, and late 
adipogenic markers such as ADIPONECTIN and LEPTIN. Overall, these studies demonstrate 
that HOPX is a repressor of adipogenesis. 
 
To determine the function of HOPX in BMSC osteogenic differentiation, HOPX 
overexpressing BMSC or vector control BMSC were cultured under control or osteogenic 
inductive media (Figure 4.11A). Measurements of extracellular calcium levels found no 
difference between HOPX overexpressing BMSC and vector control BMSC (Figure 4.11B). 
Similarly, mineralized deposits were stained with Alizarin Red after three weeks under 









Figure 4.10. Suppression of HOPX expression promotes BMSC adipogenesis. (A) siScram, 
siHOPX1 and siHOPX2 BMSC were cultured in adipogenic (Adipo) inductive conditions for 
3 weeks and HOPX expression levels were determined relative to β-actin using real-time PCR, 
n=8 donors. (B) Lipid-containing cells treated with siScram or siHOPX1 were stained with 
Nile red and DAPI, then quantified, n=3 donors. Graph represents mean ± S.E.M, Student’s t-
test p<0.05(*). (C) Lipid-containing cells treated with siScram or siHOPX2 were stained with 
Nile red and DAPI, then quantified, n=4 donors. (D) Representative images of lipid-containing 
siScram, siHOPX1 and siHOPX2 BMSC stained with Nile red and DAPI. (E) Representative 
images of lipid-containing siScram, siHOPX1 and siHOPX2 BMSC stained with Oil Red O. 
Total RNA was harvested at 7-14 days post induction from BMSC treated with siScram or 
siHOPX, n=4 donors. Real-time PCR was performed to measure levels of (F) C/EBPα, (G) 
ADIPSIN relative to β-actin. Graphs represent mean ± S.E.M, Student’s t-test p<0.05(*). (Scale 

























































































































Figure 4.11. Enforced expression of HOPX does not affect BMSC osteogenic 
differentiation. (A) HOPX overexpressing (HOPXOE) and vector only (Vector) BMSC were 
cultured in either control (Ctrl) or osteogenic inductive (Osteo) conditions and HOPX 
expression levels were determined relative to β-actin using real-time PCR, n=6 donors. Graphs 
represent mean ± S.E.M, One-way ANOVA p<0.05(*). (B) Extracellular calcium levels were 
quantitated and normalized to total DNA content per well, n=3 donors. Graph represents mean 
± S.E.M, Student’s t-test p<0.05(*). (C) Vector control and HOPXOE BMSC stained with 
Alizarin red. Total RNA was harvested at 7-14 days post induction (n=6 donors) from Vector 
and HOPXOE BMSC. Real-time PCR was used to measure levels of (D) HOPX, (E) RUNX2, 
(F) OPN relative to β-actin. Graphs represent mean ± S.E.M, Student’s t-test p<0.05(*). (Scale 

















































































































these findings, HOPX overexpressing BMSC (Figure 4.11D) showed no significant difference 
in the transcript levels of the osteogenic master regulator, RUNX2 (Figure 4.11E) and the 
mature bone marker, OPN (Figure 4.11F), compared to the vector control cells.  
 
Confirmatory studies employing siRNA-mediated knockdown of HOPX in BMSC (Figure 
4.12A) found no significant differences in the levels of Alizarin positive mineral and 
extracellular calcium levels compared with scramble siRNA-treated BMSC (Figure 4.12B-E). 
These findings demonstrate that HOPX has no direct effect on the osteogenic capacity of 
BMSC. 
 
4.2.5 HOPX inhibits BMSC adipogenic differentiation via suppression of genes 
associated with adipogenesis  
Parallel studies were performed to determine the potential mechanisms of HOPX action during 
BMSC adipogenic differentiation. Total RNA was collected from HOPX overexpressing and 
vector control BMSC cultured for two weeks under adipogenic inductive conditions, then 
processed for RNA-sequencing to identify novel HOPX-regulated genes during BMSC 
adipogenic commitment. Due to the variable gene expression patterns between different 
individuals (n=3 donors), the P-value significance was excluded as a criteria to select for 
differentially expressed genes (DE). Therefore, the top 50 DE (Figure 4.13) were selected 
based on the fold change (a log fold change (logFC) >= |1| or >=|-1|). To validate the RNA-
sequencing results, confirmatory real-time PCR was performed on a number of genes that 
appeared to change expression in HOPX overexpressing BMSC under adipogenic conditions. 
HOPX transcripts were found to be elevated in HOPX overexpressing BMSC compared to 
vector control BMSC and which were relatively higher during adipogenesis compared to 
normal growth condition for the respective population. From the transcriptional expression 
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heat map (Figure 4.13), we observed a number of genes that were upregulated during 
adipogenesis but suppressed in HOPX overexpressing cells. Table 4.1 indicates the functional 
role of these genes following Gene Ontology (GO) enrichment analysis, with 188 genes 
involved in EMT, 185 genes in adipogenesis and 127 genes in fatty acid metabolism. Table 4.2 
detailed the functions of genes selected from the heatmap that are involved in fat/lipid 
metabolism or adipogenesis. The differential gene expression levels of representative 
upregulated genes, HOPX, ADIPOQ, AOC3, FABP4, G0S2, GPD1, PLIN1 and PLIN4 were 
confirmed by real-time PCR (Figure 4.14A-H). Other genes were found to be downregulated 
during adipogenesis and promoted by HOPX expression such as CNN1 (Figure 4.14I). The 













Figure 4.12. Suppression of HOPX does not affect BMSC osteogenic differentiation. (A) 
siScram, siHOPX1 and siHOPX2 BMSC were incubated in control (Ctrl) or osteogenic 
inductive (Osteo) conditions for 3 weeks, and HOPX expression levels were determined 
relative to β-actin using real-time PCR, n=8 donors. Extracellular calcium levels were 
quantitated in siScram, (B) siHOPX1 and (C) siHOPX2 BMSC and normalized to total DNA 
content per well, n=4 donors. (D-E) siScram, siHOPX1 and siHOPX2 BMSC were stained 
with Alizarin red. Representative of one donor is shown. Graphs represent mean ± S.E.M, 
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Figure 4.13. Potential mechanisms of HOPX regulation of BMSC adipogenesis. HOPX 
overexpressing (HOPXOE) and vector only BMSC were cultured in either control (Ctrl) or 
adipogenic inductive (Adipo) conditions for 2 weeks. Total RNA was collected and assessed 
by RNA-seq analysis, n=3 donors per condition. The heat map depicts the top 50 differentially 



















Figure 4.14. Confirmation of RNA-seq data. Real-time PCR was performed to measure 
levels of (A) HOPX, (B) ADIPOQ, (C) AOC3, (D) FABP4, (E) G0S2, (F) GPD1, (G) PLIN1, 
(H) PLIN4, (I) CNN1 relative to β-actin. Graphs represent mean ± S.E.M, One-way ANOVA 






















Table 4.1. Gene ontology annotations of differentially expressed genes from RNA-seq analysis 








The bHLH transcription factor, TWIST-1 is an inhibitor of BMSC osteogenesis, whilst 
promoting adipogenesis and proliferation of BMSC [1]. The H3K27 methytransferase, EZH2, 
was found to be induced by TWIST-1 in BMSC and inhibits osteogenesis and cellular 
senescence but increases adipogenesis [2, 196]. Following studies of global ChIPseq analyses, 
EZH2 was found to regulate HOPX expression during BMSC osteogenic and adipogenic 
differentiation [224], suggesting a potential role of HOPX in regulating BMSC lineage 
specification. 
 
HOPX is the smallest known member of the homeodomain-only containing protein family 
[222, 250]. Most homeodomains are 60 amino acids, while HOPX is only 73 amino acids 
composed of three α-helices arranged around a hydrophobic core. Protein structural studies 
have demonstrated that HOPX is unable to bind to DNA, suggesting that HOPX functions 
through protein-protein interaction with partner proteins. A number of HOPX partner proteins 
have been identified, including Hdac1, Hdac2, MTA 1/2/3, MBD3 and Rbbp4/7 [223]. HOPX 
has been shown to be a key factor in cardiac development, where it regulates cell proliferation 
and differentiation at different stages during murine cardiac development [222, 250]. The dual 
role of Hopx in the developing heart correlates with its action downstream of the Nkx2.5, where 
it controls myocyte proliferation and expansion through regulation of the serum response 
factors [271-273] and Hdac recruitment [222, 250, 256, 274]. Furthermore, Hopx and Hdac2 
physically interact to mediate Gata4 deacetylation, and therefore co-ordinately regulate 
embryonic cardiomyocytes proliferation [255]. HOPX is widely expressed in diverse tissues, 
where it is critically involved in the regulation of proliferation and differentiation. BMSC 
express low level of HOPX when cultured in vitro yet expression is increased during 
osteogenesis and adipogenesis [224]. Studies of homozygous mutations of the Hopx gene (loss 
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of function mutations) in mouse showed partial penetrant embryonic lethality due to heart 
deformation during embryo development. However, those that survived display no gross 
deformities. Hopx heterozygous mutated mice are viable and comparable to wild type mice 
[222, 250]. This suggests that Hopx is critical for cardiac development. On the other hand, the 
incomplete penetrance of HOPX mutation indicates that there are other compensatory 
mechanisms that rescues part of the phenotype. However, no bone or fat-associated phenotypes 
have been observed in Hopx knockout studies. Our in vitro studies suggest that HOPX mediates 
postnatal BMSC proliferation and lineage determination.  
 
In the present study, human BMSC were found to have low HOPX expression during normal 
growth cultures, coinciding with our previous studies [224]. However, when BMSC are 
induced under osteogenic or adipogenic conditions, HOPX expression was dramatically 
upregulated. HOPX expression showed a negative correlation with TWIST-1 expression, 
however we found no evidence of TWIST-1 directly regulating the expression of HOPX. Our 
previous studies have shown that TWIST-1 can increase the lifespan and the proliferation of 
human BMSC in vitro as well as promote stemness by maintaining a more immature stem cell 
phenotype [1, 46, 54, 173]. Moreover, TWIST-1 was found to induce expression and 
recruitment of the epigenetic regulator, EZH2, to the Ink4A locus to increase the lifespan and 
prevent cellular senescence of BMSC [2]. Given that EZH2 regulates HOPX expression [224], 
it is likely that the affects of TWIST-1 on HOPX are mediated via EZH2 activity.   
 
Functional studies using siRNA-mediated knockdown of HOPX did not affect BMSC 
osteogenesis but did alter the cellular proliferation and adipogenic potential of the cells. Our 
studies have shown that siRNA-mediated HOPX knockdown in human BMSC decreased 
proliferation and increased adipogenic potential of these cells. This was demonstrated by an 
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increase of lipid formation and increased expression of early adipogenic marker C/EBPα and 
mature marker ADIPSIN, when compared to the siRNA scramble controls. Conversely, these 
results were confirmed by enforced expression of HOPX in BMSC using retroviral 
transduction. HOPX overexpressing BMSC demonstrated decreased lipid formation and 
decreased expression of adipogenic associated markers. These findings suggest that HOPX is 
a novel molecular inhibitor of BMSC adipogenesis and may have implications in the regulation 
of fat metabolism. It also indicates that HOPX could act in a negative feedback loop to counter 
balance the levels of TWIST-1. Therefore, HOPX may function to inhibit the effects TWIST-1 
on BMSC growth and differentiation [1, 2]. In fact, in our study, knockdown of HOPX had a 
greater effect on BMSC differentiation than overexpression. Furthermore, HOPX 
overexpression or knockdown studies failed to demonstrate any effects on the osteogenic 
potential of BMSC. This is likely because HOPX acts by inhibiting adipogenesis via 
suppression of C/EBPα by potentially binding to adipogenic suppressor proteins that act on its 
promoter as a complex, therefore, the differentiation pathway needs to be activated for RUNX2 
to be expressed and then HOPX can promote its recruitment. Given that both TWIST-1 and 
EZH2 inhibit BMSC osteogenic differentiation but allow adipogenesis to proceed [1, 196], 
implicates HOPX as a potential counter balance to regulate BMSC adipogenesis. Our findings 
open up further research into the role of the homeobox family members in BMSC biology and 
their complex interactions with other transcription regulators such as basic HLH factors.  
 
HOPX is known to repress transcription by direct interaction with co-repressors such as 
HDAC2 which consequently inactivate GATA6/WNT7 pathway important in development 
and differentiation [255]. However, conflicting data in the literature demonstrate the duo-
functions of HOPX in promoting and inhibiting proliferation and differentiation at different 
developmental stages, suggesting the importance of HOPX in maintaining the balance between 
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growth and differentiation in various tissues based on in vitro and in vivo systems [222, 250]. 
Our data suggests that in humans, HOPX is likely to play a role in fat metabolism. The 
suppressive effect of HOPX on C/EBPα- and ADIPSIN-mediated transcriptions also explains 
how adipogenesis can be inhibited. Intriguingly, BMSC osteogenesis appeared to be unaffected 
by HOPX, suggesting that the observed HOPX upregulation in osteogenic cultures is probably 
due to similar media supplements that also act to induce adipogenesis.  
 
In bone marrow, the differentiation of MSC into osteoblasts and adipocytes is competitively 
balanced. The commitment of BMSC to the adipogenic lineage may result in increased 
adipocyte formation and decreased osteoblast numbers as observed in age-related bone loss 
[126]. Numerous in vitro experiments performed on BMSC have revealed various factors that 
promote adipocyte formation inhibit osteogenesis, and conversely, many factors that promote 
osteoblast formation inhibit adipogenesis [127, 128]. This occurs through the interaction 
between different signalling pathways such as WNT, BMP, TGF-β, Notch, mTOR [131-133, 
138, 143, 152, 155, 160]. Of major importance is which signalling cues act on HOPX to 
regulate differentiation and stem cell renewal. Previous findings implicate the Bmp/Wnt 
signalling pathways in regulating Hopx family members [223]. Inhibition of Hopx in mouse 
and zebrafish results in disruption of cardiac development and lethality. Hopx is found to be 
expressed in cardiomyoblasts, which interacts physically with activated Smad4 and functions 
to coordinate local Bmp signals to inhibit Wnt pathway, promoting cardiomyogenesis [223]. 
However, little is known about the biological function of HOPX in BMSC during postnatal 
skeletal development and homeostasis.  
 
In order to identify novel HOPX target genes during BMSC adipogenesis, RNA-seq analysis 
was performed on HOPX overexpressing and vector control BMSC cultured under normal 
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growth or adipogenic inductive condition for two weeks. Differentially expressed genes were 
identified between normal growth and adipogenic inductive conditions. Survey of the literature 
identified 188 genes involved in EMT, 185 genes in adipogenesis and 127 genes in fatty acid 
metabolism. To identify possible signalling or molecular pathways involved in HOPX 
signalling, gene ontology (GO) enrichment analysis was performed. A heatmap was 
constructed according to the fold change of gene expression between HOPX overexpressing 
and vector control BMSC cultured under either normal growth or adipogenic conditions. Many 
of the top 50 differentially expressed genes were found to be associated with adipogenesis such 
as ADIPOQ, FABP4, PLIN1 and PLIN4, which generally showed a negative correlation with 
HOPX expression. RNA-seq analysis was validated using real-time PCR, which were found to 
be consistent between different HOPX overexpressing BMSC lines. 
 
Adiponectin (ADIPOQ) is a cytokine secreted in various tissues including BMSC [275]. 
Adiponectin signals through its cell surface receptors adipoR1 (adiponectin receptor 1) and 
adipoR2 (adiponectin receptor 2) and can acts in either endocrine, paracrine or autocrine 
pathway [276, 277]. Upon ligand binding, distinct signalling pathways are initiated across 
tissues including PPARα, mTOR, AMPK [278-280]. On the other hand, the downstream 
signalling of adipoR1 can stimulate oxidative phosphorylation, which subsequently increase 
cell differentiation via suppression of the Wnt inhibitor, sclerostin [281, 282]. Therefore, 
suppression of ADIPOQ by HOPX leads to termination of various pro-adipogenic signalling 
pathways and results in decreased adipogenic potential of BMSC.  
Interestingly, calponin 1 (CNN1) gene expression was increased in HOPX overexpressing 
BMSC (logFC = 1.52) compared to vector control BMSC, suggesting that CNN1 is positively 
regulated by HOPX. CNN1 is an actin binding protein (ABP) that regulates the dynamics of 
actin cytoskeleton by direct/indirect participating in the assembly/disassembly of actin 
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filament, which in turn regulates the cell contraction and movement [283]. CNN1 has been 
shown to play a role in bone homeostasis, where high expression of CNN1 leads to delayed 
bone formation and decreased bone mass [284-286]. Cnn1 is known to interact directly with 
activated or inactivated Smad1/5/8 protein and inhibit Bmp2-Smad1/5/8 signalling [287]. 
Although the function of CNN1 in the regulation of fat metabolism is unknown, it is involved 
in the Bmp/Smad pathway, which is a critical pathway in the crosstalk between BMSC 
osteogenesis and adipogenesis. Therefore, CNN1 is a potential candidate to be further studied 
in BMSC adipogenesis as a possible regulator of TWIST-1/EZH2/HOPX function in cell fate 
determination. 
 
Collectively, our findings suggest that HOPX promotes human BMSC proliferation and 
inhibits adipogenesis, and this is the first ever finding showing the importance of the HOPX in 
human BMSC self-renewal and cell fate determination as a possible counter balance to 
TWIST-1/EZH2 function. This study lays the foundation for further research into the role of 











Chapter 5: CMTM8 Suppresses Osteogenic 
Differentiation of Human BMSC but Promotes 







Using microarray analyses of human BMSC lines grown in culture media and osteogenic 
inducing media, our group recently identified the chemokine-like factor superfamily 8 
(CLKLSF8) gene as a possible downstream target of TWIST-1. Microarray data and real-time 
PCR data have demonstrated that CLKLSF8 expression increases in human BMSC during 
osteogenic differentiation but is suppressed in TWIST-1 overexpressing human BMSC during 
proliferation and osteogenic differentiation in vitro [3]. CLKLSF8, was renamed chemokine-
like factor (CKLF)-like MARVEL transmembrane domain containing 8 (CMTM8) and 
belongs to the chemokine-like factor superfamily (CKLFSF). The CKLFSK consists of nine 
member molecules, CKLF and CMTM1-8 [288, 289]. CMTM1 links the CKLFSF family with 
chemokine molecules and CMTM8 links it with member of the transmembrane 4 super family 
(TM4SF). The characteristics of CMTM2-7 are intermediate between CMTM1 and CMTM8, 
where CMTM2 is structurally more closely related to chemokine molecules while CMTM7 is 
more closely related to transmembrane proteins [289]. The human CMTM8 gene is located on 
chromosome 3 (3p22.3) and is transcribed into two mRNA transcripts variants (NCBI data). 
Variant 1 encodes for a 173 amino acids protein and variants 2 encodes for a 115 amino acids 
protein, lacking exon 2 (NCBI data) (Figure 5.1). In contrast, the mouse Cmtm8 gene is located 
on chromosome 9 and encodes for a 173 amino acids protein (NCBI data). Human and murine 
CMTM8 sequences share 92.5% identity at the amino acid level. CMTM8 protein contains 
four putative transmembrane regions, however due to the lack of the CCG motif, it is not a 
typical tetraspanin [290]. Moreover, it contains a MAL-related protein for vesicle trafficking 
and membrane link domain (MARVEL) domain, suggesting that CMTM8 might play a role in 
membrane protein trafficking and apposition events [291]. The CMTM8 molecules also 
contains two tyrosine-based internalization consensus sequences, YXXØ, which can bind 














Figure 5.1. Gene structures of human CMTM8. Four exons (Exon 1-Exon 4) of the human 
CMTM8 gene are represented with different colours. Introns are displayed as black lines 
between each exon. Two different spliced variants (CMTM8-V1 & CMTM8-V2) encodes for 









Other studies have demonstrated that CMTM8 enhances the ligand-induced internalization of 
epidermal growth factor receptor (EGFR) from the cell surface, attenuating EGFR-mediated 
signalling [241], leading to decreased proliferation in HEK293T, HeLa and PC3 cell lines. It 
has also been reported that the CMTM8-induced absence of EGFR-mediated signalling triggers 
HEK293T, HeLa and PC3 cell lines to undergo apoptosis via caspase-dependent and -
independent pathways, as demonstrated by decreased levels of Bad-S112 phosphorylation 
[293]. In addition, CMTM8 may be unregulated in tumours, acting as a tumour suppressor gene 
with important roles in the male reproductive, hematopoietic and immune systems [294]. 
CMTM8 was found to be a suppressor of EMT-like phenotypes in HepG2 and MCF-10A 
immortalized human breast epithelial cells via c-Met/ERK signalling [245]. EMT is a hallmark 
of cell migration and cancer cell metastasis. This suggests that CMTM8 could have an effect 
on BMSC migration. 
 
Currently, no known function of CMTM8 has been described during BMSC growth, migration 
and differentiation. The present study aimed to determine whether CMTM8 is a potential 
mediator of BMSC proliferation, migration and differentiation, using gene knockdown and 








5.2.1 Generation of CMTM8 overexpressing BMSC 
Human CMTM8 overexpression vector constructs were generated in order to study the role of 
CMTM8 in the growth and differentiation of BMSC. The full length CMTM8 coding region 
(1.2 kb) was ligated into pRUF-IRES-GFP vector (6kb) construct. Correct ligation of CMTM8 
gene fragment was determined by Xho1 and BamH1 restriction digestion (Figure 5.2). pRUF-
IRES-GFP-CMTM8 and pRUF-IRES-GFP were transformed into bacteria cultures, then 
purified DNA was sequenced to confirm the absence of mutations and correct orientation. 
Retroviral transduction was used to overexpress pRUF-IRES-GFP-CMTM8 and pRUF-IRES-
GFP in BMSC. The level of transfection and infection efficiency was observed by visualization 
of GFP expression using a fluorescent microscope (Figure 5.3). The population of high GFP-
positive BMSC were sorted using FACS (Figure 5.4) with transfection efficiency ranging from 
40% - 64% for vector only BMSC and 40% - 80% for CMTM8 overexpressing BMSC and 
then culture expanded in normal growth media. From the forward versus side scatter (FSC vs 
SSC) gating of the flow cytometry density plot (Figure 5.4), no obvious changes in the size 
distribution of cells were observed between vector only and CMTM8 overexpressing cells. 
Sanger sequencing analysis was performed to confirm correct sequences of CMTM8 inserts, as 
shown by the pairwise alignment of the vector construct sequences to the consensus sequence 
obtained from the NCBI website (Figure 5.5A). Purity of the vector constructs was assessed 
by visualizing the sequencing peaks using Chromas software (Technelysium Pty Ltd, South 
Brisbane, Australia) (Figure 5.5B).  
 
5.2.2 Evaluation of CMTM8 overexpressing BMSC 
Human CMTM8 overexpression vector constructs were generated in order to study the role of 


















Figure 5.2. Restriction digest analysis on pRUF-IRES-GFP-CMTM8 vector ligation. 1% 
agarose gel electrophoresis separation of pRUF-IRES-GFP-CMTM8 vector DNA digested 
with Xho1 and BamH1 restriction enzymes. Lane 1-8 represents individual bacteria clone 
























Figure 5.3. Enforced expression of pRUF-IRES-GFP-CMTM8 expressing cells. 
Representative micrographs showing vector only and CMTM8 overexpressing BMSC; stained 
with DAPI/ Phalloidin (Scale bar = 100μm), GFP positive (Scale bar = 200μm), unstained 
BMSC (Scale bar = 200μm) and GFP positive HEK293T cells (Scale bar = 100μm) when 

























































Figure 5.4. GFP positive BMSC selected with FACS. Representative flow cytometry density 










































































Figure 5.5. Confirmation of correct CMTM8 sequence insert in the pRUF-IRES-GFP 
vector. (A) Sanger sequencing was performed on pRUF-IRES-GFP-CMTM8 vector using the 
Pairwise Sequence Alignment Tool. (B) The purity of the vector sequence was confirmed by 
















CMTM8 consensus sequence (NCBI) 













Figure 5.6. Western blot analysis to detect expression of CMTM8 by infected BMSC. 
Protein expression of CMTM8 was assessed by Western blot analysis using two different 
antibodies against CMTM8: anti-CMTM8-1 & anti-CMTM8-2. Molecular weight of CMTM8 














































































































the infected cells, Western blot analysis was performed to assess the CMTM8 expression of 
four vector only BMSC and CMTM8 overexpressing BMSC donors at the protein level (Figure 
5.6). However, no CMTM8 protein of the expected 20kDa was detected using two different 
antibodies (over the concentration range of 1:200, 1:500 and 1:1000) against CMTM8: anti-
CMTM8-1 and anti-CMTM8-2. Immunohistochemistry was then employed as another method 
to detect levels of CMTM8 in vector only and CMTM8 overexpressing BMSC in vitro. 
Immunocytochemistry analysis was performed in order to visualize protein expression of 
CMTM8. Both populations of cells were GFP positive, demonstrating successful transcription 
of the infected vectors (Figure 5.7). The positive control for perivascular cells/ BMSC, α-SMA 
[46, 55] was detected in both populations. CMTM8 levels were assessed using two different 
antibodies against CMTM8: anti-CMTM8-1 and anti-CMTM8-2. As shown in Figure 5.7, no 
difference was observed in the intensity of fluorescence between vector only and CMTM8 
overexpressing BMSC, where staining appeared to be non-specific.  
 
Although specific detection of CMTM8 was unsuccessful with the antibodies used, when 
expression of CMTM8 transcript was determined in cells using real-time PCR, there was 
differential expression of CMTM8 in vector only BMSC compared to CMTM8 overexpressing 
BMSC. Expression levels of CMTM8 transcripts in three pRUF-IRES-GFP-CMTM8 human 
BMSC donors were found to be approximately 1,000 fold higher compared with vector only 
control pRUF-IRES-GFP BMSC (Figure 5.8A). 
 
5.2.3 CMTM8 is a promoter of BMSC proliferation 
The role of CMTM8 during BMSC proliferation was assessed by performing overexpression 
and knockdown studies followed by analysis of BrdU incorporation. The data showed that 











Figure 5.7. Immunocytochemistry staining of vector only and CMTM8 overexpressing 
BMSC. Vector only and CMTM8 overexpressing BMSC were stained with anti-CMTM8-1 
(1:200, scale bar = 100μm) & anti-CMTM8-2 (1:200, scale bar = 100μm), with negative 


































































Figure 5.8. CMTM8 promotes BMSC proliferation. (A) Empty vector transduced BMSC or 
CMTM8 overexpressing BMSC were cultured under normal growth, real-time PCR was 
performed to examine levels of CMTM8. Graph represents mean ± S.E.M, Student’s t-test 
p<0.05(*), n=3.  (B) Vector-only or CMTM8 overexpressing BMSC were incubated for 3-5 
days and BrdU assays were performed Graph represents mean ± S.E.M, Student’s t-test 
p<0.05(*), n=5. (C) Representative images of vector-only BMSC and CMTM8 overexpressing 
BMSC cultures were taken using Olympus light microscope at 20 X magnification. (D) Normal 
BMSC were treated with either negative siRNA (siScram) or siRNA to CMTM8 (siCMTM8_1 
& siCMTM8_2), real-time PCR was performed to examine levels of CMTM8, Graph 
represents mean ± S.E.M, Student’s t-test p<0.05(*), n=3. (E) BMSC treated with siScram/ 
siCMTM_1/ siCMTM-2 were incubated for 3-5 days and BrdU assays were performed, n=6. 
(F) Representative images of cells treated with siScram and siCMTM8_1, were taken using 



































































































































































































no observable effects on cell morphology (Figure 5.8B, C). The notion that CMTM8 is a 
promoter of BMSC proliferation was supported in experiments demonstrating that following 
siRNA mediated knockdown of CMTM8 gene expression (Figure 5.8D), BMSC proliferation 
rates were significantly reduced with no effect on cell morphology (Figure 5.8E, F).  
 
To investigate whether the reduced proliferation rate observed in CMTM8 knockdown BMSC 
was attributed to apoptosis, BMSC were stained with AnnexinV and 7AAD (Figure 5.9).  Flow 
cytometric analysis found that CMTM8 knockdown resulted in no difference in the number of 
live AnnexinV-/ 7AAD- cells, early apoptotic AnnexinV+/ 7AAD- or late apoptotic AnnexinV+/ 
7AAD+ cells (Figure 5.9A, B). 
 
5.2.4 CMTM8 promotes BMSC proliferation via activation of EGFR 
Previous studies from our laboratory have reported the mitogenic effect of EGF on BMSC 
[295]. The present study examined whether the effect of CMTM8 on BMSC proliferation was 
mediated via the EGFR pathway. Studies revealed that the mitogenic effect of EGF on BMSC 
was enhanced in CMTM8 overexpressing BMSC compared to vector only control BMSC 
(Figure 5.10A). In parallel studies, siRNA mediated knockdown of CMTM8 exhibited a 
suppressed proliferative response in the presence of EGF (Figure 5.10B).  
 
Previous studies have reported that CMTM8 facilitates the internalization of EGFR into 
cytoplasm, where EGFR is phosphorylated [241]. To investigate whether the CMTM8 affects 
BMSC proliferation through EGFR signalling, siRNA-CMTM8 transfected BMSC and control 
siScram transfected BMSC were stimulated with EGF and assessed by Western Blot (Figure 
5.10C). The levels of total EGFR were not significantly different between CMTM8 knockdown 
and control BMSC in the presence or absence of EGF (Figure 5.10Ci). However, when cells 
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were treated with EGF, there was an increase in the levels of phosphorylated EGFR in all cells 
at 10 minutes and 30 minutes post EGF stimulation. Nevertheless, levels of phosphorylated 
EGFR were reduced in siCMTM8 transfected cells at 10 minutes post EGF stimulation, when 
compared to siScram control transfected cells (Figure 5.10 Cii, D-F). At 30 minutes post EGF 
stimulation, reduced levels of phosphorylated EGFR in siCMTM8 transfected cells were still 
observed, compared to control, but only in cells from two out of the three donors (Figure 5.10 
Cii, D-F). Assessment of ERK1/2, a major downstream effector of EGFR, found that total 
ERK1/2 levels were not significantly different between CMTM8 knockdown and control 
BMSC in the presence or absence of EGF (Figure 5.10 Ci). When cells were treated with EGF, 
there was an increase in the levels of phosphorylated ERK1/2 post EGF stimulation in all cells. 
Levels of phosphorylated ERK1/2 were found to be reduced in siCMTM8 transfected cells at 
10 minutes post EGF stimulation when compared to siScram control transfected cells (Figure 
5.10 Cii,G-I). At 30 minutes post EGF stimulation, reduced levels of phosphorylated ERK1/2 
in siCMTM8 transfected cells were still observed, compared to control, but only in cells from 
the two donors which also demonstrated a decrease in protein levels of phosphorylated EGFR 
(Figure 5.10 Cii, G-I). Assessment of another downstream effector of EGFR, AKT did not 




















Figure 5.9. CMTM8 does not affect BMSC apoptosis. siScram and siCMTM8 treated BMSC 
were stained with AnnexinV and 7AAD and scanned with flow cytometry. (A) Flow cytometry 
density plot of siScam, siCMTM8_1, siCMTM8_2 treated BMSC. (B) Percentage of live cells 
stained with AnnexinV-/ 7AAD-, early apoptotic cells stained with AnnexinV+/ 7AAD-, late 
apoptotic cells stained with Annexin+/ 7AAD+, necrotic cells stained with AnnexinV-/ 7AAD+. 










































































































































Figure 5.10. CMTM8 promotes BMSC proliferation via activation of EGFR Signalling. 
(A) Vector-only and CMTM8 overexpressing BMSC were also treated with 20ng/mL EGF for 
3-5 days before BrdU assay was performed.  (B) siScram or siCMTM8 treated BMSC were 
incubated with 20ng/mL EGF for 3-5 days and BrdU assay was performed. (A, B) Graphs 
represent mean ± S.E.M, One-way ANOVA p<0.05(*), n=3 donors. (C) Representative 
Western Blot. Cell lysates were collected from vector-only BMSC and CMTM8 overexpressing 
BMSC treated with 20ng/mL EGF for 10 and 30 minutes or without EGF. Western Blot was 
performed to examine the total and phosphorylated form of EGFR, ERK1/2 and AKT using β-
actin as the loading control. The intensity of bands were measured by normalizing (D-F) 
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To further investigate the effect of CMTM8 on EGF-mediated proliferation, we treated vector-
only BMSC (Figure 5.11A) and CMTM8 overexpression BMSC (Figure 5.11B) with the EGFR 
inhibitor, Erlotinib and assessed for BrdU incorporation. Our results showed that both 
populations treated with EGF increased their proliferation rates compared to control DMSO 
treated cells. However, both cell populations displayed a dose-depended inhibition of cell 
proliferation in the presence of Erlotinib when compared with their respective DMSO control 
cells (Figure 5.11A, B). Further comparisons found that CMTM8 overexpressing BMSC 
showed more resistance to Erlotinib at higher drug concentrations at 2μM and above (Figure 
5.11C). Knock down of CMTM8 results in a decrease in EGFR signalling and CMTM8 
overexpression results in less sensitivity to Erlotinib. These results suggest that CMTM8 
promotes BMSC proliferation most likely via the activation of EGFR signalling.  
 
5.2.5 CMTM8 promotes BMSC migration 
Studies have shown that CMTM8 can inhibits EMT-like changes in HepG2 hepatocellular 
carcinoma cells [245], where EMT is a hallmark of cancer cell metastasis and cell migration. 
In the present study, overexpression of CMTM8 did not result in changes in the expression of 
important EMT associated gene markers (Figure 5.12). We then performed functional 
experiments to examine whether CMTM8 has a role in BMSC migration with the use of an in 
vitro scratch assay. Images of migrating CMTM8 overexpressing and vector only BMSC were 
compared between 0 hours and 16 hours (Figure 5.13A) and quantitated for area of occupation 
and migrating length. The data showed that CMTM8 overexpressing BMSC had an increase in 
length (Figure 5.13B) and area (Figure 5.13C) of invading cells after 16 hours of incubation, 
compared to vector only BMSC. To confirm this finding, scratch assays were performed using 
CMTM8 knockdown and control BMSC (Figure 5.13D). The CMTM8 knockdown BMSC 
exhibited a decrease in the length (Figure 5.13E) and area (Figure 5.13F) invaded after 16 hours 
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incubation, compared to siRNA scramble control BMSC. These data suggest that CMTM8 is a 
promoter of cell migration.  
 
5.2.6 CMTM8 inhibits BMSC osteogenic differentiation 
To assess the role of CMTM8 in human BMSC differentiation, functional studies were 
performed using CMTM8 overexpressing BMSC or empty vector alone infected BMSC from 
two donors, cultured in osteogenic induction media (Figure 5.14A). The data showed that 
CMTM8 overexpression resulted in a decrease in Alizarin red stained mineral deposits (Figure 
5.14B) and extracellular calcium levels (Figure 5.14C), following osteogenic induction, 
compared with vector only BMSC. The CMTM8 mediated suppression of BMSC osteogenic 
differentiation was further supported by the decreased expression of the osteogenic markers 
RUNX2 and OPN, in CMTM8 overexpressing BMSC compared to vector only BMSC (Figure 
5.14D, E). 
 
To verify these findings, siRNA-CMTM8 transfected BMSC were cultured in osteogenic 
differentiation media (Figure 5.14F). Suppression of CMTM8 resulted in increased Alizarin 
red staining (Figure 5.14G) and extracellular calcium levels (Figure 5.14H), compared with 
siScram transfected cells. Enhanced BMSC osteogenic differentiation was further supported 
by the upregulation of osteogenic markers RUNX2 and OPN expression (Figure 5.14I, J) 
compared to expression in siScram transfected cells. Overall, these studies demonstrated that 
















Figure 5.11. CMTM8 resists anti-proliferation effect of Erlotinib. (A) vector-only BMSC 
and (B) CMTM8 overexpression BMSC were treated with either DMSO control, 20ng/mL 
EGF, 1μm Erlotinib with 20ng/mL EGF, 2μm Erlotinib with 20ng/mL EGF, 3μm Erlotinib 
with 20ng/mL EGF, or 6μm Erlotinib with 20ng/mL EGF for 3 days and BrdU assays were 
performed. Graphs represent mean ± S.E.M, Student’s t-test p<0.05(*), n=3 donors. (C) Data 
from (A) and (B) were combined to visualize the difference between vector-only and CMTM8 
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Figure 5.12. CMTM8 does not affect expression of EMT marker genes. Vector-only and 
CMTM8 overexpressing BMSC were cultured in normal conditions expression levels of EMT 
markers: (A) VIMENTIN, (B) SLUG, (C) TWIST-1, (D) KRT19, (E) COL4A1 and (F) E-CAD 
were determined relative to β-actin using real-time PC. Graphs represent mean ± S.E.M, 
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Figure 5.13. CMTM8 promotes BMSC migration. BMSC were seeded into 24-well plate 
and in vitro scratch assays were performed. Images were taken and area and length invaded by 
cells were measured at 0 hour and 16 hours post incubation. Measurements were analysed 
relative to value obtained at 0 hour. (A) Representative images showing the area invaded by 
vector-only and CMTM8 overexpressing cells with different treatments at 0 hour (T0) and 16 
hours (T16). (B) Length invaded by vector-only and CMTM8 overexpressing cells, n=5. (C) 
Area invaded by vector-only and CMTM8 overexpressing cells, n=5. (B, C) Graphs represent 
mean ± S.E.M, Student’s t-test p<0.05(*). (D) Representative images showing the area invaded 
by siScram and siCMTM8 treated cells with different treatments at 0 hour and 16 hours. (E) 
Length invaded by siScram and siCMTM8 treated cells, n=6. (F) Area invaded by siScram and 
siCMTM8 treated cells, n=6. (E, F) Graphs represent mean ± S.E.M, Student’s t-test p<0.05(*), 
























































































































































































































Figure 5.14. CMTM8 inhibits BMSC osteogenesis. (A) Vector-only and CMTM8 
overexpressing BMSC were cultured in osteogenic (Osteo) inductive conditions for 3 weeks 
and CMTM8 expression levels were determined relative to β-actin using real-time PCR, n=8 
donors. (B) Representative image of Alizarin Red that stained the mineral deposited by vector 
only and CMTM8 overexpressing BMSC (C) Extracellular calcium levels of vector-only and 
CMTM8 overexpressing BMSC were quantified, n=4 donors. Real-time PCR was performed 
to measure levels of (D, E) RUNX2 and OPN relative to β-actin of two donors. (A, C, D, E) 
Graph represents mean ± S.E.M, Student’s t-test p<0.05(*). (F) siScram, siCMTM8_1 BMSC 
were cultured in osteogenic (Osteo) inductive conditions for 3 weeks and CMTM8 expression 
levels were determined relative to β-actin using real-time PCR, n=8 donors. (G) Representative 
image of Alizarin Red that stained the mineral deposited by siScram and siCMTM8_1 treated 
BMSC. (H) Extracellular calcium levels of cells treated with siScram or siCMTM8_1 were 
quantified, n=4 donors. Real-time PCR was performed to measure levels of (I, J) RUNX2 and 
OPN relative to β-actin of two donors. (F, H, I, J) Graphs represent mean ± S.E.M, Student’s 
























































































































































































































































































































































































5.2.7 CMTM8 has no effect on BMSC adipogenic differentiation 
To determine the function of CMTM8 in BMSC adipogenic differentiation, CMTM8 
overexpressing BMSC or vector control BMSC were cultured under growth or adipogenic 
inductive media (Figure 5.15A). Measurements of number of lipid-containing adipocytes using 
Nile red staining found no difference between HOPX overexpressing BMSC and vector control 
BMSC (Figure 5.15Bi, C). Similarly, lipid droplets were stained with Oil Red O after three 
weeks under adipogenic growth conditions with no observable differences (Figure 5.15Bii). In 
accord with these findings, CMTM8 overexpressing BMSC showed no significant difference 
in the transcript levels of the adipogenic master regulator, C/EBPα (Figure 5.15D) and the 
mature fat marker, ADIPSIN (Figure 5.15E), compared to the vector control cells.  
Confirmatory studies employing siRNA-mediated knockdown of CMTM8 in BMSC (Figure 
5.15F) found no significant differences in the number of nile red positive lipid-containing 
adipocytes compared with scramble siRNA-treated BMSC (Figure 5.15Gi-J). Similarly, lipid 
droplets were stained with Oil Red O after three weeks under adipogenic growth conditions 
with no observable differences (Figure 5.15Gii). Overall, these findings demonstrate that 


















Figure 5.15. CMTM8 does not affect BMSC adipogenic differentiation. (A) CMTM8 
overexpressing (CMTM8OE) and vector only (Vector) BMSC were cultured in adipogenic 
inductive conditions and CMTM8 expression levels were determined relative to β-actin using 
real-time PCR, n=3 donors. Graphs represent mean ± S.E.M, One-way ANOVA p<0.05(*). 
(B) Representative images of lipid-containing Vector BMSC and CMTM8OE BMSC stained 
with (i) Nile Red and (ii) Oil Red O. (C) Lipid-containing cells stained with Nile red and DAPI 
were quantified,  n=3 donors. Graph represents mean ± S.E.M, Student’s t-test p<0.05(*).  
Total RNA was harvested at 7-14 days post induction (n=3 donors) from Vector and 
CMTM8OE BMSC. Real-time PCR was used to measure levels of (D) C/EBPα and (E) 
ADIPSIN in relative to β-actin. Graphs represent mean ± S.E.M, Student’s t-test p<0.05(*) (F) 
siScram and siCMTM8_1 treated BMSC were incubated in adipogenic inductive conditions 
for 3 weeks, and CMTM8 expression levels were determined relative to β-actin using real-time 
PCR, n=4 donors. Graph represents mean ± S.E.M, Student’s t-test p<0.05(*). (G) 
Representative images of lipid-containing siScram and siCMTM8_1 infected BMSC stained 
with (i) Nile Red and (ii) Oil Red O. (H) Lipid-containing cells stained with Nile red and DAPI 
were quantified,  n=4 donors. Total RNA was harvested at 7-14 days post induction (n=4 
donors) from siScram and siCMTM8_1 infected BMSC. Real-time PCR was used to measure 
levels of (I) C/EBPα and (J) ADIPSIN in relative to β-actin. Graphs represent mean ± S.E.M, 
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The present study identified a new role for CMTM8 in regulating BMSC growth and 
differentiation. CMTM8 encodes a 173 amino acids protein consists of four putative 
transmembrane regions which is structurally similar to the transmembrane 4 super family 
(TM4SF11) [241]. In addition, CMTM8 contains a predicted MARVEL domain, suggesting a 
role in membrane protein sorting and trafficking, and membrane apposition events such as 
transportation of vesicle biogenesis, neurotransmitter secretion and polarized membrane 
trafficking [241, 291]. Moreover, in the cytosolic loop domain of CMTM8, there are 2 
internalization consensus sequence YXXØ (Ø is a bulky hydrophobic residue), which can bind 
directly to the adaptor protein 2 (AP2) μ2 subunit [241, 296]. Therefore, CMTM8 is a factor 
similar to a transmembrane protein but equipped with domains for extra functions.  
 
Functional studies using siRNA-mediated knockdown or retroviral mediated overexpression 
of CMTM8 demonstrated that CMTM8 promotes cellular proliferation and migration whilst 
inhibiting osteogenic differentiation. Interestingly, the effect of CMTM8 overexpression on 
BMSC proliferation was not as dramatic as in the knockdown studies. Reports in the literature 
have demonstrated the ability of CMTM8 to induce apoptosis via caspase-dependent and –
independent pathways [293].  Furthermore, CMTM8 overexpression has previously been 
reported to lead to decreased levels of Bad-S112 phosphorylation and induced apoptosis in 
cancer cell lines such as HeLa, PC3 and human breast adenocarcinoma cell line (MCF-7) [293]. 
In the present study, AnnexinV and 7AAD staining determined that the decrease in 
proliferation due to CMTM8 knockdown was not due to the cells undergoing apoptosis. 
Therefore, CMTM8 appears to have a reverse function in promoting postnatal stem cell growth 




Other studies have reported that enforced expression of CMTM8 facilitated ligand-induced 
internalization of EGFR from the cell surface, and therefore silencing EGFR-mediated 
signalling [241]. Corresponding to CMTM8, a typical tetraspanin, CD82 comprised of a 
YXXØ motif has been shown to regulates EGFR internalization in epithelial cells [297]. 
Therefore, with two YXXØ motifs and one MARVEL domain, CMTM8 is to accelerate the 
internalization of EGFR [241]. It was also shown that enforced expression of CMTM8 inhibited 
cell proliferation, whilst suppression of CMTM8 promoted cell proliferation, following EGF 
stimulation of HEK293T, PC3 and HeLa cell lines. [241]. EGF stimulation induced activation 
of its receptor, EGFR and led to phosphorylation of its downstream component proteins, 
ERK1/2. However, after the initial intense ERK1/2 phosphorylation, phosphorylation 
decreased dramatically in CMTM8 overexpressing cancer cell lines following EGF treatments 
[241]. On the other hand, siCMTM8 treated cells showed a slow and steady decrease in 
ERK1/2 phosphorylation. These studies suggest a negative effect of CMTM8 on EGF-induced 
signalling [241]. Most of the internalized EGFR are directed for lysosomal degradation and 
therefore desensitization of the EGFR signalling. However, there are also studies reporting that 
the endocytosed EGF–EGFR complex preserves its capability to generate signalling cascade 
from endosomes [298-300]. Therefore, the biological significance of compartment-restricted 
signalling in the context of the EGFR system remains unclear.  
 
Our previous studies have demonstrated that EGF is a potent mitogen for human colony 
forming BMSC [295]. In our study western blot analysis demonstrated that EGF treatments 
did not alter that the expression of total EGFR, but did increase the levels of phosphorylated 
EGFR following stimulation with EGF. Interestingly, siRNA mediated knockdown of CMTM8 
in BMSC resulted in lower levels of phosphorylated EGFR compared to control, suggesting 
that CMTM8 promotes EGFR phosphorylation. We then assessed levels of ERK1/2, a major 
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downstream effector of EGFR, and found that total ERK1/2 levels were not altered but 
phosphorylated ERK1/2 levels were decreased following CMTM8 knockdown when 
compared to control. These data indicate that CMTM8 regulates total EGFR/ phosphorylated 
EGFR ratios in BMSC, in the presence of EGF to promote cell proliferation via the EGFR 
signalling pathway. In addition, no total or phosphorylated AKT was observed in siScram and 
siCMTM8 treated BMSC (Figure 5.10C), indicating that CMTM8 regulates EGFR/ ERK1/2 
signalling but not EGFR/ AKT in BMSC. Confirmatory studies investigated the effect of 
CMTM8 on EGF-mediated proliferation, following treatment with the EGFR inhibitor, 
Erlotinib. The data showed that CMTM8 overexpressing and vector control BMSC displayed 
a dose dependent decrease in proliferation in the presence of Erlotinib. Interestingly, when 
comparing the proliferation rates between vector-only BMSC and CMTM8 overexpressing 
BMSC, the later showed higher proliferation rates when treated with Erlotinib at 2μm and 
above, suggesting that CMTM8 overexpressing cells have the ability to resist the anti-
proliferation effect of Erlotinib. 
 
As a tumour suppressor gene, CMTM8 was reported to inhibit the EMT potential of the HepG2 
and MCF-10A cells via c-Met signalling [245], which is an important feature of cell migration, 
metastasis and invasion. The tyrosine kinase receptor, c-Met resides transmembrane and on the 
cell surface activated by its ligand, HGF [76, 301-303]. Previous studies have demonstrated 
that downregulation of CMTM8 result in EMT-like morphological changes that can be blocked 
by suppressing MEK and ERK2 in HepG2 and MCF-10A cell lines [245]. In addition, the 
protein expression levels of c-Met and HGF-induced c-Met/ERK signalling were increased 
when CMTM8 expression was downregulated in HepG2 and MCF-10A cell lines. It was also 
confirmed by CMTM8 overexpressing HepG2 and MCF-10A cells where HGF-induced c-
MET/ERK signalling was inhibited and cell migration rate was reduced [245]. Together, these 
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findings suggest that CMTM8 functions as a negative regulator of HGF/c-MET signalling to 
ERK in HepG2 and MCF-10A cell lines, which then leads to decreased EMT-like changes. 
However, in the present study, siCMTM8 treated BMSC showed a decreased migration 
potential. In parallel studies, CMTM8 overexpressing cells showed increased BMSC migration, 
suggesting that CMTM8 is a promoter of BMSC migration. However, examination of the 
expression levels of EMT associated mesenchymal (VIMENTIN, SLUG, TWIST-1) and 
epithelial (KRT19, COL4A1 and E-CAD) genes did not show any significant differences, 
suggesting that CMTM8 does not promote BMSC migration through regulating the expression 
of EMT genes. As a transmembrane protein, CMTM8 could affect the cell-cell communication 
and the sensitivity towards stimulants, which could then effect the migration of cells. The 
different responses observed in EMT capacity between BMSC and other cell types by alteration 
of CMTM8 expression could be due to the differences between cell types from morphology to 
molecular and to functional levels. BMSC are primary cells while HepG2 and MCF-10A are 
modified cell lines. Moreover, in the present study, it is possible that CMTM8 regulates BMSC 
migration through EGFR signalling and has no effect on c-Met signalling. This could explain 
the different outcome observed between the present study and other studies that showed 
decreased EMT-like changes by CMTM8.   
 
To date, studies have focused on the functional role of CMTM8 in proliferation, migration and 
apoptosis of different cancer lines [243, 245, 293, 304-309]. However, the effect of CMTM8 
on BMSC cell fate determination has yet to be explored. Work presented in this thesis shows 
that CMTM8 knockdown in BMSC resulted in an enhanced capacity for osteogenesis. 
Consistent with the loss-of-function studies, CMTM8 overexpressing BMSC demonstrated 
decreased osteogenic differentiation potential. Collectively, these findings suggest that 
CMTM8 is a novel molecular inhibitor of BMSC osteogenic differentiation. Interestingly, 
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CMTM8 was found to have no affect on BMSC adipogenic differentiation. Therefore, CMTM8 
appears to act as a switch to block BMSC differentiation in order to allow for cellular 








































To date, there is strong evidence in the literature describing the critical role of BMSC in skeletal 
tissue development and homeostasis [52, 310-312]. The molecular factors modulating BMSC 
proliferation, differentiation and cell fate commitment involve complex interactions driven by 
transcription factors and epigenetic modifiers [1, 138, 313-319]. The Twist family of proteins 
have been identified in MSC proliferation, differentiation and cell fate commitment, where 
their association in bone development, fracture repair and disease have been reported [1, 320, 
321]. Patients with mutations in TWIST-1 gene display Saethre-Chotzen Syndrome, 
characterized by premature fusion of the sutures in the skull and other skeletal deformities such 
as shortened limbs and polydactyly [189, 193, 322]. Furthermore, studies have shown an 
association between TWIST-1/ TWIST-2 and osteoporosis, where heterozygous TWIST-1 
patients displayed higher bone mineral density values in the femoral neck and proximal femoral 
sites [321]. Previous works from our laboratory has identified possible functional roles of 
TWIST-1/ TWIST-2 in osteoporotic bone using ovariectomy induced osteoporotic murine 
model. The study showed that inhibition of TWIST-1 expression results in maintenance of 
bone mass following ovariectomy. Moreover, it has been shown that enforced expression of 
TWIST-1 in BMSC resulted in enhanced BMSC proliferation and adipogenic differentiation, 
whilst decreased osteogenic/ chondrogenic differentiation and senescence [1, 2].  
 
As TWIST-1 has been shown to be a critical regulator of BMSC function including growth, 
survival, lifespan and cell fate determination, the question arises as to what are the downstream 
molecular mechanisms of TWIST-1 mediating these processes. A limited number of studies 
have identified TWIST-1 target genes such as EZH2, HES4, C-ROS-1, RUNX2, PPARγ2 [1-3, 
179]. Moreover, it has been reported that TWIST-1 mediates these complex processes via 
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different signalling pathways, including Wnt, Bmp, TGFβ and FGF2 [129-133, 135, 136, 138-
141, 143, 145, 148, 150, 161-164, 166, 168]. However, the precise downstream molecular 
mechanisms of TWIST-1 action during BMSC proliferation and cell fate determination have 
yet to be determined. This thesis focused on identifying potentially novel TWIST-1 target 
genes and examined the roles of these genes during the process of BMSC proliferation, 
migration and cell fate commitment.  
 
Previous work from our laboratory has shown that enforced expression of TWIST-1 in MSC 
extends their lifespan in vitro and maintains the cells in an immature state by inhibiting cellular 
senescence in association with epigenetic factors such as EZH2 [1, 48]. To determine possible 
gene targets of TWIST-1 in BMSC osteogenic differentiation, a microarray analysis to 
determine which genes were differentially expressed in TWIST-1 overexpressing BMSC was 
also performed [3]. Microarray analysis identified a number of differentially expressed genes 
when TWIST-1 expression was enforced during BMSC osteogenesis. One of the differentially 
expressed gene was receptor tyrosine kinase proto-oncogene 1, C-ROS-1. TWIST-1 was found 
to directly bind to the proximal C-ROS-1 promoter region and negatively regulate C-ROS-1 
expression, leading to decreased BMSC osteogenesis and increased adipogenesis via the 
PI3K/AKT/mTORC1 signalling pathway [3]. To further investigate the downstream effectors 
of TWIST-1, a few genes of interest that are novel in BMSC growth and cell fate determination 
were identified, including HOPX, CMTM8 and SCARA3. However, using the transcription 
factor binding site predictor tool, no TWIST-1 binding sites have been identified near SCARA3 
promoter regions, while CMTM8 contains three putative TWIST-1 binding sites in the intron 
1; and HOPX contains TWIST-1 downstream effector, EZH2 binding sites in its promoter 
regions. Therefore, HOPX and CMTM8 were selected for further evaluation in this thesis. 
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The findings of this study demonstrated that HOPX and CMTM8 are upregulated during BMSC 
osteogenic differentiation but are downregulated when TWIST-1 is overexpressed. The 
question arises as to whether TWIST-1 interacts directly or indirectly with HOPX or CMTM8. 
This was addressed in Chapter 3 using ChIP analysis. The data generated from these studies 
failed to confirm direct interactions between TWIST-1 and HOPX or CMTM8. However, the 
interactions between HOPX and the TWIST-1 downstream effector, EZH2 were confirmed 
using ChIP analysis. This study also confirmed a negative correlation between TWIST-1 and 
HOPX, supported by data showing higher levels of TWIST-1 expression and lower levels of 
HOPX expression during normal growth conditions and higher HOPX expression levels during 
differentiation. ChIP analaysis was also used to confirm putative EZH2 binding sites along the 
CMTM8 promoter but failed to show direct interaction between the two molecules, suggesting 
that TWIST-1 may regulated the expression of CMTM8 indirectly through other mechanisms. 
CMTM8 was reportedly found to present as cell surface antigen. In future experiments, it is 
worth examining the expression levels of other cell surface antigens affected by TWIST-1, 
such as C-ROS-1 and ITGA5. This may help identify novel potency markers of BMSC 
proliferation or differentiation following ex vivo expansion.  
 
The second aspect of this thesis focused on identifying the role of HOPX and CMTM8 in 
BMSC proliferation and differentiation potential. In this thesis, retroviral transduction was 
employed to transduce HOPX and CMTM8 vector constructs into human BMSC. The 
expression vector constructs contained a GFP reporter gene that indicated successful 
transduction and allowed the purification of infected BMSC by FACS, therefore avoiding the 
antibiotic selection method, which is often associated with cellular toxicity [323]. Confirmation 
of enforced HOPX and CMTM8 expression at the mRNA level was confirmed by real-time 
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PCR analysis. However, confirmation of the enforced HOPX and CMTM8 expression at the 
protein level using Western blot analysis was unsuccessful using different commercially 
available antibodies at different concentrations. While retroviral transduction offers a relatively 
efficient mode of genetically modifying BMSC, the initial infection efficiencies prior to 
selection by FACS varied between 10% and 70%. Therefore, the selected cells are a 
heterogeneous population of BMSC. This may explain the different properties between the 
donors analysed given that the transduction efficiency varied between populations. The use of 
multiple, independent assays (such as Alizarin Red, Calcium production and analysis of 
expression levels of osteogenic markers) helped confirm observations and reduce the effects 
of variation between different HOPX and CMTM8 overexpressing lines. In general, the 
observations made when multiple assays were used gave further confidence of low 
experimental error when similar results were generated using BMSC derived from the same 
donor.  
 
The studies presented in this thesis are the first to show direct binding of EZH2 on the HOPX 
promoter by ChIP analysis, creating an association between TWIST-1/ EZH2/ HOPX. 
Assessment of HOPX expression levels in EZH2 overexpressing BMSC revealed a negative 
correlation between EZH2 and HOPX, supporting the notion that TWIST-1 induces EZH2 and 
EZH2 suppresses HOPX. In addition, this thesis examined the functional role of HOPX in 
human BMSC proliferation and differentiation. Consistent with functional analyses, the in vitro 
data presented herein, showed that enforced expression of HOPX promoted BMSC 
proliferation. Notably, complementary studies in which HOPX was transiently knocked down 
in BMSC using two different siRNA molecules, resulted in decreased cell proliferation. 
Moreover, HOPX was shown to be an inhibitor of BMSC adipogenic differentiation. Although 
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the molecular mechanisms and signalling pathways activated/ repressed by HOPX-mediated 
cell proliferation remains to be fully elucidated, pathway analysis from transcriptomic data 
suggested that HOPX inhibits adipogenic associated genes such as ADIPOQ, FABP4, PLIN1 
and PLIN4. It is known that TWIST-1 and EZH2 inhibit BMSC osteogenic differentiation, 
promote adipogenesis and maintain BMSC in an immature state [1, 2]. Since EZH2 negatively 
regulates HOPX, the inhibitory effect by HOPX on BMSC adipogenic differentiation is 
consistent with the previous studies (Figure 6.1). However, HOPX was found to be a promoter 
of BMSC proliferation, which is contradictory to the effects of TWIST-1 and EZH2. One 
possible explanation could be the effect on BMSC proliferation by HOPX is not mediated 
through TWIST-1/EZH2. This explanation could also be true during BMSC osteogenesis, 
where no significant role of HOPX was observed. Future efforts will attempt to decipher the 
binding partners of HOPX, the genome wide binding sites of HOPX protein complexes and 
the role of putative HOPX targets in human BMSC growth and lineage determination. 
 
A limited number of studies have been published investigating the role of CMTM8 primarily 
in cancer biology [243, 245, 293, 294, 304, 305, 308, 309], but no study has examined its role 
in BMSC biology. Studies using other cell types including HeLa, PC3, HepG2 and HEK293T 
cell lines have reported the association of CMTM8 in cellular proliferation, apoptosis and 
cancer cell metastasis. This thesis failed to show direct binding of TWIST-1 and EZH2 on the 
CMTM8 promoter by ChIP analysis. However, assessment of CMTM8 expression levels in 
TWIST-1 and EZH2 overexpressing BMSC revealed a negative correlation between TWIST-1 
and EZH2 on CMTM8, suggesting that TWIST-1 and EZH2 may suppress CMTM8 expression 
via indirect mechanisms. The reason that no enrichment of TWIST-1 or EZH2 binding could 
be limited by the coverage of the predictor tool and promoter regions assessed by real-time 
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PCR. Three putative TWIST-1 binding sites were identified in the first intron of CMTM8 using 
the GTRD transcription binding site prediction tool. Different prediction tools could be used 
in the future to identify more putative TWIST-1 binding sites. Multiple putative EZH2 binding 
sites were found in the 5’ region of CMTM8 transcription start sites spanning around 20kb 
distant. In this study, only two putative EZH2 binding sites were assessed. Therefore, future 
studies will continue to examine binding of EZH2 on the other putative sites.  
 
In Chapter 5, the novel role of CMTM8 in BMSC proliferation, differentiation and migration 
was investigated by employing CMTM8 overexpressing BMSC and siRNA-mediated transient 
knockdown of CMTM8 in vitro. Given that there is a negative correlation between TWIST-
1/EZH2 and CMTM8, CMTM8 was initially thought to be a potential inhibitor of proliferation/ 
migration and/ or a promotor of BMSC osteogenesis. However, the present thesis showed, for 
the first time, that CMTM8 is a promoter of BMSC proliferation and migration via modulating 
EGFR signalling, whilst inhibiting osteogenic differentiation. It has been reported that 
CMTM8 accelerates the internalization of EGFR from the cell membrane but does not lead to 
degradation of the EGFR [241]. Therefore, the fate of internalized EGFR is unknown, where 
it could be destined for lysosomal degradation and inactivation of the receptor signalling or it 
could enter the nucleus and maintains its signalling [298-300]. One study has reported the 
regulation of TWIST-1 by EGFR signalling pathway in prostate cancer cell lines, where 
translocation of EGFR into the nucleus results in enhanced TWIST-1 activities [178]. 
Interestingly, Western blot analysis from this thesis showed that when CMTM8 is suppressed, 
the levels of phosphorylated (active form) EGFR decreased, suggesting that CMTM8 activates 
EGFR signalling in BMSC. Therefore, from these studies, we speculate that CMTM8 activates 
EGFR signalling, which in turn activates TWIST-1 expression and consequently increases 
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EZH2 expression. A negative feedback loop is then formed between EZH2 and CMTM8 where 
EZH2 negatively regulates CMTM8 (Figure 6.2). This signalling pathway could explain the 
results observed in this thesis and other studies. A similar role of CMTM8 in vivo is yet to be 
investigated. This study provides insight into new strategies in controlling the fate of BMSC 
by regulating the expression of CMTM8. Future efforts will attempt to confirm the relationship 
between EZH2 and CMTM8; and to decipher the binding partner proteins or downstream 
signalling pathways of CMTM8 action and the role of putative CMTM8 targets in human 
BMSC growth and lineage determination. Moreover, many growth factors exert mitogenic 
effects on mesenchymal stem cells. Most notably, FGF2 is one of the most abundantly secreted 
factors during BMSC growth and regulated by TWIST-1. Future experiments could look into 
identifying the link between TWIST-1/CMTM8/FGF2 pathways.  
 
Questions arise as to how HOPX and CMTM8 mediate the effects of TWIST-1 on the function 
of BMSC. Given that there is a negative correlation between HOPX or CMTM8 expression 
and TWIST-1 expression, HOPX or CMTM8 would be predicted to have opposite effects on 
BMSC to that of TWIST-1. However, in our studies, HOPX or CMTM8 did not show complete 
opposing effects to TWIST-1. For example, TWIST-1 and CMTM8 both inhibit BMSC 
osteogenesis. It is important to note that, as a critical factor of bone development and post natal 
homeostasis, TWIST-1 mediates BMSC growth and differentiation via direct regulation of 
osteogenic inductive gene such as binding to RUNX2 and inhibits its expression; and indirect 
regulation such as mediating expression of CMTM8. This study demonstrates the possible 
existence of a negative feedback loop between TWIST-1 and CMTM8 (Figure 6.2). Moreover, 
as a transcription factor, TWIST-1 modulates BMSC function via the regulation of a diverse 
array of gene targets and signalling pathways. Among the TWIST-1 targeted genes/pathways, 
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there are activating and inhibiting regulators for more precise controls of cell growth and 
differentiation. Therefore, the inhibition effect of TWIST-1 on BMSC osteogenic 
differentiation is the overall effect of an array of signalling pathways, while the effects of 
CMTM8 on BMSC osteogenesis exclude many TWIST-1 targeted genes/pathways.  
 
This study confirmed that both HOPX and CMTM8 act as promoters of BMSC proliferation. 
Interestingly, TWIST-1 was also reported as a promoter of BMSC proliferation [1]. Given that 
there is a negative correlation, one possible explanation for this is that HOPX and CMTM8 act 
through different mechanisms in the absence of TWIST-1 in BMSC. This can be further 
examined by assessing the expression of cell cycle genes and cell cycle signalling molecules 
in the HOPX and CMTM8 overexpressing and siRNA knock down BMSC. 
 
The gap in knowledge of the molecular mechanisms underlying the differentiation of human 
mesenchymal stem cells into different cell lineages hinders the application of MSC for cell-
based therapy. In this study, we identified a critical role of HOPX in inhibiting the molecular 
program that leads to BMSC adipogenic differentiation, while CMTM8 inhibits the osteogenic 
differentiation. These findings provide novel mechanistic insights into proliferation and 
lineage specification of BMSC. This information could be exploited in future studies to 
manipulate mesenchymal stem cells using small peptide or chemical inhibitors/ activators for 











Figure 6.1 Model for HOPX modulation of BMSC adipogenesis. HOPX mediates the 
regulation of TWIST-1 and EZH2 via suppressing of adipogenic genes such as C/EBPα, 












Figure 6.2 Model for CMTM8 modulation of TWIST-1 signalling. CMTM8 activates 
EGFR signalling, where EGFR promotes BMSC proliferation, while represses expression of 
TWIST-1 inhibitor, miR-1, allowing transcription of TWIST-1. TWIST-1 then induces 
expression of EZH2, where both TWIST-1 and EZH2 are inhibitors of BMSC osteogenic 
differentiation. However, EZH2 simultaneously acts in a negative feedback loop to suppress 
CMTM8 expression, which is also an inhibitor of BMSC osteogenesis. The overall effects of 







6.2 Future Directions 
6.2.1 Does HOPX plays a role in BMSC migration and adhesion?  
TWIST-1 has been shown as an EMT marker and promotes cell migration [170, 178, 324]. 
TWIST-1 contributes to cancer cells invasion and metastasis [178]. Other studies have reported 
a positive correlation between TWIST-1 and EZH2 expression, while E-cadherin (epithelial 
marker) expression showed a negative correlation with both TWIST-1 and EZH2 in prostate 
cancer cells [325]. Since TWIST-1 was shown to promote EZH2 expression [2, 224], where 
EZH2 inhibits HOPX expression, it is interesting to investigate if HOPX can mediate the effect 
of TWIST-1 during BMSC migration and adhesion. One strategy is to perform wound healing 
assays and transwell migration assays using siRNA-mediated HOPX knockdown or HOPX 
overexpressing BMSC to assess the effect of HOPX in BMSC migration and adhesion, 
respectively. In this thesis, wound healing assays have been performed in siRNA-mediated 
CMTM8 knockdown or CMTM8 overexpressing BMSC, and showed that CMTM8 is a 
promoter of cell migration. To assess the effect of CMTM8 in BMSC adhesion, transwell 
migration assays can be performed.  
 
After confirming the effects of HOPX and CMTM8 in BMSC migration and adhesion, it is 
important to identify the downstream molecular pathways of both molecules in these processes. 
HOPX or CMTM8 siRNA-mediated knockdown or overexpressing BMSC can be stimulated 
with different factors known to promote BMSC migration such as EGF, HGF, PDGF, SDF-1 
and IGF-1; or treated with chemical inhibitors to these factors to inhibit BMSC migration, 




6.2.2 Generation of conditional knockout HOPX-/- homozygous mice. 
The present study has been limited to in vitro analyses. It is important to determine whether 
HOPX plays a similar role in BMSC proliferation and cell fate determination in vivo. Although 
it has been shown that HOPX-/- homozygous mice display cardiac defects and 10% lethality 
rate [222, 250], no phenotype of the skeletal system/ body size/ weight of the mice have been 
described. To date no HOPX floxed mouse has been reported. CRISPR-Cas9 genome editing 
technique could be used to generate Loxp sites on the HOPX alleles [326, 327] . Therefore, 
future studies could lead to the generation of conditional knockout HOPX-/- homozygous mice 
specifically in the mesenchymal stem/ progenitor cells as we have previously reported for 
EZH2 affecting bone/ cartilage  and adipose tissues, using HOPX floxed mice mated with the 
Cre-driver Prrx1 [328].  
 
6.2.3 Does HOPX inhibits marrow fat formation in osteoporotic skeletal system? 
Osteoporosis is characterised by reduced bone mass and increased marrow fat formation. In 
the present thesis, an association between TWIST-1/EZH2/HOPX was reported. Given that 
TWIST-1 and EZH2 are inhibitors of BMSC osteogenesis and promoters of adipogenesis [1, 
2, 48, 196] while HOPX is an inhibitor of BMSC adipogenesis, we speculate that HOPX may 
delay the onset of osteoporosis. Analysis of skeletal parameters of HOPX-/- homozygous 
conditional knockout mice from 6.2.2 could help address this issue using an ovariectomy or 
sham surgery mouse model [328, 329] and compared with wild type animals.  
 
6.2.4 Proteomic and epigenomic analysis in different disease models. 
Our future efforts will attempt to decipher the proteomic profile of HOPX such as binding 
partners of HOPX, the genome wide binding sites of HOPX protein complexes and the role of 
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putative HOPX targets in human BMSC, osteoporotic-induced mice model and high fat diet 
mice model, since HOPX was found to be an inhibitor of adipogenesis. Moreover, HOPX has 
been shown to be hypermethylated in its promoter CpG island in pancreatic cancer cells and 
other cancer cell types [265]. Therefore, quantitative-methylation-specific PCR (Q-MSP) can 
be carried out to quantitate the value of methylation on the HOPX promoter during growth or 
differentiation. This will provide the methylation profile on the HOPX promoter during these 
processes and provide better understanding of the epigenetic regulation of HOPX under normal 
physiological or pathological conditions, which could facilitate development of possible future 
therapeutic strategies that will alter the function of HOPX.  
 
6.2.5 Generation of CMTM8-/- homozygous mice. 
To date, no CMTM8-/- homozygous mouse strains have been reported. To demonstrate the role 
of CMTM8 during BMSC proliferation and cell fate determination in vivo, CRISPR-Cas9 
genome editing technique could be used to generate Loxp sites on the CMTM8 alleles [326, 
327] as described in 6.2.2. Therefore, future studies could lead to the generation of conditional 
knockout CMTM8-/- homozygous mice specifically in the mesenchymal stem/ progenitor cells 
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